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SUMMARY 
 A major challenge in the transplant field is achieving a fine balance between 
achieving sufficient immunosuppression to prevent donated tissue rejection while 
managing the many side effects that occur in both the acute and chronic timeframe after 
induction of immunosuppressive therapy. There have been great advances made in the field 
of post-organ transplant prevention of rejection, but acute wound healing complications 
following transplant surgery still occur at unacceptably high rates compared to analogous 
non-transplant surgeries. Patient factors including age, obesity, and pre-existing conditions 
such as diabetes can put patients at greater risk for wound healing complications after organ 
transplant. Organ transplant is currently the only treatment for end-stage organ failure, so 
therefore the need exists for therapies that are able to accelerate post-transplant surgical 
wound closure while subsequently allowing for acceptance and integration of the 
transplanted tissue. 
 Cells of the innate and adaptive branches of the immune system have emerged as 
critical cellular mediators that can play roles in modulating the immune response after 
tissue injury towards enhanced wound healing and tissue regeneration. Specifically, 
alternatively activated subsets of monocytes and macrophages, along with tolerogenic 
Interleukin-10 (IL-10)+ dendritic cells, and regulatory T cells have been shown to promote 
vascular remodeling, tissue repair, and return to homeostasis in numerous tissues. While 
therapies that are able to target a single pro-regenerative cell subset at a time have 
previously been developed, little work has been done attempting to recruit wound healing 
cells from both myeloid and lymphoid lineages. Recognizing the complex interplay that 
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exists between the innate and adaptive branches of the immune system, we developed and 
characterized a novel immunomodulatory hydrogel with the ability to promote the 
recruitment and accumulation of wound healing immune cells of varied lineage. 
 Using localized delivery of aspirin-triggered resolvin d1 (AT-RvD1) a lipid 
specialized proresolving mediator, we demonstrated that injured tissue can be enriched 
with anti-inflammatory, pro-angiogenic populations of neutrophils, monocytes and 
macrophages. Local delivery of AT-RvD1 modulates the local cytokine profile and 
enhances vascular remodeling at early timepoints following injury. We then expanded 
upon these findings and developed a hydrogel system capable of the dual delivery of AT-
RvD1 and IL-10 with differing release kinetics. Dual delivery of IL-10+AT-RvD1 not only 
increases anti-inflammatory monocyte and macrophage recruitment as was seen with local 
delivery of AT-RvD1 alone, but also results in significant accumulation of IL-10+ dendritic 
cells and regulatory T cells while recapitulating the vascular remodeling processes 
observed previously. Finally, we delivered these immunomodulatory hydrogels following 
allogeneic and syngeneic skin transplant. We observed significant modulation in the local 
immune response with combination IL-10+AT-RvD1 treatment with little effect on the 
makeup of immune cells populating the blood or draining lymph nodes. We observed 
allograft rejection across all treatment groups by our final timepoint, however, indicating 
that local immunomodulation is not sufficient to provide acceptance signals to the host. 
 This research presents a novel immunomodulatory hydrogel system that may aid in 
soft tissue regeneration by recruiting pro-regenerative immune cell subpopulations and 
stimulating vascularization after injury. These findings represent an improved 
understanding of how we may target pro-regenerative cells from different branches of the 
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immune system, and this treatment has the potential to enhance tissue regeneration and 






CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
1.1 Introduction 
 Ongoing advances in transplantation surgical techniques, together with 
improvements in immunosuppression regimens (IS), have led to an appreciable reduction 
in the rate of postoperative morbidity and graft loss. Despite these advances, wound 
complications due to systemic IS are a common post-transplant surgical complication. 
Therefore, there is a need for therapies that have the ability to allow for wound healing 
while also preventing rejection without the off-target side effects of systemic IS. One 
method that has the potential of mediating these complications is the delivery of 
immunomodulatory factors that are able to accelerate wound healing and tissue integration 
through the local recruitment and education of anti-inflammatory, pro-regenerative subsets 
of immune cells, such as regulatory T cells (Treg), macrophages (M2a/c), and dendritic 
cells (tolDCs), that work to enhance tissue regeneration and alloimmunity by dampening 
immune activation and cytokine production of factors involved in pathologic inflammation 
and rejection. 
 Resolvins, a class of endogenous small lipid molecules, play a multifocal role in 
the resolution of acute inflammation. Recently, resolvins have also been shown to promote 
transplant acceptance through actions on dendritic cells and Tregs and can reduce graft 
injury via reduction of neutrophil recruitment. Resolvins can also preferentially recruit Ly-
6CLo anti-inflammatory monocytes, which are skewed toward long-term anti-
inflamamtory fate. The cytokine IL-10 is necessary for Treg-mediated allotolerance and 
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can participate in the local education of DCs capable of promoting Treg activity and 
allograft acceptance. Combining the delivery of these factors using degradable 
polyethylene glycol-maleamide (PEG-MAL) hydrogels is a novel method has the potential 
to accelerate wound closure and allotransplant integration with the host by concentrating 
the presentation of cells vital to wound healing in a therapeutic window while reducing 
complications in wound healing associated with systemic immunosuppression regimens. 
 We will exploit endogenous mechanisms of proregenerative immune signaling 
within immune cell populations to improve transplant surgical wound healing and 
transplanted tissue integration. Our approach is to engineer a degradable, injectable 
biomaterial scaffold to spatially localize and induce defined leukocyte and lymphocyte 
subpopulations that are critically involved in inducing immune tolerance. We have shown 
that biomaterials-mediated delivery of AT-RvD1 or IL10 is able to modulate macrophage 
activity in vitro and in vivo. In addition, studies using AT-RvD1-loaded PLGA films have 
demonstrated superior anti-inflammatory monocyte recruitment compared to cutaneous 
infusion. The central hypothesis of this proposal is that local recruitment of subsets of 
macrophages, dendritic cells, and T cells via delivery of AT-RvD1 and on-site IL-10-
mediated induction of alloimmunity-promoting phenotypes will promote wound healing 
associated with allograft transplantation. 
1.2 Specific Aims 
 Aim 1. To evaluate the effects of enhancing the recruitment of anti-inflammatory 
and pro-regenerative cell subsets to areas of inflammation using locally delivered AT-
RvD1 after injury. Aim 1 characterizes the changes in immune cell recruitment and 
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associated vascular remodeling after local treatment with AT-RvD1 following tissue 
injury. In Aim 1A, we will assess the kinetics of pro- and anti-inflammatory immune cell 
recruitment and cytokine profile modulation in the murine dorsal skinfold window chamber 
after biomaterial delivery of AT-RvD1 model by flow cytometry, whole mount 
immunohistochemistry (IHC), and multiplexed cytokine array. In Aim 1B, the effects of 
local delivery of AT-RvD1 on post-injury vascular remodeling will be assessed by 
intravital imaging analysis and whole mount IHC. 
 Aim 2. To develop an injectable, degradable, PEG hydrogel-based delivery system 
for AT-RvD1 and IL10 and quantify in vivo changes in the origin, recruitment dynamics, 
and differentiation fate of immune cell subsets after gel implantation. Aim 2 develops a 
PEG hydrogel system capable of releasing IL-10 and AT-RvD1 and characterizes the 
modulation in the local immune response in the dorsal skinfold window chamber. In Aim 
2A, we will characterize the encapsulation and release of AT-RvD1 and IL-10 from PEG 
hydrogels in vitro. In Aim 2B, we will implant hydrogels into the dorsal skinfold window 
chamber injury model and assess cell phenotypes surrounding the implant by flow 
cytometry, whole mount immunohistochemistry (IHC), and multiplex cytokine and growth 
factor profiling analysis after 1, 3, and 7 days. Internally controlled studies will compare 
unloaded gels to gels releasing IL-10 and/or AT-RvD1. 
 Aim 3. To investigate how modulation of cell recruitment and activation via local 
immunomodulation with AT-RvD1 and IL10 from PEG hydrogels regulates the immune 
response to transplanted tissue and promotes early wound healing and integration. Aim 3 
examines the kinetics of immune cell recruitment and associated enhancement of syngeneic 
or allogeneic skin transplant integration. In Aim 3A, we will characterize syngeneic skin 
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transplant wound healing and integration after transplantation with PEG hydrogels 
releasing IL-10 and AT-RvD1. In Aim 3B, we will characterize skin allograft healing and 
acceptance after transplantation with PEG hydrogels releasing IL-10 and AT-RvD1. We 
will identify the response kinetics of immune cells to transplanted grafts by flow cytometry 
and immunohistochemistry. We will also assess molecular signals of rejection by 
immunostaining for deposition of donor derived IgG and IgM and through multiplexed 
cytokine profiling. 
1.3 Significance 
 The current standard for preventing allograft rejection consists of systemic 
immunosuppression utilizing multiple drugs that vary in their mechanisms of action. While 
the use of systemic IS has reduced the rates of transplanted organ rejection, complications 
related to IS are still unacceptably high[1-3]. One potentially successful approach is to 
induce graft tolerance by acting intrinsically on the myeloid cells that are recruited to 
allograft tissue after transplant with engineered immunomodulatory cues delivered locally 
via biomaterial by tuning the recruitment of anti-inflammatory cell progenitors and 
inducing polarization into tolerogenic cell subsets through on-site education[4, 5]. The use 
of biomaterials for the local delivery of immunosuppressive of immunomodulatory factors 
is an underexplored area that has the potential to reduce these complications while 
preventing allograft rejection[6, 7]. Our proposed research will show how selective 
recruitment of anti-inflammatory immune cell subsets within allografts by dual delivery of 
AT-RvD1 and IL-10 to enhance generation of intrinsic mononuclear subsets with 
suppressive activity in order to inhibit graft-reactive T cell immunity, facilitate induction 
of Tregs, and induce transplantation tolerance. 
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CHAPTER 2. BACKGROUND 
2.1 Systemic immunosuppressive therapy after transplantation can cause 
significant complications. 
 Solid organ transplantations have increased 20% in the United States in the last 5 
years to over 30,000 procedures in 2016, and organ transplant is the most effective 
treatment option for patients suffering from end-stage organ failure [2, 8]. Currently, the 
use of post-transplantation immunosuppressive regimens (IS) has resulted in significant 
increases in survival after solid organ allograft, with rates nearing 90% after one year[9]. 
Despite decreases in acute rejection of transplants with IS, significant complications 
stemming directly from systemic IS are still prevalent, in both the acute and chronic time 
frame after transplant. Chronic use of systemic IS is associated with an increased risk of 
opportunistic infection, particularly fungal infection, lymphoproliferative disorders, and 
wound toxicity including cardiovascular disease or renal failure[2, 3]. In the acute phase, 
surgical wound complications associated with transplantation procedures are reported at 
rates over ten times higher than similar surgical procedures that do not involve 
immunosuppression [3]. Because of the early post-surgical complications associated with 
immunosuppressive therapy, there is an opportunity for the development of alternative 
therapies that are able to exploit endogenous mechanisms of wound healing and tissue 
acceptance to prevent acute wound closure complications and promote early tissue 
integration. 
 Impaired wound healing after transplant surgery is one of the most common 
complications arising from high doses of systemic immunosuppression. Wound dehiscence 
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and other complications have been reported in the context of nearly every transplant 
procedure, including heart, kidney, and liver [3, 10]. For example rates of surgical wound 
complications including superficial or deep wound infection, lymphocele, and wound 
dehiscence have been reported in 8-15% and sometimes up to 40% of heart transplant 
recipients compared with 0.5-10% of patients after similar general cardiac surgery 
procedures that do not involve transplantation [3]. These complications can be exacerbated 
by a multitude of patient risk factors, including age, obesity, and diabetes [11]. Given the 
aging population and rising obesity rates, wound healing complications following 
transplant are at risk of becoming more and more common.  
 Many immunosuppressive drugs utilized after transplant have been shown to impair 
or interfere with wound healing. The use of mTOR inhibitors such as sirolimus and 
everolimus after transplant have been implicated in increases in wound complications, with 
one study demonstrating an incidence of complications of 47% in patients receiving 
sirolimus following kidney transplant, compared to 8% in patients not receiving 
sirolimus[1]. In animal models, animals receiving sirolimus had reduced tensile strength in 
regenerating abdominal wounds compared to control[12]. When combined with 
corticosteroids, this effect was amplified, and tensile wound strength was reduced even 
further. These findings are further corroborated in a study utilizing pigs that received 
rapamycin after ureteric anastomosis [13]. Another mTOR inhibitor, everolimus, has also 
been shown to reduce anastomotic breaking strength in the rat intestine, indicating adverse 
effects on wound healing [14]. Other common immunosuppressive drugs such as 
cyclosporine A, tacrolimus, and mycophenate motefil have been studied with regards to 
their roles in wound healing and have been shown to impair wound healing processes [15-
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17]. These studies indicate that the common combinatorial approach of 
immunosuppression taken to prevent the rejection of transplanted organs may be 
compounding the impairment of processes necessary to ensure proper healing of surgical 
sites and prevent wound healing complications. 
2.2 Roles of the innate immune system in wound healing 
The innate immune system plays a vital role in the restoration of homeostasis 
following tissue injury. Because of this, there exists an opportunity to exploit the 
mechanisms of wound repair driven by the innate immune system to accelerate or enhance 
healing after injury in a variety of contexts, including cutaneous wound healing [18, 19], 
ischemic cardiac injury[20], and nervous tissue regeneration[21]. The immune response to 
traumatic injury is characterized by a cascade of repair processes that result in the rapid 
accumulation of neutrophils that act as first-line defenders against microorganisms and 
signal amplifiers to recruit other immune cells to the injured tissue[22]. Secondly, there is 
an infiltration of mononuclear phagocytes that serve to clear debris, remodel and expand 
vasculature, and signal to circulating and parenchymal cells that help restore cellular and 
matrix composition[23, 24]. Studies investigating the depletion of neutrophils or 
mononuclear phagocytes have demonstrated delayed wound closure in aged mice[25], or 
failure to regenerate amputated zebrafish tail fins [26] or salamander limbs [27], suggesting 
that there is a complex interaction of all of these cellular subsets that is necessary for tissue 
repair to proceed after injury. 
2.2.1 Neutrophils act as first responders to tissue injuries 
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 Neutrophils are innate immune cells of the myeloid lineage that develop from 
hematopoetic progenitors in the bone marrow. In humans, they are the most abundant 
immune cell in human blood, and their role in homeostasis is to patrol and protect the host 
from pathogens and other harmful reagents [28]. Neutrophils play a major role in the 
response to pathogens, and are vital to stemming the tide of infection, although while 
carrying out anti-infectious effector functions, neutrophils may cause collateral damage to 
tissues surrounding the infected area. In sterile inflammation, such as acute tissue damage 
that occurs as a result of surgery, damage-associated molecular patterns (DAMPs) released 
from injured and dying cells provide the initial recruitment signals to circulating 
neutrophils [29]. Many of these DAMPs can act as chemoattractants to neutrophils, while 
others can activate surrounding tissues and induce the production of strong inducers of 
neutrophil chemotaxis, such as C-X-C motif chemokine ligand 8 (CXCL8) and leukotriene 
B4 [30-32]. Neutrophils responding to DAMPs can contribute to and perpetuate sterile 
tissue injury through amplification of the inflammatory response and the release of toxic 
effectors, such as reactive oxygen species (ROS) and proteolytic enzymes capable of 
damaging tissue [33, 34]. Neutrophils can also release neutrophil extracellular traps (NETs) 
that can be injurious to tissue [35, 36] and even contribute to the development of diseases 
such as systemic lupus erythematous, rheumatoid arthritis, diabetes, and thrombosis [37]. 
NETs contain nuclear contents as well as granular and cytosolic proteins, which result in 
the potential presentation of auto-antigens to the host immune system and the release of 
DAMPs that could further amplify ongoing immune reactions and cause tissue injury, and 
there have been several strategies employed to interfere with NETs that have resulted in 
decreases in tissue damage [38]. 
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 Although neutrophil activation and activity can have a detrimental role on tissue 
during inflammation, there is evidence that neutrophils can also promote tissue repair 
processes and the resolution of inflammation. In the context of tissue repair, it has been 
demonstrated that neutrophils are important for efficient wound repair, as neutropenic 
individuals often have difficulty healing wounds [39]. Additionally, mice deficient in 
formyl peptide receptors FPR1 and FPR2 exhibit delayed wound closure [40] and mice 
whose leukocyte recruitment is impaired by deletion of CXCR2 displayed decreased 
epithelialization and neovascularization following tissue injury [41]. These studies 
highlight a direct role for neutrophils in wound healing, although specific effector functions 
that neutrophils possess that may contribute to wound healing remain unclear. 
 One possible mechanism of neutrophil participation in wound repair is through the 
emerging evidence of neutrophilic subsets. Heterogeneity of neutrophils, similar to 
monocyte or macrophage heterogeneity, has shown that there are several subsets of 
neutrophils that may contribute to wound healing and angiogenesis. Revascularization and 
formation of new blood vessels are a vital process to wound repair. Newly formed vessels 
participate in provisional granulation tissue formation and are able to provide oxygen and 
nutrients to growing tissues [42]. Growth factors, such as vascular endothelial growth 
factor (VEGF), fibroblast growth factor (FGF), and transforming growth factor-beta 
(TFGB) have been identified as potent mediators of vascular remodelling during wound 
repair. Both human and murine neutrophils have been demonstrated to be a source of 
VEGF. Recently, a subset of neutrophils has been described that is able to promote vascular 
remodelling after hypoxic injury [43, 44]. These neutrophils express high levels of CD49d, 
VEGFR1, and CXCR4 and are important in the initiation of angiogenesis following injury. 
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Neutralization of these neutrophils resulted in impaired integration and angiogenesis of 
implanted islets. Additionally, these pro-angiogenic neutrophils are an important source of 
matrix metalloproteinases (MMPs) that are responsible for the degradation of extracellular 
matrix components and the release of VEGF. These studies indicate a clear role for 
neutrophils in the larger wound repair process.  
2.2.2 The mononuclear phagocyte system 
The mononuclear phagocyte system is comprised of monocytes and macrophages. 
These cell subsets exhibit a wide phenotypic heterogeneity and can carry out a variety of 
effector functions, including the coordination of innate and adaptive immune responses[24, 
45-47], the killing of microbial pathogens and parasites [48], and the promotion of tissue 
repair[20, 49-51]. Monocytes are also able to differentiate into macrophages and dendritic 
cells after extravasation[52-54]. In response to tissue injury, these cells traditionally secrete 
many factors, such as inflammatory cytokines and chemokines, matrix and protein 
degrading factors, and growth factors[53, 55].  In vivo, monocytes and macrophages exist 
on a spectrum ranging from “classical” or “inflammatory” to “alternatively activated” or 
“anti-inflammatory”, respectively [56]. The subset heterogeneity present among both 
monocytes and macrophages presents an opportunity to develop therapies that are able to 
specifically target subsets and manipulate their activity for the promotion of tissue repair 
after injury. 
 Monocytes are myeloid leukocytes that traffic to the blood and spleen during 
homeostasis. They are immunophenotyped as CD11b+CD115+SSClow cells. Circulating 
blood monocytes are comprised of at least two functionally distinct subsets[47]. Classical 
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“inflammatory” monocytes are characteristically Ly6Chi CCR2hi CX3CR1lo in mice and 
CD14+CD16- in humans. Non-classical “anti-inflammatory” monocytes are Ly6Clo CCR2lo 
CX3CR1hi in mice and CD14loCD16+ in humans. Classical monocytes predominate the 
acute phases of injury and are recruited to injury following neutrophil infiltration by 
migrating towards gradients of inflammatory cytokines such as MCP-1[53, 57]. Classical 
monocytes secrete inflammatory cytokines such as IL-6, iNOS, and TNFα[58], produce 
high levels of matrix metalloproteinases and cathepsins, and phagocytose debris[20]. 
During homeostasis, non-classical monocytes patrol the endothelium and after injury they 
predominate in later phase inflammation, secrete higher levels of VEGF, TGFβ, and IL-10 
and lower levels of TNFα and IL-1β, and promote angiogenesis and matrix deposition[20, 
59]. While studies of toxin-induced muscle injury[51], acute liver injury[50], and 
autoimmune disease[60] show that classical monocytes are recruited from circulation and 
subsequently convert in situ into non-classical monocytes and M1 or M2 macrophages, 
other studies in myocardial infarction[20] and excisional skin injury[18] indicate that non-
classical monocytes can be recruited directly from blood. Until recently, it was unknown 
whether non-classical versus classical monocytes give rise to distinct macrophage 
phenotypes. Our group is the first to show that non-classical monocytes recruited from 
blood may serve as biased progenitors of M2 “alternatively activated” macrophages[61]. 
Macrophage phenotype and function is described as spectrum of M1 “inflammatory” 
to M2 “alternatively-activated” or “regenerative” macrophages[24]. M1 polarization from 
naive macrophages in vitro is accomplished by stimulation with IFNγ, lipopolysaccharide, 
and/or TNFα[62]. These M1 macrophages produce reactive oxygen species and many 
inflammatory cytokines that support necrotic tissue clearance, and growth factors such as 
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VEGF and FGF2[63-66] upon stimulation. The release of these pro-inflammatory 
cytokines in vivo aids in pathogen and necrotic tissue clearance and sets off a signal cascade 
that allows for the recruitment of additional immune populations. While it has been found 
that an M1 response is necessary for normal wound healing to occur, over-activation or 
excessive persistence of M1 macrophages can propagate tissue damage and result in an 
unresolved inflammatory response [24]. 
M2 “alternatively activated” macrophages are differentiated in vitro via a 
mechanism separate from M1 macrophages. M2 macrophages can be further subdivided 
into M2a, M2b, and M2c subsets that all differ in their surface markers and effector 
functions. M2a polarization requires IL-4 and/or IL-13 in vitro, and these macrophages 
support extracellular matrix deposition and epithelial wound closure via high expression 
of arginase-1 (CD206), which allows them to generate precursors for collagen and 
fibroblast stimulating factor, [24, 62, 63, 66-68].  M2b polarization requires immune 
complexes combined with toll-like receptor (TLR) or IL-1R ligands, whereas M2c 
macrophages arise via IL-10 stimulation[62, 63, 67, 69]. M2b and M2c contribute to 
suppressing inflammation through secretion of IL-10. Due to macrophage plasticity in vivo 
and lack of distinguishing biomarkers, specific functions of M2a-c subtypes in tissue repair 
remain poorly understood. Nevertheless, the dominant presence of M2 versus M1 
macrophages is associated with positive healing outcomes in numerous contexts[18, 23, 
70-72]. 
2.3 The adaptive immune system and wound healing 
 In contrast to innate immunity, the adaptive immune provides more of a delayed 
and specific response. The innate immune system is comprised of the lymphocytes B cells 
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and T cells. Currently, there is little evidence for the role of B cells in tissue healing, 
although this is an area that has not received much study. On the other hand, there is 
growing evidence pointing towards T cells playing a crucial role in tissue repair and 
regeneration – however the exact function of T cell subsets and their level of accumulation 
at injury sites is largely unknown and seems to vary from tissue to tissue. 
 T cells are capable of secreting a diverse range of cytokines and growth factors, 
which can have detrimental of beneficial effects on tissue healing. For example, it has been 
shown that CD4+ T helper 1 (TH1) cells and cytotoxic CD8+ T cells inhibit bone 
regeneration via secretion of IFN-y and TNF- α [73]. On the other hand, biomaterials that 
promote CD4+ T helper 2 (TH2) cell activity have been shown to guide interleukin-4 
dependent macrophage polarization after traumatic muscle injury, which is critical for 
muscle tissue regeneration [72]. Additionally, CD4+ regulatory T cells (Treg) are critical 
for the repair and regeneration of several tissues including skin, bone, lungs, kidney, 
skeletal muscle, and cardiac muscle [74-78]. Tregs are potent suppressors of the immune 
system and have recently been rediscovered as indirect and direct regulators of tissue 
healing. Tregs can modulate regeneration by controlling neutrophils, inducing macrophage 
polarization, regulating other subsets of helper T cells, and activating local tissue 
progenitor cells[79-84]. This growing body of evidence suggests that there is complex 
interplay between both the innate and adaptive immune systems in the processes of wound 
healing, and that these processes can be harnessed to direct tissue healing using a 
multifactorial approach that acts on multiple key regulators of wound healing. 
2.4 Cells of the innate immune system are active mediators of transplant acceptance 
and rejection in concert with the adaptive immune system. 
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It has long been recognized that T cells play a major role in directing both transplant 
rejection and tolerance. Indeed, much of the research in the field of transplant immunology 
has focused on modulating the response of the adaptive immune system after allograft 
surgery. However, targeting of innate immune cells including mononuclear phagocytes and 
granulocytes has gained increasing interest due to their ability to play both detrimental and 
beneficial roles[4]. Neutrophils are recruited to graft tissue in response to ischemia 
reperfusion injury (IRI) inherent in all transplant procedures[85]. There they can 
exacerbate graft tissue damage through the release of metalloproteinases and neutrophil 
elastase, and actively mediate acute rejection through CD8+ cytotoxic T cell signaling[86-
88]. Additionally, while the interaction of neutrophils and cells of humoral immunity is not 
well-understood, it has been found that neutrophils have the capacity to leave peripheral 
sites of injury and deliver antigen to lymph nodes[89]. On the other hand, there are subsets 
of neutrophils that may promote wound healing and tissue repair, and aid in the reperfusion 
of graft tissue[43]. Mononuclear cell infiltration, including monocytes (MO), dendritic 
cells (DCs) and macrophages, and the production of pro-inflammatory cytokines such as 
tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1α, and IL-1β are inherent to the 
transplant milieu[5]. Macrophages of both donor and recipient origin infiltrate the allograft 
and proliferate in situ, and comprise 40-60% of cellular infiltrate in acute rejection[90]. 
Up-regulation of surface MHC class II and increased expression of T cell costimulatory 
molecules by activated DCs are also implicated in acute rejection. Upon functional 
maturation, “passenger” DCs in donor tissue migrate to recipient secondary lymphoid 
organs along chemokine gradients where they are key mediators in alloantigen 
presentation. Early activation of DCs also leads to allotransplant injury due to accumulation 
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of interferon-γ-producing neutrophils, infiltrating macrophages, CD4+ T cells, B cells, and 
invariant natural killer T (NKT) cells[91]. Conversely, the phenotypic plasticity of 
monocyte precursors and DCs in response to microenvironmental signals, the presence of 
tolerogenic mononuclear phagocyte subsets that coincide with allograft acceptance, and 
their roles in Treg expansion are evidence that MO and DC subsets are key targets in the 
quest for transplant acceptance[92, 93]. For example, we have shown that Ly6CLo anti-
inflammatory monocytes (AMs)  are skewed toward long-term anti-inflamamtory cell 
fate[61, 94]. These AMs can also promote Treg differentiation through PD-1 signaling[95]. 
Additionally, after differentiation into M2a/c macrophages, these cells can release 
cytokines that reduce inflammatory DC activity and suppress T cell activation[92, 93]. 
2.5 Endogenous biomolecules can promote wound healing and tissue acceptance 
2.5.1 Resolvins play a multi-factorial role in modulating innate and adaptive immune 
responses. 
Resolvins are a class of bioactive small molecule lipids derived from the omega-3 
polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA)[96]. Resolvins are potent proresolving lipid mediators that act to drive cellular 
processes toward the resolution of inflammation and have been deemed “specialized 
proresolving mediators” (SPMs). Specifically, the D-series resolvins including resolvin D1 
(RvD1) and Aspirin-triggered Resolvin D1 (AT-RvD1) are derived from DHA act as 
endogenous agonists of the cellular receptors GPR32 and ALX/FPR2, which are broadly 
expressed in immune cells, including neutrophils, monocytes, macrophages, dendritic 
cells, and lymphocytes, and in certain types of specialized epithelial cells[97-100]. These 
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SPMs have a multi-faceted role in modulating the cellular response to tissue injury and 
inflammation. Ligation to these receptors can decrease the transendothelial migration of 
neutrophils, enhance macrophage phagocytosis of apoptotic cells and microbes, modulate 
cytokine release from macrophages, and stimulate phagocyte efflux from inflamed tissues, 
all of which are considered hallmarks of active resolution of inflammation[100]. More 
recently, studies have shown that these SPMs are able to modulate the activity of cells in 
the adaptive immune system in ways that were previously unknown. Resolvins D1 and D2 
are able to inhibit human T cell activation by various means, including reducing cytokine 
production by CD8+ and CD4+, reducing differentiation of naïve CD4+ T cells into T 
helper 1 and 17 (TH1/TH17) subsets, and concomitantly enhanced the de novo generation 
and function of FoxP3+ Tregs through GPR32 signaling[101]. Use of systemically-
delivered resolvins in various transplant models have shown that resolvins can preserve 
allotransplant function by modulating the activity of neutrophils, DCs, and T cells[102-
104]. 
2.5.2 IL-10 modulates dendritic cell activation and function to promote transplant 
acceptance 
IL-10 is a cytokine which plays a critical role in the control of immune responses. 
It is expressed by both innate and adaptive immune cells including monocytes, 
macrophages, dendritic cells, and virtually all T cell subsets[105]. IL-10 signaling can have 
direct effects on both innate and adaptive immune cells. For example, IL-10 treatment of 
premature DCs prevents maturation, resulting in decreased MHC-II expression on the DC 
surface, and subsequently increases DC release of IL-10[106]. These IL-10 producing DCs 
have been termed “tolerogenic DCs” (tolDCs) and have the ability to induce functional 
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Tregs[107]. IL-10 also has the ability to block T cell costimulation and prevent 
proliferation in both TH1 and TH2 T cell subsets[108]. IL-10 signaling is also required for 
Tregs to mediate tolerance to alloantigens in vivo[109]. These studies highlight the role 
that IL-10 plays not only in the education of tolerogenic immune cells but also in the 
induction and maintenance of transplant tolerance. 
  
 18 
CHAPTER 3. ASPIRIN-TRIGGERED RESOLVIN D1-MODIFIED 
MATERIALS PROMOTE THE ACCUMULATION OF PRO-
REGENERATIVE IMMUNE CELL SUBSETS AND ENHANCE 
VASCULAR REMODELING1 
3.1 Abstract 
Many goals in tissue engineering rely on modulating cellular localization and 
polarization of cell signaling, including the inhibition of inflammatory infiltrate, 
facilitation of inflammatory cell egress, and clearance of apoptotic cells. Omega-3 
polyunsaturated fatty acid-derived resolvins are gaining increasing recognition for their 
essential roles in inhibition of neutrophil invasion into inflamed tissue and promotion of 
macrophage phagocytosis of cellular debris as well as their egress to the lymphatics. 
Biomaterial-based release of lipid mediators is a largely under-explored approach that 
provides a method to manipulate local lipid signaling gradients in vivo and direct the 
recruitment and/or polarization of anti-inflammatory cell subsets to suppress inflammatory 
signaling and enhance angiogenesis and tissue regeneration. The goal of this study was to 
encapsulate Aspirin-Triggered Resolvin D1 (AT-RvD1) into a degradable biomaterial in 
order to elucidate the effects of sustained, localized delivery in a model of sterile 
inflammation. Flow cytometric and imaging analysis at both 1 and 3 days after injury 
showed that localized AT-RvD1 delivery was able significantly increase the accumulation 
                                               
1 Adapted from: M.C.P. Sok, M.C. Tria, C.E. Olingy, C.L. San Emeterio, E.A. Botchwey, Aspirin-Triggered 
Resolvin D1-modified materials promote the accumulation of pro-regenerative immune cell subsets and 
enhance vascular remodeling, Acta Biomater 53 (2017) 109-122. Reprinted with permission from Elsevier 
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of anti-inflammatory monocytes and M2 macrophages while limiting the infiltration of 
neutrophils. Additionally, cytokine profiling and longitudinal vascular analysis revealed a 
shift towards a pro-angiogenic profile with increased concentrations of VEGF and SDF-
1α, and increased arteriolar diameter and tortuosity. These results demonstrate the ability 
of locally-delivered AT-RvD1 to increase pro-regenerative immune subpopulations and 
promote vascular remodeling. 
3.2 Introduction 
Resolvins are a class of bioactive small molecule lipids derived from the omega-3 
polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA)[96].  Resolvins are potent proresolving lipid mediators that act to drive cellular 
processes toward the resolution of inflammation. Specifically, the D-series resolvins 
derived from DHA act as endogenous agonists of the cellular receptors GPR/32 and 
ALX/FPR2, which are broadly expressed in immune cells, including neutrophils, 
monocytes, macrophages, and lymphocytes, and in certain types of specialized epithelial 
cells[97, 98, 110]. Ligation to these receptors results in a number of different actions, 
including decreased transendothelial migration of neutrophils, enhancement of 
macrophage phagocytosis of apoptotic cells and microbes, modulation of cytokine release 
from macrophages, and stimulation of phagocyte efflux from inflamed tissues, all of which 
are considered hallmarks of active resolution of inflammation [100]. Treatment with 
resolvins can be used to promote the resolution of inflammation and healing in in many 
pathological conditions, including bacterial infection, peritonitis, and asthma [111-113]. 
Additionally, subcutaneous resolvin D2 injections have been shown to increase collateral 
circulation after ischemic injury [114]. While these studies have been promising, many 
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utilized systemic delivery of resolvins, which limits its bioavailability at the site of 
inflammation and can result in rapid degradation, requiring multiple injections at high 
dosages [115, 116].  
Currently, biomaterial-based delivery systems for localized delivery of resolvins 
have not widely been developed [117, 118]. Others have shown that local delivery of 
resolvin D1 (RvD1) using a biomaterial wrap can reduce neointimal hyperplasia after 
vascular injury [119, 120], but more exploration is needed to fully characterize the effects 
of local resolvin delivery in other models. Utilization of biomaterial-mediated delivery of 
resolvins to areas of injured tissue has the potential to amplify the effect of resolvins 
produced endogenously during inflammation. Aspirin-triggered Resolvin D1 (AT-RvD1) 
is a D-series resolvin that can be produced physiologically when the enzyme 
cyclooxygenase-2 (COX-2) is acetylated in the presence of aspirin [115]. It possesses the 
same mechanism of action as RvD1, but due to a conformational change of a hydrogen 
molecule from (S) to (R) around the seventeenth carbon, can resist rapid degradation by 
oxidoreductases, resulting in a longer in vivo half-life [115, 121-123]. The longer activity 
of AT-RvD1 in vivo makes it an attractive small molecule for incorporation into 
biomaterials that seek to promote resolution of inflammation and enhance wound healing. 
One strategy to promote resolution of inflammation is to modulate the profile and activities 
of cells involved in the inflammatory response [18, 124-126]. Neutrophils have classically 
been viewed as a largely homogeneous population of myeloid immune cells that do not 
possess the ability to polarize into subsets, unlike other leukocyte populations with multiple 
phenotypes, such as T lymphocytes or macrophages. It was long thought that neutrophils 
were only able to act as the immune system’s short-lived “first responders” to infection or 
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injury and that these responses were well-defined and limited in scope. Classical 
neutrophils are able to carry out pro-inflammatory effector functions and these can 
exacerbate tissue injury under pathologic conditions [127]. Prevention of excessive 
neutrophil accumulation enhances wound healing in non-healing diabetic wounds and 
increases cardiac function after acute myocardial infarction due to reduced release of 
reactive oxygen species, proinflammatory mediators, and proteases - which resulted in a 
reduction in tissue damage [82, 128-130]. However, there is now significant evidence for 
the existence of heterogeneous subsets within the larger neutrophil population, and these 
subsets are able to carry out functions in both homeostatic and pathogenic immune 
responses. 
 One such subset of neutrophils that has been defined is able to promote vascular 
formation after hypoxic injury [44]. These circulating neutrophils express high levels of 
CD49d, VEGFR1, and CXCR4 and are able to extravasate into tissues in a mechanism 
independent from classical neutrophils and are recruited by VEGF-A [43]. These 
neutrophils are necessary for early angiogenic processes, and inhibition of these cells 
results in a significant decrease in new vessel formation in vivo. The existence of this pro-
angiogenic neutrophil population presents a new cellular target whose recruitment or 
function may be manipulated to promote early vascular network expansion processes that 
are crucial to wound healing and tissue regeneration, but currently these strategies have not 
been explored. 
 Previously, we have shown that the preferential recruitment of non-classical “anti-
inflammatory” monocytes (CD45+CD11b+Ly6Clow in mice and CD14lowCD16+ in humans) 
as opposed to classical “inflammatory” monocytes (CD45+CD11b+Ly6Chi in mice and 
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CD14+CD16- in humans) promotes microvascular network expansion after sterile injury 
through modulation of the local inflammatory environment [18, 71, 131]. Following 
recruitment to inflamed tissue, monocytes may transiently persist in their undifferentiated 
state or differentiate into macrophages. In addition to tuning monocyte recruitment, 
modulation of macrophage phenotype has been utilized as a strategy to direct tissue 
regeneration [63, 64, 70, 132-134].  Macrophages exhibit different phenotypes based on 
their gene and protein expression profiles, and these phenotypes have distinct effector 
functions that can drive inflammatory processes or promote tissue regeneration[23, 24, 51]. 
Classically-activated (M1) macrophages that are activated in response to injurious or 
infectious stimuli are strongly microbicidal, produce reactive nitrogen and oxygen 
intermediates, and release pro-inflammatory cytokines such as tumor necrosis factor-a 
(TNF-a), interleukin (IL)-1b, and IL-12[45, 52, 66, 135]. M1 macrophages are implicated 
in initiating and sustaining inflammation, especially in the context of biomaterial implants, 
where persistent M1 activation can lead to chronic inflammation and fibrosis[136, 137].  
In contrast, alternatively activated (M2) macrophages can be activated by canonical anti-
inflammatory cytokines such as IL-4, IL-10, and IL-13, as well as in response to fungal 
cells, parasites, and apoptotic cells[45, 138]. M2 macrophages are in turn considered to 
generally possess anti-inflammatory actions through the release of cytokines such as IL-
10, as well as support angiogenesis and tissue repair [70, 132, 133]. Therefore, dual-acting 
therapies that both suppress damaging inflammation via blockade of excessive neutrophil 
accumulation acutely and also promote the action of anti-inflammatory, proresolving 
monocytes and macrophages throughout the progression of inflammation represent a 
promising strategy to enhance tissue repair after injury.  
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In this study, we investigate how localized delivery of AT-RvD1 from polymer scaffolds 
modulates the accumulation of circulating neutrophils and monocytes after injury.  We 
show that AT-RvD1 released from poly(lactic-co-glycolic acid) (PLGA) scaffolds retains 
the ability to inhibit neutrophil function and increase macrophage activity. Using the 
murine dorsal skinfold window chamber as a model of sterile inflammation and 
inflammatory vascular remodeling, we demonstrate that AT-RvD1-loaded PLGA scaffolds 
decrease the frequency of neutrophils and their infiltration into tissue while simultaneously 
increasing the frequency of anti-inflammatory Ly6Clo monocytes and CD206+ 
alternatively activated macrophages. Biomaterial delivery of AT-RvD1 resulted in 
significantly higher numbers of anti-inflammatory monocytes than a single topical dose of 
dissolved AT-RvD1 immediately following injury. In this work, we show that local 
delivery of aspirin-triggered resolvin D1 (AT-RvD1) via biomaterial scaffold is able to 
enrich injured tissue with pro-angiogenic neutrophils, presenting a novel small molecule-
based strategy for enhancing early angiogenesis through neutrophil subsets. Additionally, 
we observed a shift in the peri-implant cytokine profile towards a pro-angiogenic 
microenvironment. AT-RvD1 materials increased microvascular arteriolar diameter and 
vascular tortuosity, and increased the density of CD31+ microvasculature. These results 
indicate that biomaterial delivery of AT-RvD1 can alter the tissue microenvironment after 
injury to one that supports resolution of inflammation and tissue regeneration. 
3.3 Results 
3.3.1 PLGA films release bioactive AT-RvD1 
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PLGA thin films were fabricated to encapsulate and rapidly release encapsulated 
AT-RvD1. The release of AT-RvD1 was measured through the use of a gradient method 
via HPLC using a UV-Vis detector at a wavelength of 301nm. Known concentrations of 
AT-RvD1 were tested using this method and the retention time was found to be centered 
around 8.6 minutes. To assess AT-RvD1 release kinetics, unloaded PLGA films or films 
loaded with AT-RvD1 were incubated in PBS. The AT-RvD1 peak was detected during 
analysis of the AT-RvD1 release samples, while no peaks were detected corresponding to 
this retention time when empty PLGA films were tested (Figure 1A-B). The AT-RvD1-
loaded PLGA films released 1.2±0.2ng of the loaded AT-RvD1 after 1 hour, 7.2±0.3ng 
after 24 hours, 8.6±0.2ng after day 3, and 10.3±0.1ng after day 7 (Figure 1C-D). Release 
after 7 days was below the limits of detection. To further characterize the films, scanning 
electron microscopy was used to observe the surface of the films. No observed differences 
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were seen in the surface morphology of AT-RvD1-loaded or empty PLGA films (Figure 
1E-F). 
 
Figure 1  HPLC Measurements of AT-RvD1 Release. (A) HPLC chromatograph of 
unloaded PLGA scaffold. (B) HPLC chromatograph of PLGA scaffold loaded with AT-
RvD1. Arrow demonstrates AT-RvD1 elution peak. (C) Release profile of AT-RvD1 
loaded into PLGA scaffolds. (D) Early release of nearly 80% of AT-RvD1 is achieved over 
3 days. 
After we verified release of AT-RvD1 from PLGA films, the bioactivity of released 
AT-RvD1 was assessed. Previous studies have shown that exposure to resolvins increase 
macrophage phagocytic ability, therefore a phagocytosis assay was used to confirm AT-
RvD1 bioactivity after release from PLGA films[139].  Cell culture media was incubated 
with AT-RvD1-loaded PLGA films or empty PLGA films AT-RvD1 for 24 hours and then 
used to treat RAW264.7 macrophages. Based on HPLC measurements, the films released 
an average of 7.5±0.6ng AT-RvD1 into RAW264.7 cell culture media over 24 hours. After 






































4 hours of treatment, phagocytic ability was measured using fluorescent latex beads. 
RAW264.7 macrophages that were treated with media containing released AT-RvD1 
exhibited increased phagocytosis of latex beads, as visualized using fluorescence 
microscopy (Figure 2A-B). Quantification of the number of phagocytosed latex beds 
indicated increases in the overall phagocytic activity of macrophages treated with AT-
RvD1 film release media (Figure 2C). As a secondary metric of bioactivity, we treated 
MPRO neutrophils with release media derived from AT-RvD1 films. Neutrophils treated 
with media incubated with AT-RvD1-loaded PLGA films exhibited significantly decreased 
MPO activity after both 30 and 60 minutes compared to neutrophils treated with media 
incubated with unloaded PLGA films (Figure 2D).  Taken together, these results 
demonstrate that AT-RvD1 maintains its bioactivity after release from PLGA films and 
promotes myeloid cell functions induced by native AT-RvD1. 
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Figure 2. Released AT-RvD1 promotes macrophage phagocytosis and inhibits 
neutrophil myeloperoxidase (A-B) Brightfield and epifluorescence micrographs of 
RAW264.7 macrophages treated with PLGA film-conditioned media (Vehicle CM) or AT-
RvD1 conditioned media (AT-RvD1 CM). White arrowheads indicate engulfed beads by 
macrophages. Scale bar, 5µm (C) Quantification of phagocytic activity of RAW264.7 
macrophages. (D) Myeloperoxidase activity of MPRO-differentiated neutrophils decreases 
significantly after treatment with AT-RvD1 conditioned media. Data presented as mean ± 
S.E.M. Statistical analyses were performed using two-tailed t-tests *p<0.05, **p<0.01 n=3 
samples per group. 
3.3.2 AT-RvD1 delivery decreases neutrophil infiltration in the acute phases of 
inflammation 
To explore myeloid cell influx during the inflammatory cascade, the murine dorsal 














imaging of host responses to biomaterial implants including remodeling of microvascular 
networks and changes to the innate immune response following injury and material 
implantation[18, 71, 131]. To evaluate the in vivo infiltration of circulating neutrophils, we 
utilized whole mount immunohistochemistry (IHC) and flow cytometry at days 1 and 3 
after implantation of AT-RvD1-loaded PLGA or unloaded PLGA onto the dorsal tissue. 
For initial analysis, an additional group consisting of 100ng AT-RvD1dissolved in 200	µL 
sterile saline was added to compare the effects of one-time bolus delivery with biomaterial-
mediated delivery. This dosage was chosen based on previous studies utilizing AT-
RvD1[121]. Neutrophils were immunophenotyped as CD45+CD11b+Ly-6C+Ly-
6G+[140]. At day 1, neutrophils were the dominating cell type present out of all 
CD45+CD11b+ myeloid cells. In the tissue, animals treated with AT-RvD1 scaffolds and 
saline-AT-RvD1 solution had a significantly lower frequency of neutrophils compared to 
animals that received unloaded PLGA scaffolds (Figure 3A). This decrease in neutrophils 
present in the tissue was accompanied by a significant increase in the neutrophil frequency 
within the blood of AT-RvD1-treated mice, but not in mice receiving the saline-AT-RvD1 
solution (Figure 3B). All groups undergoing dorsal skinfold window chamber surgery 
demonstrated elevation of blood neutrophils relative to uninjured control animals; 
however, neutrophils were even further elevated in the AT-RvD1 scaffold group (Figure 
3C). By day 3, there were no differences in tissue or blood neutrophils in either group, but 
the overall proportion of neutrophils out of all CD45+CD11b+ cells decreased greatly, 
likely due to the influx of CD45+CD11b+ monocytes (Figure 4A-B). After 1 day, the 
proportion of pro-angiogenic neutrophils expressing CD49d remained unchanged between 
animals given AT-RvD1-loaded implants and PLGA-only implants in both blood and 
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tissue (Figure 3D-E). However, after three days there were significantly more CD49d+ 
neutrophils present in the tissue of animals treated with AT-RvD1 scaffolds, but no 
differences were observed in the blood (Figure 3F-G).  
 
Figure 3. AT-RvD1 treatment sequesters neutrophils in the blood compartment after 
1 day. Flow cytometric analysis of neutrophils after 1 day in the (A) blood and (B) tissue. 
(C) Fold change in blood neutrophils after 1 day compared to blood from an uninjured 
mouse. (D-G) Analysis of CD49d+ neutrophils in tissue and blood at 1 and 3 days after 
film implantation  (H-I) Whole mount immunostaining of Ly-6G+ neutrophil infiltration 
into tissue one day after PLGA or AT-RvD1-loaded PLGA film implant. Scale bars, 
100µm. Data presented as mean ± S.E.M. Statistical analyses were performed using one-
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Figure 4 Tissue and Blood Neutrophils three days after PLGA film implant. The 
overall proportion of neutrophils out of CD45+ CD11b+ cells decreases after three days. 
Flow cytometric analysis of neutrophils in the (A) dorsal tissue and (B) blood three days 
after surgery. 
Qualitative confocal micrographs taken 24 hours after surgery reveal a larger 
number of Ly-6G+ neutrophils in the tissue of mice treated with control PLGA films 
compared to AT-RvD1 film treated animals (Figure 3H-I). A 3D transformation 
representing the distance from CD31+ vasculature was overlaid onto Imaris-rendered 
images to analyze the distance that neutrophils had invaded into the extravascular tissue 
space (Figure 5A-D). Neutrophils in the peri-implant area of PLGA-only scaffolds were 
able to migrate significantly further into the interstitial tissue than neutrophils in the peri-
implant area of AT-RvD1-loaded PLGA scaffolds after 1 day post-injury (Figure 5C). 
However, no difference was found in neutrophil migration through interstitial tissue after 
3 days (Figure 5D). Additionally, 3D analysis of total cell numbers revealed that tissue 
surrounding AT-RvD1 implants have significantly fewer Ly-6G+ neutrophils at both days 
1 and 3 after scaffold implantation (Figure 5E-F). Collectively, these data suggest that local 
A B
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release of AT-RvD1 can suppress neutrophil infiltration and migration in the early stages 
of inflammation. 
 
Figure 5. Localized AT-RvD1 delivery limits neutrophil migration through inflamed 
dorsal tissue. (A-B) Renderings of neutrophil distance from CD31+ vasculature one day 
after film implantation (representative Imaris renderings of Ly-6G+ cells, color-coded 
according to distance from the closest CD-31+ blood vessel: purple=0µm, red= 30µm) (C-
D) Quantification of neutrophil distance to vessel at post-implant days 1 and 3. Imaris 3-d 
quantification of neutrophil numbers after (E) one day and (F) three days. Statistical 
analyses were conducted using two-tailed Mann-Whitney test (C-D) and two-tailed t-test 
(E-F) *p<0.05, ***p<0.001, n>100 cells, across 3-4 animals per group. Scale bars, 100µm 
3.3.3 AT-RvD1 Delivery Increases the Proangiogenic Neutrophil Population After Injury 
 At one and three days following surgery and implantation of either AT-RvD1-
loaded or empty PLGA (vehicle) biomaterial films onto dorsal tissue, the accumulation of 












data (Figure 6A). The resultant SPADE trees are displayed in Figure 6B and Figure 7A. 
The SPADE partitioning algorithm was first able to separate a cluster of CD49d+ cells 
from the greater Ly6G+ neutrophil tree (Figure 6B) and a smaller subset of neutrophils 
expressing high levels of VEGFR1, and CXCR4 from this CD49d+ branch (black box, 
Figure 6B). This second cluster of CD49d+ CXCR4+ VEGFR1+ cells was determined to 
be the pro-angiogenic neutrophils described by Massena et al, and the frequencies of cells 
within these clusters were measured compared to the rest of the SPADE tree[44].  
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Figure 6. SPADE Analysis of Neutrophil Subsets. (A)Experimental schematic  (B) 
SPADE trees colored by pro-angiogenic neutrophil marker expression. The black box 
indicates the population identified by SPADE as proangiogenic neutrophils. (C) Cell 
frequency within highlighted branches at day 3 in AT-RvD1 vs vehicle. (D) Cell frequency 
in the same branches comparing day 1 AT-RvD1 and day 3 AT-RvD1 Data presented as 
mean ± S.E.M. Statistical analyses were performed using two-tailed t-tests *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 n=4 samples per group When comparing the 
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AT-RvD1-loaded films at 1 day after biomaterial implant or when comparing groups 
receiving unloaded films at days 1 and 3 (Figure 7B-C). We then analyzed cell frequencies 
between vehicle and AT-RvD1-loaded films at day 3 and found that delivery of AT-RvD1 
significantly increased CD49d+ neutrophils (Figure 6C). Additionally, we found that 
within the CD49d+ cluster, cells contained in the pro-angiogenic neutrophil cluster were 
significantly increased after AT-RvD1 treatment, comprising nearly 80% of the CD49d+ 
cluster and 40% of the total neutrophils (Figure 6C). Finally, we analyzed AT-RvD1-
treated neutrophils at days 1 and 3 and saw significant increases in the pro-angiogenic 
neutrophil clusters at day 3 (Figure 6D). We also applied tSNE, another dimensionality 
reduction technique to the flow cytometry data and were able to visualize clusters of 
CD49d+ neutrophils at days 1 and 3, and we saw increased clustering of AT-RvD1-treated 
samples around the CD49d+ cluster, lending further support to our SPADE analysis 
(Figure 8). These results demonstrate that treatment of injured tissue with AT-RvD1, a 
proresolving lipid mediator, is able to increase CD49d+ pro-angiogenic neutrophils by day 
3 after injury.  
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Figure 7. Additional Neutrophil SPADE Analysis.(A) SPADE trees colored by marker 
expression levels of remaining panel markers (B-C) Analysis of cell frequency in the 
highlighted SPADE branches comparing Day 1 vehicle vs AT-RvD1 and Day 1 vehicle vs 

































































































































Day 1 Vehicle vs. AT-RvD1








































































































two-tailed t-tests n=4 samples per group .
 
Figure 8. tSNE of Neutrophils at Days 1 and 3. tSNE analysis applied to Ly6G+ 
neutrophils at days 1 and 3 following PLGA film implantation. Plots show separation of 
CD49d+ neutrophils from total neutrophils by CXCR4 and VEGFR1 surface marker 
expression . 
3.3.4 Proangiogenic Neutrophils Treated with AT-RvD1 Display Enhanced Perivascular 
Positioning  
 We then utilized while mount IHC and 3d rendering of confocal images to visualize 
the position of classical Ly6G+ CD49d- and pro-angiogenic neutrophils in peri-implant 
areas (Figure 9A-B). Contrary to SPADE analysis, we observed significant increases in the 
numbers of CD49d+ neutrophils in AT-RvD1-treated peri-implant tissue one day after 
surgery compared to vehicle (Figure 9C,E). This finding is most likely due to local changes 
near the implants that are too small in magnitude to affect the overall cellular profile 
assessed by SPADE. This significant increase in CD49d+ neutrophils was also observed at 
































were accompanied by subsequent significant decreases in both CD49d- neutrophils but also 
total neutrophil numbers compared to vehicle at days 1 and 3 (Figure 10A-D). It has been 
established that AT-RvD1 is able to inhibit the extravasation of classical neutrophils into 
inflamed tissue. Due to the ability of pro-angiogenic neutrophils to migrate independently 
from classical neutrophils, their infiltration is not inhibited and even enhanced by AT-
RvD1 treatment. In addition to observed increases in total CD49d+ numbers, the 
neutrophils exposed to local AT-RvD1 were significantly closer to CD31+ vasculature 
versus vehicle control at both days 1 and 3 (Figure 9 F,H and Figure 10). Given the 
importance of these CD49d+ pro-angiogenic neutrophils to the process of vascular 
remodeling, and recent findings that pro-angiogenic neutrophils migrate to areas of new 
vascular budding, their proximity to CD31+ vessels after injury may indicate their 
participation in forming new vessel networks.  
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Figure 9. Recruitment and infiltration of CD49d+ neutrophils into dorsal tissue(A) 
Experimental schematic. (B) 10x image of the whole mount dorsal skin tissue (C) Confocal 
images and Imaris renderings of neutrophil infiltration into tissue at day 1 (D) Confocal 
images and Imaris renderings of neutrophil infiltration into tissue at day 3 (E-H) 












































































































































vessel at days 1 and 3. Statistical analyses were conducted using two-tailed Mann-Whitney 
test (G-H) and two-tailed t-test (E-F) *p<0.05, ***p<0.001, n>100 cells, across 3-4 animals 
per group. Scale bars, 500 µm for 10x confocal, 100µm for 20x confocal, and 30 µm for 
Imaris  
Figure 10. Neutrophil population distance to vessel measurements(A-D) 
Quantification of Imaris renderings for total neutrophils and CD49d- neutrophils. (E) 
Histograms showing number of neutrophils found within each distance to vessel 
measurement. Statistical analyses were conducted using two-tailed Mann-Whitney test 
(B,D) and two-tailed t-test (A,C) *p<0.05, **p<0.01, ***p<0.001, n>100 cells, across 3-4 
animals per group . 
 These findings represent not only a previously unknown action of AT-RvD1, but 
also promotes the idea that specific subsets of neutrophils are able to be targeted. 


























































































































































































































































































































































































after injury. Previously, other immune subpopulations including monocytes and 
macrophages have been targeted for their roles in the angiogenic process but targeting the 
newly discovered pro-angiogenic neutrophil subset has not been explored until now. These 
exciting new findings have the potential to further our understanding of what mechanisms 
govern early angiogenesis and how we are able to direct the cells involved through 
exogenous factors to enhance vascular network expansion in many contexts. 
3.3.5 AT-RvD1 increases anti-inflammatory monocyte and macrophage populations 
In addition to exploring the effect of local AT-RvD1 on neutrophil infiltration, we 
examined the accumulation of monocyte and macrophage subsets after injury to the dorsal 
skin. After 3 days, 3D renderings show more CD68+ monocytes/macrophages in the peri-
implant tissue of mice treated with AT-RvD1-loaded scaffolds (Figure 11A-B). Following 
quantification, AT-RvD1-treated animals were found to have significantly more CD68+ 
monocytes/macrophages than PLGA-only animals (Figure 11C). Further analysis of 3D 
renderings reveals a significantly lower neutrophil-to-monocyte/macrophage ratio in 
animals treated with AT-RvD1 scaffolds compared to animals that received unloaded 
PLGA scaffolds (Figure 11D). An increase in the ratios of neutrophils to other subsets of 
white blood cells have been associated with persistent inflammation and poor clinical 
outcomes in malignancy and wound healing[141-143].  
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Figure 11. Local delivery of AT-RvD1 increases CD68+ monocytes and macrophages. 
(A-B) Imaris renderings of CD68+ macrophage and Ly-6G+ neutrophil accumulation.  (C) 
Quantification of CD68+ cells found in each Imaris rendering after 3 days. (D) Neutrophil 
to monocyte/macrophage ratio. Scale bars, 100µm. Data presented as mean ± S.E.M. 
Statistical analyses were performed using two-tailed t-test *p<0.05, ***p<0.001, n>100 
cells, across 3-4 animals per group. 
In order to further examine the hypothesis that biomaterial-delivered AT-RvD1 can 
influence the accumulation of anti-inflammatory immune cells, we performed flow 
cytometry to further characterize myeloid cell subpopulations present in the inflamed 
dorsal tissue. Analysis 1 day after injury indicated that there were no differences in 
CD45+CD11b+Ly-6CLo anti-inflammatory monocytes (AM) or CD45+CD11b+Ly-6CHi 
inflammatory monocytes (IM) in the tissue for all groups (Figure 13A-B). After 3 days, 
there were significantly more AMs present in dorsal tissue that had received an AT-RvD1-











immediately following surgery (Figure 12A). Conversely, there were significantly fewer 
IMs present in the AT-RvD1 treated dorsal tissue compared to PLGA-only and topical AT-
RvD1 treatments (Figure 12B). The ratio of AM to IM in the dorsal tissue was significantly 
higher in the AT-RvD1 film-treated animals than in AT-RvD1 topical application or empty 
PLGA implant-treated animals (Figure 12C).  
 
Figure 12. Biomaterial delivery of AT-RvD1 promotes AM and CD206+ macrophage 
accumulation. Flow cytometric analysis of (A) Ly-6CLo AMs and (B) Ly-6CHi IMs. (C) 
Tissue AM/IM ratio. Analysis of (D) M2 (F4/80+ CD206+ CD86-) macrophages and (E) 
M1 (F4/80+ CD206- CD86+) macrophages at day 3. (F) M2/M1 “regenerative ratio” 
analysis. Data presented as mean ± S.E.M. Statistical analyses were performed using one-
way ANOVA with Tukey’s post-hoc test or two-tailed t-test *p<0.05, **p<0.01, 











Figure 13. Tissue monocyte and macrophage levels are unchanged 1 day after 
surgery. Flow cytometric analysis of (A) AMs, (B) IMs, (C) M2s, and (D) M1s present in 
dorsal tissue 
We next immunophenotyped subpopulations of macrophages to explore how AT-
RvD1 delivery impacts macrophage accumulation. No differences were found in the 
frequency of total macrophages between AT-RvD1-loaded PLGA implants and PLGA-
only implants after 1 day (Figure 13C-D). Analysis of digested dorsal tissue after 3 days 
showed that there was a significant increase in the presence of F4/80+CD86-CD206+ 




macrophages[138], in the AT-RvD1 treated mice (Figure 12D). The proportion of M1 
classically activated F4/80+CD86+CD206- macrophages showed a trend of decrease 
(Figure 12E); however, the ratio of M2 to M1 macrophages was significantly increased in 
animals treated with AT-RvD1-loaded implants. Increases in the ratio of M2 to M1 
macrophages have been correlated with increased tissue healing and has consequently been 
called the “regenerative ratio” [70] (Figure 12F). Taken together, this data shows that local 
AT-RvD1 treatment both increases the overall frequency of macrophages present in 
inflamed dorsal tissue after 3 days and induces accumulation of monocyte and macrophage 
subsets that have been associated with tissue regeneration and wound healing. 
3.3.6 AT-RvD1 modulates cytokine expression levels in dorsal tissue 
To better understand how AT-RvD1 delivery impacts the production of 
inflammatory mediators, multiplexed protein analysis was performed on peri-implant 
dorsal tissue both 1 and 3 days post-surgery. The expression levels of known pro-
angiogenic and anti-inflammatory cytokines were significantly increased both 1 and 3 days 
after surgery. There was an increase in the level of VEGF in the AT-RvD1 implant tissue 
after 1 day compared to PLGA implant tissue, which decreased for both groups by day 3 
(Figure 14A). IL-4 expression levels were significantly increased at both day 1 and day 3 
in AT-RvD1 implant tissue, but day 3 expression in AT-RvD1 treated animals was 
decreased compared to day 1 levels (Figure 14B) and the level of SDF-1α was significantly 
increased at day 3 in animals treated with AT-RvD1 implants (Figure 14C). Expression 
levels of other proteins such as MMP-9 and FGF-b were unchanged between AT-RvD1-
implant and PLGA implant animals (Figure 15A-B). Levels of IL-10 were found to be no 
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different between AT-RvD1-implant and PLGA implant animals after 1 day, but all 
samples had IL-10 levels below the limit of detection at day 3 (Figure 15C). 
 
Figure 14. Local delivery of AT-RvD1 modulates the peri-implant cytokine profile 
towards regeneration and angiogenesis. (A) VEGF expression at 1 and 3 days post film 
implantation. (B) IL-4 expression at 1 and 3 days post film implantation. (C) SDF-1𝛂 
expression at 1 and 3 days post film implantation. Data presented as mean ± S.E.M. 
Statistical analyses were performed using two-way ANOVA with Tukey’s post-hoc test 




Figure 15. Cytokine levels in the dorsal skin tissue at 1 and 3 days post-surgery. 
Luminex multi-plex analysis of (A) MMP-9, (B) FGF-β, and (C) IL-10 expression is 
unchanged between groups after dorsal skinfold window chamber surgery. 
3.3.7 AT-RvD1 enhances microvascular remodeling 
In order to determine if the local delivery of AT-RvD1 to injured tissue promotes 
expansion and remodeling of microvascular networks, brightfield imaging of window 
chambers was conducted after material implantation (day 0) and again at day 3 after injury 
(Figure 16A-E). Micrographs were then assessed for changes in the vascular parameters of 
total length, arteriolar diameter, and vascular tortuosity, all of which are classic signs of 
microvascular remodeling[131]. The total length of vasculature normalized to the area of 
analysis (i.e. length density) was unchanged between groups after 3 days (Figure 16E). 
Conversely, a significant increase in both the arteriolar diameter and vascular tortuosity of 
AT-RvD1-treated animals was observed compared to animals receiving PLGA-only 
implants (Figure 16F-G). These changes to the vasculature can be observed in the 
micrographs of AT-RvD1 treatment (Figure 16D), and are absent in the peri-implant area 






























































Figure 16. Delivery of AT-RvD1 promotes vascular remodeling. Brightfield 
micrographs of dorsal tissue at (A, C) day 0 and at (B, D) day 3 following treatment with 
AT-RvD1 loaded PLGA films. Quantification of the vascular metrics (E) length density, 
(F) arteriolar diameter, and (G) tortuosity. Data presented as mean ± S.E.M. Statistical 
analyses were performed using two-tailed t-tests *p<0.05, ***p<0.001 n=6 animals per 














 While we were unable to discern differences in vascular length density using 
brightfield imaging, we have previously demonstrated that whole mount CD31 
immunostaining can reveal changes to capillary-level microcirculation that is undetectable 
by brightfield microscopy[71]. Whole mount confocal images of both background tissue 
away from the biomaterial implant and peri-implant CD31+ immunostained vessels 
revealed small vessels that were not observable with brightfield microscopy (Figure 17A-
D). Analysis of CD31 length per unit area at one day after surgery revealed no differences 
in length density between background and peri-implant area in animals receiving AT-
RvD1-loaded or empty PLGA implants (Figure 17E). However, at day 3, AT-RvD1 
delivery from PLGA films significantly increased the density of CD31+ vessels near the 
implant compared to background and also compared to PLGA-only implant in the window 
chamber (Figure 17F). 
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Figure 17. AT-RvD1 delivery enhances growth of CD31+ microvasculature. Whole 
mount confocal images of dorsal tissue at day 3 following treatment with AT-RvD1-loaded 
PLGA films. (A, C) Background microvasculature and peri-implant vasculature treated 
with (B) PLGA films and (D) AT-RvD1-loaded films. Quantification of microvascular 


























































vasculature, l= peri-implant vasculature. Statistical analysis was performed using 
Repeated Measures two-way ANOVA with Sidak’s post-hoc test for multiple comparisons 
*p<0.05 compared to background, ̂ p<0.05 compared to PLGA implant, n=6, lines connect 
paired analysis of background and peri-implant vasculature in each animal. 
3.4 Discussion 
Acute inflammation is a protective response mounted by the host after injury and/or 
infection[91].  During acute inflammation, polymorphonuclear neutrophils are recruited to 
the site of inflammation through the expression of pathogen- or damage-associated 
molecular patterns [53]-[55].  These neutrophils, along with activated tissue resident 
macrophages, trigger the sequential release of proinflammatory mediators such as 
eicosanoids, cytokines, chemokines, and proteases, and these mediators drive leukocyte 
recruitment and activation[22, 53, 144].  In the case of a minor injury or infection, the acute 
inflammatory response will subside and return to homeostasis via the active process of 
inflammation resolution, signified by diminished number and activity of neutrophils and 
macrophage phenotype switching, phagocytosis, and egress[145, 146].  However, in large 
wounds or in diseases such as arthritis or atherosclerosis, acute inflammation may continue 
unabated and progress to chronic inflammation, where persistent accumulation and 
activation of neutrophils and mononuclear cells results in fibrosis and tissue damage[147-
150].  In the field of biomaterials and tissue engineering, inflammation that is allowed to 
continue unabated can impair host-implant integration and tissue regeneration, leading to 
implant failure[151-154]. Therefore, balancing processes of inflammation and resolution 
are vital to ensuring the success of biomaterial and tissue engineered scaffolds. Here, we 
utilized a locally-delivered dual-acting lipid mediator to regulate active inflammatory 
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processes and drive resolution by inhibiting neutrophil infiltration and increasing the 
presence of anti-inflammatory monocytes and macrophages. 
Resolvins are in a class of molecules that have been deemed specialized pro-resolving 
mediators that are produced during the acute inflammatory response. Their actions drive 
the restoration of tissue homeostasis and prevention of fibrosis after the acute inflammatory 
response through a dual anti-inflammatory pro-resolution mechanism by which the 
activities of pro-inflammatory cells are dampened and those of anti-inflammatory cells are 
enhanced[113]. Currently, there are many studies investigating resolvins for various 
therapeutic applications that seek to leverage their pro-resolving function. For example, 
intravenous AT-RvD1 can suppress inflammatory responses and protects against kidney 
injury in a murine model of acute kidney injury[155]. Additionally, RvD1 can modulate 
human and murine T cell differentiation, while enhancing the generation of T-regulatory 
cells[101]. While these studies have shown promising therapeutic uses for AT-RvD1, little 
exploration has been done into the utilization of biomaterials to locally deliver AT-RvD1 
to areas of inflammation after injury. We have shown here for the first time that sustained 
delivery of AT-RvD1 from PLGA scaffolds over several days results in differences in 
myeloid cell accumulation to skin after injury compared to a one-time dose of dissolved 
AT-RvD1. The dosage of AT-RvD1 delivered via topical saline was 100ng, while 10.2ng 
AT-RvD1 on average were loaded into each biomaterial film. We found that both 
biomaterial-delivered AT-RvD1 and AT-RvD1 solution were able to significantly reduce 
neutrophil infiltration after one day, but only AT-RvD1-loaded scaffolds were able to 
increase Ly6Clo AMs, while decreasing Ly6Chi IMs after three days, indicating that 
sustained release at a lower dose is better able to modulate the cellular response after injury. 
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These findings motivated us to investigate further how local delivery of AT-RvD1 via a 
biomaterial is able to modulate inflammation and promote tissue regeneration. 
In the process of wound healing without infection, it was previously believed that 
neutrophils had little to no bearing on the outcome of tissue repair[156]. However, recent 
studies exploring the role of neutrophils in wound healing have shown that excessive 
neutrophil infiltration into tissue can impair repair through the release of neutrophil 
extracellular traps (NETs), reactive oxygen species (ROS) and proteolytic enzymes, 
specifically in the context of diabetes and post-myocardial infarction cardiac remodeling 
[82, 128, 130, 156-158]. Excessive neutrophil recruitment and persistent activation is 
associated with chronic inflammation, fibrosis, and poor healing [33, 159, 160] . 
Additionally, targeted depletion of neutrophils in mice has been found to accelerate wound 
closure[161].  High neutrophil counts in relation to lymphocytes and macrophages have 
also been clinically associated with poor outcomes in a number of diseases, including colon 
cancer and atherosclerosis[162, 163].  For instance, patients with an elevated neutrophil to 
lymphocyte ratio are more likely to experience cardiac death and mortality after acute 
myocardial infarction [158, 164], and mice with pancreatic cancer that have an elevated 
neutrophil-to-macrophage ratio are more likely to develop severe ascites or bowel 
obstruction[142].  In the present study, we demonstrate reduced neutrophils present at one 
day after injury in mice treated with AT-RvD1-loaded films via flow cytometry and 
quantification of whole mount IHC. Resolvins have been shown to block neutrophil 
transendothelial migration through inhibition of neutrophil chemotaxis towards cytokine 
gradients created during the inflammatory process[165]. Neutrophil levels were elevated 
in the blood but reduced in tissue, and neutrophils that did migrate into the tissue were 
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unable to infiltrate further through the tissue. These data suggest that the local delivery of 
AT-RvD1 can not only block transendothelial migration of neutrophils as has been 
demonstrated previously via systemic treatment with resolvins, but can also prevent further 
tissue damage by inhibiting neutrophil migration through the interstitial tissue. Animals 
treated with AT-RvD1 also had a lower neutrophil-to-monocyte/macrophage ratio at 3 days 
after surgery, and we propose that this metric can be used to indicate a positive correlation 
to inflammation resolution and the prevention of chronic inflammation.  
During tissue regeneration, the remodeling and expansion of wound-associated 
vasculature is critical to ensure tissue oxygenation, nutrient delivery, and cell recruitment 
[71]. Recently, a newly discovered subset of neutrophils has been described that stimulate 
angiogenesis in response to VEGF[44]. We have found that CD49d+ neutrophils 
accumulate in injured dorsal tissue three days after treatment with AT-RvD1-loaded films, 
and these neutrophils can actively participate in vascular remodeling and network 
expansion. We have previously shown that the recruitment of Ly6Clo AMs using SDF-1α-
loaded hydrogels or FTY720-releasing films is associated with increased angiogenesis and 
arteriogenesis during inflammation[18, 71, 166]. Here we have shown that the local 
delivery of AT-RvD1 is able to enhance accumulation of AMs in the dorsal tissue as early 
as three days after surgery. In addition to increasing the ratio of AMs to IMs, M2 
alternatively activated macrophages were also increased in the tissue of AT-RvD1-loaded 
film-treated animals. These specific subsets of monocytes and macrophages are able to 
directly influence vascular remodeling [59, 167, 168], and increased AM/IM and M2/M1 
ratios are associated with enhanced tissue regeneration and healing[70, 71]. The 
mechanisms of these observed increases in anti-inflammatory subsets of monocytes and 
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macrophages could be a result of increased monocyte recruitment from circulation.  
Alternatively, AT-RvD1 may alter in situ monocyte/macrophage polarization towards 
AM/M2 due to direct action by AT-RvD1 on macrophages or through external factors, 
such as phagocytosis of apoptotic neutrophils[169]. Local AT-RvD1 delivery was also able 
to modulate the peri-implant cytokine profile towards a pro-angiogenic/arteriogenic 
environment, with significant elevation in VEGF, SDF-1α, and IL-4, cytokines that 
contribute to vascular remodeling and the recruitment of cells that participate in vascular 
remodeling[170-173]. Indeed, the enhanced arteriolar diameter and vascular tortuosity we 
observed with brightfield microscopy and expansion of microvasculature observed with 
confocal imaging 3 days after implantation are early hallmarks of sustained arteriogenesis 
and vascular remodeling. 
Taken together, localized delivery of AT-RvD1 allows for dual targeting of both 
pro-inflammatory and pro-regenerative cells involved in inflammation and wound healing. 
Modulation of initial neutrophil infiltration allows for reduced overall tissue damage and 
primes the tissue for regeneration and healing. Enhanced accumulation of anti-
inflammatory monocyte and macrophage cell subsets further reduce inflammation and 
promote early tissue regeneration and vasculogenesis. These results establish localized 
delivery of AT-RvD1 as a promising approach to modulate the innate immune response to 
reduce tissue damage associated with excessive inflammation and promote therapeutic 
outcomes such as vascular remodeling. 
3.5 Materials and Methods 
3.5.1 Fabrication of loaded and unloaded polymeric thin films 
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Films loaded with AT-RvD1 or unloaded were made as previously described[18]. 
Briefly, PLGA (50:50 DLG 5E – Evonik Industries) was solubilized in dichloromethane 
using a sonicator at 37°C until dissolved. Ten µg (100µL) AT-RvD1 (Cayman Chemical) 
were added to make AT-RvD1-loaded films. Solutions were cast in Teflon molds, and 
stored at -20°C until full organic solvent evaporation was observed. Films were then 
lyophilized for 24 hours. A 1mm biopsy punch was used to produce films used in studies. 
The morphology of the films were examined by scanning electron microscopy (SEM). 
Films were coated with Au for 45 seconds by a Quorum Q-150T ES sputter coater and 
imaged with a Hitachi SU8010 field emission scanning electron microscope. 
3.5.2 Quantification of AT-RvD1 release from PLGA films via High Performance Liquid 
Chromatography (HPLC) measurements 
The in vitro release of AT-RvD1 from PLGA films was quantified with HPLC. In 
the release study, 1mm diameter films were placed into 200µL phosphate-buffered saline 
(PBS) and incubated at 37°C. At predetermined timepoints, the PBS was removed for 
analysis and replaced with new PBS. Samples were analyzed with a Shimadzu UFLC High 
Performance Liquid Chromatograph (Columbia, MD, USA) equipped with a Shimadzu 
Premier C18, 5µm (250x4.6mm) column. AT-RvD1 elution was measured at 8.6 minutes 
using a wavelength of 301nm. Known quantities of AT-RvD1 were used to generate a 
standard curve relating AT-RvD1 mass to total peak area. Using serial dilutions, we 
determined that the limit of detection was below 0.5pg/µL. The total amount of AT-RvD1 
in each release sample was calculated using the standard curve. 
3.5.3 In vitro macrophage phagocytosis assay 
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AT-RvD1-loaded PLGA films and empty PLGA films were placed into 1mL 
Dulbecco's modified Eagle medium (Gibco) containing 1mM sodium pyruvate (Gibco) and 
2mM L-glutamine (Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco) 
overnight. Conditioned media was added to 1x105 RAW264.7 cells (ATCC) cultured in 
24-well plates. After one hour of treatment, Fluoresbrite® Polychromatic Red latex beads 
(0.5μm, Polysciences) that were opsonized in 10% FBS for 60 minutes were added at a 
ratio of 5:1 beads per cell and were allowed to incubate at 37°C for 4 hours. After 
incubation, the media was removed and cells were fixed with ice cold methanol for 10 
minutes. Fixed cells were then imaged via brightfield and epifluorescence microscopy to 
detect both cells and phagocytized latex beads. These images were merged in ImageJ, and 
the total number of beads internalized by cells were counted. 
3.5.4 Myeloperoxidase activity of neutrophils 
MPRO neutrophil progenitor cells (ATCC) were cultured using Iscove's modified 
Dulbecco's medium (Gibco) containing 10 ng/ml murine granulocyte macrophage colony 
stimulating factor, 80% and heat-inactivated horse serum, 20%. Terminal granulocytic 
differentiation of MPRO cells was initiated by replating cells in fresh medium containing 
1 × 10−5 M all-trans Retinoic Acid and culturing for one week to ensure full differentiation.  
AT-RvD1-loaded PLGA films and empty PLGA films were placed into 1mL MPRO 
differentiation medium overnight. Release media was added to 1x106 differentiated 
neutrophils and cells were treated for four hours. Myeloperoxidase (MPO) activity was 
then measured using a Colorimetric Activity Assay Kit (MAK068, Sigma) according to kit 
instructions at a sample size of 1x105 cells per well. 
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3.5.5 Dorsal skin fold window chamber surgery 
Animal experiments were performed using sterile techniques in accordance with an 
approved protocol form the Georgia Institute of Technology Institutional Animal Care and 
Use Committee. Male C57BL/6 mice (Jackson) aged 6-12 weeks were anesthetized by 
inhaled isofluorane and surgically fitted with sterile dorsal skinfold window chambers (APJ 
Trading Co.) as previously described[18] . Briefly, the dorsal skin was shaved, depiliated, 
and sterilized via three washes with 70% ethanol and chlorhexidine. The dorsal skin was 
drawn away from the back of the mouse and one side of the titanium frame was attached 
to the underside of the skin. Sterile surgical micro scissors were then used to expose the 
microvasculature through the removal of the epidermis and dermis in a 12mm diameter 
circle. Mice were implanted with two of the same films (either empty PLGA vehicle film 
or AT-RvD1-loaded PLGA film) placed on opposite sides of the window chamber. Before 
implantation, the films were washed in 70% ethanol for 30 seconds, followed by washing 
with sterile Ringer’s solution for 30 seconds. Exposed tissue was then sealed with a sterile 
glass coverslip. Mice were administered sustained-released buprenorphine i.p. (0.1-0.2 
mg/kg) and allowed to recover in heated cages.  All mice received standard laboratory diet 
and water ad libitum throughout the course of the experiment. 
3.5.6 Vascular metrics 
Mice were anesthetized with isofluorane, the glass window was removed, and 
dorsal tissue was superfused with adenosine in Ringer’s solution (1mM) to prevent 
desiccation and to maximally dilate exposed vessels. The mouse was mounted on a 
microscope stage and imaged non-invasively at 5x magnification on a Zeiss Imager.D2 
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microscope with AxioCam MRC 5 color digital camera (Zeiss). Images were acquired on 
day 0 immediately following film implantation and again on day 3. Microvascular length 
density measurements were made within a 4000x4000 pixel square region of interest (ROI) 
around the film. Vessels within these ROIs were traced and total vessel length per unit area 
was quantified via ImageJ. Arteriolar diameter measurements were made within the ROIs 
by identifying arteriolar-venular pairs at day 0. Internal diameter changes were measured 
via ImageJ and day 3 diameters were normalized to day 0. Vascular tortuosity 
measurements were made within the ROIs by measuring the distance metric – the path 
length of a meandering curve divided by the linear distance between endpoints in ImageJ. 
3.5.7 Tissue harvest and flow cytometry 
To collect samples for flow cytometry analysis, mice were euthanized via CO2 
asphyxiation. Peripheral blood was collected via cardiac puncture. Erythrocytes within 
blood were lysed with ammonium chloride (StemCell Technologies) and the remaining 
leukocytes were isolated for flow cytometry analysis. Bone marrow was collected via 
centrifugation (1000g for 5 mins) of isolated tibiae. The dorsal tissue was excised and 
digested with collagenase type 1-A (1mg/ml, Sigma) at 37°C for 30 minutes and further 
separated with a cell strainer to create a single cell suspension. Single cell suspensions of 
tissues, blood, and bone marrow were stained for flow cytometry analysis using standard 
methods and analyzed on a FACS-AriaIIIu flow cytometer (BD Biosciences). The 
antibodies used for identifying cell populations of interest were: PerCP-Cy5.5 conjugated 
anti-CD45 (BioLegend), APC-Cy7 conjugated anti-CD11b (BioLegend), BV421 
conjugated anti-CD11b (BioLegend), APC conjugated anti-Ly6C (BioLegend), BV510 
conjugated anti-Ly6C (BioLegend), APC-Cy7 conjugated anti-Ly-6G (BioLegend), PE-
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Cy7 conjugated anti-GR-1 (BioLegend), APC conjugated anti-F4/80 (BioLegend), PE-Cy7 
conjugated anti-CD206 (BioLegend), AlexaFluor488 conjugated anti-CD86 (BioLegend), 
PE conjugated anti-CD49d (BioLegend), PerCP-Cy5.5 conjugated anti-CXCR4 
(Biolegend), APC conjugated anti-VEGFR1 (Biolegend), and PE-Cy7 conjugated anti-
VEGFR2 (Biolegend). Staining using BV dyes was performed in the presence of Brilliant 
Stain Buffer (BD Biosciences). Positivity was determined by gating on fluorescence minus 
one controls. 
3.5.8 High dimensional analysis of flow cytometry data 
 t-SNE is a nonlinear dimensionality reduction algorithm developed by van der 
Maaten and Hinton21. T-SNE is able to embed high-dimensional data into a space of two 
or three dimensions, which is then be visualized in the form of a scatter plot, where similar 
cells are represented by nearby points and dissimilar cells are represented by distant points. 
Prior to tSNE dimensional reduction, each flow cytometry sample was pre-gated to select 
live, single cells, CD11b+ Ly6G+ neutrophils and then downsampled to up to 1500 events 
in FlowJo Version 10.2. After downsampling, each sample was electronically barcoded so 
that all samples could be concatenated to into a single file for tSNE analysis. A composite 
tSNE map that utilized data points from all samples (8 total samples: 4 vehicle and 4 AT-
RvD1, repeated for day 1 and day 3). tSNE analysis was executed in FlowJo software using 
the following surface markers: CD11b, Ly6G, CD49d, CXCR4, VEGFR1, and VEGFR2. 
The following tSNE parameters were used: 1000 iterations, 30 perplexity, 200 Eta 
(learning rate), and 0.5 theta. 
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 SPADE1,2 is a visualization tool that was initially designed to organize 
heterogeneous populations of single-cell data onto a 2D tree representation on the basis of 
similarities across user-selected markers. The nodes of the tree represent clusters of cells 
that are similar in marker expression. SPADE uses the size and color of each node to denote 
the number of cells and median marker expression. SPADE was performed through 
MATLAB. MATLAB-based SPADE automatically generates the tree by performing 
density-dependent down-sampling, agglomerative clustering, linking clusters with a 
minimum spanning-tree algorithm and up-sampling based on user input. The SPADE tree 
was generated by exporting uncompensated pre-gated live, single cells, CD11b+ Ly6G+ 
neutrophils. The markers used to build the SPADE tree were SSC, FSC, CD11b, Ly6G, 
CD49d, CXCR4, VEGFR1, and VEGFR2. The following SPADE parameters were used: 
Apply compenstation matrix in FCS header, Arcsinh transformation with cofactor 150, 
neighborhood size 5, local density approximation factor 1.5, max allowable cells in pooled 
downsampled data 50000, target density 20000 cells remaining, and number of desired 
clusters 100. The resultant SPADE tree was auto-annotated by MATLAB based on 
differences in marker expression. 
3.5.9 Tissue whole mount immunohistochemistry and confocal imaging 
Following euthanasia, mouse vasculature was perfused with warm saline and then 
with 4% paraformaldehyde until tissues were fixed. The dorsal tissue was excised and 
permeabilized overnight at 4°C with 0.2% saponin. The tissues were blocked overnight in 
10% mouse serum at 4°C. Tissues were incubated at 4˚C overnight in staining solution 
containing 0.1% saponin, 5% mouse serum, 0.5% fatty-acid free bovine serum albumin, 
and the following fluorescently conjugated antibodies: Alexa Fluor 594 anti-CD31 
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antibody (1:100 dilution, BioLegend) for blood vessel visualization, Alexa Fluor 488 anti-
Ly-6G (1:200 dilution, BioLegend) for visualization of neutrophils, Alexa Fluor 647 anti-
CD68 (1:200 dilution, ABD Serotec) for visualization of monocytes/macrophages, and 
Alexa Fluor 647 anti-CD49d (1:200 dilution, BioLegend) for visualization of pro-
angiogenic neutrophils[174]. Tissues were washed four times for 30 minutes with 0.2% 
saponin and once with PBS and then mounted in 50/50 glycerol/phosphate buffered saline. 
Mounted samples were imaged on a Zeiss LSM 710 NLO confocal. Tiled z-stacks at 10x 
magnification were taken for analysis of CD31+ vasculature. Crops of 1000x1000 pixels 
of background vasculature or peri-implant vasculature were used for measurement of 
CD31+ length density. For vessel density measurements, vessels were traced and total 
vessel length per unit area was quantified via ImageJ. Crops of 332x332µm at 20x 
magnification in the peri-implant area were taken for image analysis in Imaris™ (Bitplane). 
Images were then blinded and rendered in Imaris by a third party. Cells expressing Ly-6G 
or CD68 were identified in Imaris using the surface tool. Pro-angiogenic neutrophils co-
expressing CD49d and Ly-6G were also identified using the surface tool. Ly-6G+, CD68+, 
or Ly-6G+CD49d+ surfaces were identified by smoothing with a 1µm grain size and 
automatic thresholding on absolute intensity. Touching objects were split using a seed 
points diameter of 10µm. CD31+ vasculature was identified in Imaris using the same 
surface method as described above, also applying a 1µm grain size, but instead manually 
selecting the threshold value optimized for each image, and manually applying the volume 
filter to remove small debris. Distance to vasculature calculations between neutrophils and 
CD31+ vasculature were made by applying a distance transformation to the CD31+ surface 
and recording the median position of each neutrophill relative to CD31+ vessels.  
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3.5.10 Cytokine measurements 
For cytokine measurements, 4mm biopsy punches of tissue centered around each 
biomaterial implant were harvested after euthanasia. Tissue biopsy punches were 
combined for each animal, digested for 30 min at 37°C in 1mg/mL collagenase-type 1A, 
and disaggregated through a cell strainer. Protein was isolated from the single cell 
suspension in RIPA buffer containing Halt™ Protease and Phosphatase Inhibitor Cocktail 
(diluted to 1X, ThermoFisher Scientific) for 45 minutes on ice. Following cell lysis, total 
protein was obtained by centrifugation for 15 minutes at 14,000xg and 4°C. To determine 
the total protein concentration in each sample, a bicinchoninic acid assay (BCA assay) was 
carried out using a Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific) according 
to kit instructions. Cytokine measurements were made using the Mouse Magnetic Luminex 
Screening Assay (catalog number LXSAMSM, R&D Systems) according to kit 
instructions. Kit analytes included CCL2/MCP-1/JE, CXCL12/SDF-1α, FGF-β, G-CSF, 
GM-CSF, IFN-γ, IGF-1, IL-10, IL-12p70, IL-4, IL-6, MMP-9, TNF-α, and VEGF. 
Cytokine results were normalized to sample total protein. 
3.5.11 Statistical analysis 
All statistical analyses were performed using Graphpad Prism version 6.0 (La Jolla, 
CA). Results are presented as mean ± standard error of the mean (SEM). For pairwise 
comparisons, unpaired two-tailed t-tests with Welch’s correction, if variance was 
significantly different, were used. For grouped analyses, one-way ANOVA with Tukey’s 
post-test was used for multiple comparisons. For grouped analyses comparing data over 
time, two-way ANOVA with Tukey's post-hoc test was used. Unless otherwise noted, 
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p<0.05 was considered statistically significant. For analysis of cellular distance to 
vasculature, data reflect cells counted from three ROIs acquired across 3-4 animals per 
group, and statistical comparisons were made using a two-tailed Mann-Whitney test. 
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CHAPTER 4. DUAL-LOADED IMMUNOMODULATORY 
HYDROGELS RECRUIT PRO-REGENERATIVE INNATE AND 
ADAPTIVE IMMUNE CELLS TO AREAS OF INJURY 
4.1 Introduction 
 The immune response to injury is a complex process that involves the orchestration 
of functions of many different cell populations that work in coordination to restore tissue 
homeostasis. In healthy individuals or in the case of small wounds, tissue regeneration and 
the return to normal function proceed without any necessary outside intervention. 
However, in the case of large wounds or in disease states such as diabetes or after organ 
transplant, the process of the immune response to wound healing is dysregulated and may 
prevent normal tissue regeneration, leading to wound closure failure or a chronic 
inflammatory state. In order to mitigate the immune dysregulation present during these 
states, there is a rapidly expanding body of research dedicated to the targeting and 
manipulation of the immune response to injury and inflammation. Extensive research has 
been carried out describing the roles of single immune populations during the process of 
tissue regulation. For example, depletion of neutrophils has been shown to delay wound 
closure in aged mice, and clinical observations note that neutropenic individuals often have 
difficulty healing wounds [25, 39]. Additionally, ablation of monocyte and macrophage 
pools in zebrafish and salamanders have resulted in failure of limb or tail regeneration, 
indicating their indispensability to the regenerative process  [26, 27]. These studies 
demonstrate the extensive crosstalk and interplay between cell types during wound healing 
– that no one cell is the master orchestrator of tissue regeneration. 
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 Although it is clear that there is no one cell responsible for the coordination of the 
regenerative process, there are specific cell subsets within the larger umbrella of immune 
cells that have been positively identified as “pro-regenerative”. Within the monocyte and 
macrophage families, subsets have been identified in both mice and humans that have 
disparate functions and roles during inflammation. Monocytes may exist as classical 
monocytes (CD11b+Ly6Chi in mice and CD14+CD16- in humans) that exhibit largely 
pro-inflammatory characteristics – or as patrolling non-classical monocytes 
(CD11b+Ly6Clow in mice and CD14lowCD16+ in humans) [47]. These non-classical 
monocytes patrol the resting endothelium during homeostasis, but after injury they 
infiltrate into tissue and secrete VEGF, TGF-ß, and IL-10 and are able to promote 
angiogenesis and matrix deposition [49, 175-177]. We have shown that targeted 
recruitment of these specific monocytes enhances microvascular network expansion after 
sterile injury, and that they are able to preferentially expand the population of “anti-
inflammatory” macrophages [61, 94, 166, 178]. By extension, macrophages exist in vivo 
on a spectrum from M1 “pro-inflammatory” to M2 “anti-inflammatory” [179]. M2 anti-
inflammatory macrophages are identified by their expression of the mannose receptor 
CD206 along with canonical macrophage markers MerTK and CD64 [168]. These M2 
macrophages can be further divided into M2a-c subsets, and the M2a and M2c subsets 
have, in particular, been shown to exhibit pro-regenerative, anti-inflammatory 
characteristics, such as the ability to release IL-10, support angiogenesis, and ameliorate 
fibrosis and tissue damage in the context of kidney injury, lung injury, and myocardial 
infarction [18, 23, 70-72]. In addition to the mononuclear phagocyte system, we now know 
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that other cells in the innate and adaptive immune systems can also positively influence 
regeneration. 
 Dendritic cells (DCs) are antigen presenting cells that release cytokines and are 
responsible for influencing both innate and adaptive immune responses after microbial 
infection or tissue injury. Traditionally, their function is to detect and capture foreign 
antigen and present those antigens to T lymphocytes to induce their activation, 
differentiation, and subsequent action [180]. Additionally, DCs are also involved in 
promoting tolerance to self-antigens and can induce regulatory T cell (Treg) expansion 
under the correct conditions[181]. Previously, their roles in wound healing were 
unexplored, but new studies have shown that DCs are active mediators of healing after 
injury, and depletion of DCs adversely affects burn wound healing and ventricular function 
after myocardial infarction [182-184]. These studies indicate an under-studied cell 
population that has the ability to tune the wound healing response. On the adaptive immune 
side, the role of Tregs in wound healing is gaining increased recognition. Tregs are 
CD3+CD4+CD25+ lymphocytes that have the ability to suppress T effector cell responses 
and induce anergy. Tregs are most commonly recognized for their roles in inhibiting 
autoimmunity through the release of immune inhibitory cytokines such as TGF-ß and IL-
10 and blocking T lymphocyte costimulation via CTLA-4 [86, 109, 185, 186]. Recently, 
Tregs have also been shown to be critical for repair and regeneration in numerous tissues 
after injury, including skin, lungs, skeletal muscle, and cardiac muscle [74-78]. It is clear 
that there are a multitude of immune cell subsets that can aid in the promotion of tissue 
repair after injury and enriching the wound microenvironment with as many of these pro-
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regenerative cells as possible is one strategy in the quest to increase the body’s ability to 
respond to injuries. 
 One strategy for modulating the local immune cell population after injury is through 
local delivery of biomolecules via implanted biomaterials. Because we are seeking to 
recruit immune cells able to stimulate repair from many branches of the immune, it is 
unlikely that delivery of one biomolecule will be able to sufficiently affect the recruitment 
of all cell subsets of interest. Therefore, we have identified two bioactive factors capable 
of eliciting this response: aspirin-triggered resolvin d1 (AT-RvD1) and IL-10. AT-RvD1 
is part of a class of “specialized proresolving mediators” (SPMs) capable of redirecting the 
immune response towards resolution [187]. SPMs have broad effects over a variety of 
myeloid cells, including the limitation of neutrophil transendothelial migration, the 
modulation of cytokine release from monocytes and macrophages, and the prevention of 
dendritic cell maturation[113, 155, 188]. AT-RvD1 has been shown to mitigate tissue 
injury after asthma-induced lung injury, acute kidney injury, and in a model of the 
autoimmune disease Sjögren’s syndrome [121, 155, 189]. 
 Interleukin 10 (IL-10) is a cytokine which plays a critical role in the control of 
immune responses. It is expressed by both innate and adaptive immune cells including 
monocytes, macrophages, dendritic cells, and T cell subsets [105]. IL-10 treatment of 
dendritic cells prevents maturation, resulting in decreased MHC-II surface receptor 
expression and subsequent increased release of IL-10 [107]. These IL-10-producing DCs 
have the ability to induce functional Tregs, and IL-10 signaling on Tregs is required for 
Treg suppression of the TH17 responses [106, 190]. Additionally, IL-10 can act on other 
T helper subsets to prevent their costimulation and proliferation [105]. Aside from its 
 68 
actions on antigen presenting cells and adaptive immune cells, IL-10 has been shown to 
play an essential role in the regulation of scar formation during wound healing and can 
reduce fibrotic deposition and scar formation after injury [106, 191]. These qualities of IL-
10 make it an attractive agent for the promotion of wound healing due to its ability to direct 
anti-inflammatory effector functions of lymphoid cell subsets.  
 Previously, we have shown that local delivery of AT-RvD1 via biomaterial is able 
to increase the recruitment and accumulation of anti-inflammatory, pro-regenerative 
myeloid immune cells. Here, we seek to draw upon and extend our previous findings 
through the development of a dual-delivery hydrogel system capable of enriching the injury 
niche with not only known anti-inflammatory myeloid populations, but anti-inflammatory 
lymphocyte populations as well. We chose to co-deliver the lipid small molecule AT-RvD1 
along with the protein IL-10 with the goal of attaining dual delivery kinetics of these two 
factors. We characterize the release kinetics and bioactivity of a hydrogel loaded with 
modified human IL-10 and AT-RvD1 and show that thiolation of IL-10 can allow for 
tethering to the PEG-MAL hydrogel backbone without affecting the bioactivity of IL-10. 
Using the murine dorsal skinfold window chamber as a test bed to measure the response to 
immunomodulatory hydrogels, we demonstrate that not only is the recruitment of anti-
inflammatory myeloid cells enhanced by AT-RvD1 delivery, but combination IL-
10+ATRvD1 treatment is able to concurrently increase populations of dendritic cells and 
T cells involved in wound healing. These results indicate that dual delivery of IL-10 and 
AT-RvD1 has broad effects on the recruitment of pro-regenerative, anti-inflammatory 
innate and adaptive immune cells and can result in the modulation of the immune response 




4.2.1 Thiolation of IL-10 modulates the release profile but maintains bioactivity 
 We engineered degradable poly(ethylene glycol) (PEG) hydrogels using 10 kDa 4-
arm PEG macromers containing terminal maleimide groups (PEG-MAL) that can react 
with free cysteines on peptides or full-length proteins.  PEG-MAL macromers were 
crosslinked with the cysteine-flanked peptide GCRDVPMSMRGGDRCG (VPM) that 
contains a protease cleavage site (Figure 18A). Combination of functionalized PEG-MAL 
with VPM spontaneously forms a hydrogel in less than 1 minute (Figure 18B). Human IL-
10 does not possess a free cysteine in its structure and cannot interact with PEG-MAL 
macromers during hydrogel formation. We loaded 250ng fluorescently tagged unmodified 
human IL-10 into a hydrogel and measured its release. The hydrogels released the 
unmodified IL-10 very quickly, with 58.24 ± 0.67ng released within the first 30 minutes 
(Figure 18C), 175 ±1.34ng after 2 hours and 209.62 ± 1.73ng after 6 hours. At 24 hours, 
the gels had released 227.40 ± 1.71ng of the loaded IL-10, over 90% of the initial dose. By 
day 5, 235 ± 1.73ng total IL-10 was released from the gel, and only 22.39 ± 4.85ng was 
recovered from the digested gel. We then attempted to functionalize the IL-10 with free 
cysteines in order to allow for interaction with the PEG-MAL macromer, which could then 
result in a more gradual release. We chose to thiolate the iL-10 using Traut’s reagent (2-
iminothiolane), a thioimidate compound that reacts with primary amines to form sulfhydryl 
groups. Using a molar excess of 30 for Traut’s reagent, the concentration of thiol groups 
found on the IL-10 was determined to be 0.893 ± 0.98 uM. This corresponds to roughly 3 
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free cysteine groups per IL-10 molecule. When the release of thiolated IL-10 from PEG-
MAL hydrogels is measured, we found that the thiolation greatly affects the kinetics. In 
contrast to the unmodified IL-10, thiolated IL-10 releases 7.67 ± 2.76 ng after 30 minutes, 
26.91 ± 2.91 ng at 2 hours, 32.39 ± 2.67ng at 6 hours, and 42.03 ± 2.45ng by 24 hours 
(Figure 18C). The thiolated IL-10 released gradually with a measured release of 73.28 ± 
3.55ng at 5 days, with 176.72 ± 5.42 ng remaining IL-10 that recovered from the gel after 
digestion (Figure 18D). We also measured the release of AT-RvD1 from the PEG-MAL 
hydrogels. AT-RvD1 was released from the gels in a manner similar to that of the 
unmodified IL-10, with 87.66 ± 1.29ng of the total loaded 100ng  dose released by 24 
hours. By day 5, only four more nanograms were released, and the total release was 
measured to be 91.24 ± 1.11ng (Figure 18E). When the release was measured from dual-
loaded gels, no effect of dual loading was observed on either release profile (not shown). 
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Figure 18. Hydrogel schematics, release profiles, and bioactivity. (A)Hydrogel 
fabrication method (B) Resultant macroscopic image of preformed hydrogels (C) Release 
of unthiolated and thiolated IL-10 from 10kDA PEG-MAL hydrogels over the course of 5 
days (D) Amount of IL-10 or thiolated IL-10 remaining in the gels at the end of the release 
study. (E) HPLC measurements of AT-RvD1 release from PEG-MAL hydrogels. (F) 
Bioactivity assay schematic (G) Bioactivity of IL-10 following thiolation and PEG 
conjugation (H) Bioactivity of AT-RvD1 and IL-10 combinations. Statistical analysis was 
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 We then wanted to ensure that the thiolation of IL-10 or subsequent conjugation 
with PEG-MAL did not have an effect on its bioactivity. IL-10 has previously been shown 
to suppress TNF- α release by RAW264.7 macrophages after treatment with LPS [192]. 
We adapted the assay reported previously and utilized intracellular cytokine staining and 
flow cytometric analysis to assess TNF- α levels in RAW264.7 macrophages (Figure 18F). 
First, we compared unmodified IL-10, thiolated IL-10 (t-IL-10), and thiolated IL-10 
conjugated with PEG-MAL (PEG-t-IL-10) and found that all three were able to 
significantly reduce TNF- α expression after treatment with LPS compared to vehicle 
control (Figure 18G). We then compared thiolated IL-10 to AT-RvD1 and co-treatment of 
AT-RvD1 and IL-10. Again, we observed a significant reduction in TNF- α expression 
across all groups after LPS treatment compared to control (Figure 18H). Altogether, this 
characterization data indicates that thiolation with Traut’s reagent is able to modify the 
release of IL-10 while maintaining its bioactivity, and that dual loaded hydrogels 
containing thiolated IL-10 and AT-RvD1 have temporally independent release profiles. All 
subsequent experiments utilized thiolated IL-10, and IL-10 in text and figures will refer to 
thiolated IL-10. 
4.2.2 Immunomodulatory PEG-MAL hydrogels alter myeloid recruitment dynamics  
 We utilized the murine dorsal skinfold window chamber model to characterize the 
immune response to immunomodulatory PEG-MAL hydrogels after tissue injury. This 
model allows for quantification of host responses to injury and biomaterials through 
methods including flow cytometry and cytokine measurements, as well as longitudinal 
intravital imaging to track real-time inflammation-mediated remodeling of microvascular 
networks [18, 61, 71]. To examine the recruitment of circulating myeloid cells to the 
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injured dorsal tissue we utilized flow cytometry at days one, three, and seven after injury 
and implantation of the hydrogels. Animals received one unloaded hydrogel injected on 
one side of the window chamber and a hydrogel loaded with AT-RvD1, thiolated IL-10, or 
both AT-RvD1 and thiolated IL-10 combination treatment (Figure 19A). 
 
Figure 19. In vivo experimental overview and flow gating strategy (A) Experimental 
overview of dorsal skinfold window chamber experiments and hydrogel placement. (B) 



























































 The hydrogels contained 100ng AT-RvD1 and 250ng IL-10, and these doses were 
chosen based on prior studies utilizing these treatments [193, 194]. Neutrophils and 
monocytes were gated out of T cells, B cells, macrophages, and dendritic cells (Figure 
19B). Neutrophils were immunophenotyped as CD11b+Ly6G+, and monocytes were gated 
on CD11b+CD64+SSClo with differential Ly6C expression to discriminate between 
Ly6Chi and Ly6CLow populations. Neutrophils dominated the CD11b+ cell population at 
day 1, comprising nearly 80% of Cd11b+ cells across all groups at day 1 (Figure 20A), 
with a decrease in abundance at days 3 and 7. However, AT-RvD1 and combination IL-
10+AT-RvD1 hydrogels had significantly decreased percentages of neutrophils in the 
tissue compared to internal unloaded hydrogel control across all surveyed timepoints 
consistent with previous findings, although there were no significant differences in 
neutrophil accumulation over time between treatment groups (Figure 20A).  
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Figure 20. Neutrophil and Monocyte recruitment kinetics in the dorsal tissue. Flow 
cytometric analysis of (A) neutrophil, (B) Ly6Chi monocyte, and (C) Ly6CLow monocyte 
recruitment into the dorsal skinfold window chamber following treatment with 
immunomodulatory PEG-MAL Hydrogels. Open circles correspond to unloaded internal 
control, closed circles are treated tissue. Statistical analysis was performed using two-way 
repeated measures ANOVA with Tukey’s or Bonferroni post-hoc test. Data presented as 
internal control and treatment with connecting lines. *p>0.05, **p>0.01 compared to 
internal control, ^p>0.05, ^^p>0.01, ^^^p>0.001 compared to other treatment group, n=4. 
 Monocyte recruitment and dynamics are also affected by immunomodulatory PEG-
MAL hydrogels. We previously have shown that biomaterial films loaded with AT-RvD1 
are able to decrease Ly6CHI monocyte infiltration in tissue while increasing the population 
of Ly6CLow monocytes. Using the PEG-MAL delivery system, we again observe 
significant decreases in Ly6CHI monocytes compared to internal control at days 3 and 7 


























































































































































































































































with IL-10, with dual loaded hydrogels significantly decreasing the proportion of Ly6Chi 
monocytes when compared to IL-10 treatment. Ly6Chi monocyte recruitment to injured 
tissue peaks at around 3 days and gradually decreases after[47, 61]. In gels loaded only 
with IL-10, there is no change in the recruitment of Ly6Chi monocytes to injured tissue 
compared to internal control at day 3, but at day 7, however, the population of Ly6Chi 
monocytes around IL-10-loaded gels is decreased significantly (Figure 20B). This delay in 
treatment effect may be due to the slower release profile of IL-10 compared to AT-RvD1. 
Ly6CLo monocyte recruitment was unaffected at day 1 across all groups but increased 
significantly compared to control at days 3 and 7 with AT-RvD1 or combination therapy. 
The release of IL-10 alone had no effect on the recruitment dynamics of Ly6CLow 
monocytes (Figure 20C). At days 3 and 7, Ly6CLow monocytes in AT-RvD1 or IL-
10+AT-RvD1 groups were significantly higher than in IL-10 treatment. Additionally, at 
day 7, the Ly6CLow population after dual-loaded hydrogel implant was significantly 
higher than AT-RvD1-only hydrogels, indicating a possible synergistic effect of AT-RvD1 
and IL-10 on Ly6CLow recruitment and accumulation. 
4.2.3 Anti-inflammatory macrophages accumulate after AT-RvD1 local delivery 
 After profiling the recruitment of circulating immune cell subsets in response to 
immunomodulatory hydrogels, we extended our analysis to macrophages and specific 
macrophage subpopulations. We examined dynamic changes in macrophages at days 1, 3, 
and 7 after tissue injury and implantation of PEG-MAL hydrogels. Macrophages are 
identifiable with flow cytometry by their surface receptor expression of MerTK and CD64 
(Figure 19B). Initially, macrophages comprised a small percentage of the total cells found 
in the injured tissue but increased to nearly 10 percent of the live cell population in all 
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treatment groups by day 7, significantly higher than internal control (Figure 21A). 
Expansion of macrophage populations is a hallmark of the resolution of inflammation and 
is necessary for tissue regeneration and wound healing [195]. We then used flow cytometry 
and whole mount immunohistochemical staining to identify specific macrophage 
























































































































































































































































































Figure 21. Macrophage recruitment and polarization in dorsal tissue. Flow cytometric 
analysis of (A) macrophage, (B) CD86+ M1 Macrophage, and (C) CD206+ M2 
macrophage popluations in the dorsal skinfold window chamber following treatment with 
immunomodulatory PEG-MAL Hydrogels. (D) Whole mount confocal microscopy 
showing M2 macrophage and total macrophage accumulation in the tissue following 
immunomodulatory hydrogel treatment. Open circles correspond to unloaded internal 
control, closed circles are treated tissue. Statistical analysis was performed using two-way 
repeated measures ANOVA with Tukey’s or Bonferroni post-hoc test. Data presented as 
internal control and treatment with connecting lines. *p>0.05, **p>0.01 compared to 
internal control, ^p>0.05, ^^p>0.01, ^^^p>0.001 compared to other treatment group, n=4, 
scale bar 100µm. 
Macrophages were subclassified into M1 and M2 phenotypes as previously described 
[196]. M1 classically activated macrophages were characterized by their expression of the 
costimulatory molecule CD86 and did not express the mannose receptor CD206. At day 1, 
CD86+ macrophages made up a small fraction of the total macrophage population. There 
were no differences between treatment and corresponding internal controls at day 1, 
however, the proportion of CD86+ M1 macrophages was significantly higher in animals 
treated with the combination IL-10+AT-RvD1 hydrogels compared to animals treated with 
AT-RvD1-only hydrogels (Figure 21B). This increase was transient, as there were no 
differences between any groups by day 3 after injury and gel implant. Temporally, we 
observed an increase in the M1 population at day 3 when M1 macrophages comprised on 
average 15% of the total macrophage population. The M1 population decreased by day 7 
and was significantly decreased after AT-RvD1 or combination IL-10+AT-RvD1 
treatment compared to control. Conversely, M2 alternatively activated macrophages were 
characterized as CD86-CD206+. At day 1, these macrophages made up a higher proportion 
of the total macrophage population, possibly due to pre-existing populations of tissue 
resident macrophages that express CD206[197]. We observed significant increases in the 
M2 macrophage population at 24 hours in the AT-RvD1-treated and IL-10+AT-RvD1 
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treated animals compared to internal control. At days 3 and 7 the average proportion of M2 
macrophages had increased compared to the previous timepoint but did not change between 
IL-10 treated tissue and internal control. Similar to day one, we saw significant increases 
in the M2 population after AT-RvD1 and dual delivery of IL-10 and AT-RvD1 compared 
to control at days 3 and 7 (Figure 21C). This accumulation of M2 macrophages occurred 
at a faster rate with dual delivery hydrogels, as the population of M2 macrophages was 
significantly increased in IL-10+AT-RvD1 treated animals compared to AT-RvD1-only 
delivery (Figure 21C) at day 3, indicating a modulation in recruitment or differentiation 
kinetics driven by co-delivery of these two factors. 
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Figure 22. 3D analysis of M2 macrophage populations in dorsal tissue (A) Imaris 
renderings of CD68+ macrophage and CD206+ M2 macrophage accumulation over time.  
(B-D) Quantification of total CD68+ CD206+ double positive cells found in Imaris 
renderings after each timepoint. Scale bars, 30µm. Data presented as mean ± S.E.M. 
Statistical analyses were performed using Mann-Whitney Test *p<0.05, **p>0.01 




























































































































 Additionally, we stained whole mount dorsal tissue for the pan-
monocyte/macrophage marker CD68 and M2 marker CD206 and used Imaris to render and 
quantify the accumulation of M2 macrophages compared to the total monocyte and 
macrophage population over time. Representative 20x confocal images are seen in figure 
4d, demonstrating the increase in the total CD68+ population over time. Qualitatively, 
these images show increased CD68+CD206+ cellular expression in the AT-RvD1 and IL-
10+AT-RvD1 groups (Figure 21D). We found that quantification of 3D renderings 
confirms the qualitative findings and shows a steady increase over time from day one to 
day seven in the accumulation of CD68+ CD206+ macrophages following AT-RvD1-only 
or combination IL-10+AT-RvD1 treatment (Figure 22A-D) Single treatment with IL-10 
only did not significantly increase the population of CD206+ macrophages over time. 
4.2.4 Characterization of Dendritic Cell and Lymphocyte Recruitment Dynamics  
Given the increasing knowledge of the roles immune system and plays in promoting wound 
healing and tissue regeneration, we quantified the temporal response of dendritic cells and 
lymphocytes to immunomodulatory PEG-MAL hydrogels. Dendritic cells have been 
shown to play previously unknown roles in the wound healing cascade, and specifically 
the CD11c+ IL-10+ tolerogenic or regulatory subset has been shown to enhance left 
ventricle function and remodeling following acute myocardial infarction and is able to 
stimulate the proliferation of Tregs[184, 198] .Here, we show that dual delivery of AT-
RvD1 and IL-10 is able to reduce the overall frequency of CD11c+ dendritic cells at day 3 


















































































































































































































































































Figure 23. Dendritic cell populations in the dorsal tissue Flow cytometric analysis of 
(A) total CD11c+ dendritic cell, (B) DC TNF-a intracellular cytokine staining, and (C) IL-
10+ DC populations in the dorsal skinfold window chamber following treatment with 
immunomodulatory PEG-MAL Hydrogels. (D) Whole mount confocal microscopy 
showing dendritic cells and IL-10 staining in the tissue following immunomodulatory 
hydrogel treatment. Open circles correspond to unloaded internal control, closed circles are 
treated tissue. Statistical analysis was performed using two-way repeated measures 
ANOVA with Tukey’s or Bonferroni post-hoc test. Data presented as internal control and 
treatment with connecting lines. *p>0.05, **p>0.01 compared to internal control, ^p>0.05, 
^^p>0.01 compared to other treatment group, n=4, scale bar 100µm. 
At day 7, the frequency of total dendritic cells was reduced across all groups compared to 
internal control, and the combination treatment was able to significantly reduce dendritic 
cell proportion in injured tissue compared to gels loaded with only AT-RvD1 or IL-10 
(Figure 23A). Like monocytes and macrophages, dendritic cells are able to carry out pro- 
and anti-inflammatory effector functions, and pathologic dendritic cell activation leading 
to increased inflammatory cytokine production and stimulation of the adaptive immune 
system has been associated with chronic inflammatory disorders such as systemic lupus 
erythematosus and rheumatoid arthritis [199]. Consistent with our hypothesis that IL-10 
and AT-RvD1 delivery are able to reduce the activation of pro-inflammatory pathways, we 
observe decreased intracellular TNF- α expression in CD11c+ dendritic cells at day 3 in 
the IL-10 and IL-10+AT-RvD1 hydrogel treatment groups, and reduced TNF- α expression 
across all groups at day 7 (Figure 23B). We also observe significant increases in IL-10+ 
dendritic cells after one week across all groups and found that IL-10+DCs were 
significantly increased in combination IL-10+AT-RvD1 treatment compared to IL-10 only 
and AT-RvD1 only treatments (Figure 23C).  
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Figure 24. 3D analysis of dendritic cell and IL-10 colocalization. (A) Imaris renderings 
of CD11c+ dendritic cell and IL-10 staining over time.  (B-D) Quantification of total 
CD11c+ surface and IL-10+ spot colocalization found in Imaris renderings after each 
timepoint. Scale bars, 30µm. Data presented as mean ± S.E.M. Statistical analyses were 
performed using Mann-Whitney Test *p<0.05, **p>0.01 ***p<0.001, n>100 cells, across 

























































































































These findings were further confirmed through quantification of immunohistochemical 
staining for CD11c and IL-10. Imaris renderings of dorsal tissue were used to measure 
CD11c and IL-10 coexpression levels (Figure 24A). The number of CD11c cells also 
coexpressing IL-10 was significantly higher after IL-10+AT-RvD1 treatment compared to 
control at all time points (Figure 24B-D). This constrasts with our flow cytometric findings, 
indicating that there may be an early localized enrichment of CD11c+IL-10+ DCs in the 
peri-implant area that is drowned out by the larger pool of conventional DCs in the 
surrounding tissue. At day 7, there were significantly more IL-10 expressing CD11c DCs 
following treatment with IL-10. AT-RvD1 treatment increased IL-10 DC populations 
compared to control, but not to the level of IL-10 or IL-10+AT-RvD1 treatments. 
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Figure 25. Lymphoid recruitment kinetics in the dorsal tissue Flow cytometric analysis 
of (A) B cell, (B) total T cell, (C) CD8+ T cell, (D) CD4+ T cell, and (E) CD25+ Treg 
recruitment into the dorsal skinfold window chamber following treatment with 
immunomodulatory PEG-MAL Hydrogels. Open circles correspond to unloaded internal 
control, closed circles are treated tissue. Statistical analysis was performed using two-way 
repeated measures ANOVA with Tukey’s or Bonferroni post-hoc test. Data presented as 
internal control and treatment with connecting lines. *p>0.05, **p>0.01, ***p>0.001 


























































































































































































































































































































































































































































 To complete our inquiry into the immune response to PEG-MAL 
immunomodulatory hydrogels, we used flow cytometry to quantify lymphocyte infiltration 
after dorsal skinfold window chamber surgery. We chose to quantify CD19+ B cells, total 
CD3+ T cells, CD8+ cytotoxic T cells, CD4+ helper T Cells, and CD4+ CD25+ regulatory 
T cells (Treg). The overall proportion of both B cells and T cells out of the total live cell 
population found in the dorsal skin remained relatively constant across all timepoints, with 
B cells comprising less than 1% of the total cells measured and T cells ranging from 0.5% 
to 2% at the highest levels (Figure 25A-B). At day 3, we found that AT-RvD1 and IL-
10+AT-RvD1 treatment significantly increases the B cell population compared to IL-10 
treatment (Figure 25A). However, the potential roles that B cells play in tissue regeneration 
and wound healing remain unknown. We observed a significant increase in the total T cell 
population at day 3 in animals treated with AT-RvD1 or combination IL-10+AT-RvD1 
compared to internal control. At day 7, there was a subsequent decrease in total T cells, 
and this level was significantly decreased after IL-10+AT-RvD1 treatment compared to 
IL-10-only hydrogels (Figure 25B). CD8+ cytotoxic T cells and CD4+ helper T cells made 
up small fractions of the T cell population one day after injury (Figure 25C-D). The 
majority of CD3+ T cells at one day were CD4-CD8- double negative cells, which are a 
population of T cells currently being investigated for having context-dependent disparate 
functions[200]. At later timepoints, we see expansion of the CD4+ and CD8+ populations 
until day 7, where there is a significant reduction in CD8+ t cells in all treatment groups 
compared to internal controls (Figure 25C-D). We then tracked the kinetics of CD25+ Treg 
accumulation over time and found that, while there were no differences after one and three 
days, by day 7, Tregs comprised over 50% of the total CD4+ T cell population in all groups, 
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a proportion significantly higher than corresponding internal controls (Figure 25E). 
Additionally, we found that the dual-loaded IL-10+AT-RvD1 hydrogels significantly 
increase the population of Tregs in tissue compared to both IL-10-only and AT-RvD1-only 
hydrogels. 
4.2.5 Vascular remodeling as a model outcome measure following immunomodulatory 
hydrogel implantation 
 Finally, we examined vascular bed remodeling in the window chamber as a measure 
of tissue regeneration, given the major role that vascular expansion and remodeling plays 
during wound healing. We used longitudinal brightfield intravital microscopy to track 
changes in the dorsal skin vascular networks after implantation of immunomodulatory 
hydrogels. We took brightfield images on day 0 immediately following surgery and gel 
injection and used those images as baseline measurements. We took images again on 
postoperative days 3 and 7. After 7 days, there are marked increases in vascular tortuosity 
and overall vascularity of the dorsal skin compared to day 0 and also compared to the 
internal control, especially noticeable in the AT-RvD1 and IL-10+AT-RvD1-treated skin 
(Figure 26A).  
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Figure 26. Vascular remodeling following immunomodulatory hydrogel injection 
(A)Brightfield micrographs of dorsal tissue at day 0 and at  day 7 following treatment with 
immunomodulatory PEG-MAL hydrogels. Quantification of the vascular metrics (B) 
length density and (C) arteriolar diameter. Data presented as mean ± S.E.M. Statistical 
analyses were performed two-way repeated measures ANOVA with Tukey’s and 
Bonferroni post hoc tests. *p<0.05, **p>0.01, ***p<0.001 compared to internal control, 
^p>0.05 compared to treatment group. n=4 animals per group. Scale bars, 1mm. 
 We quantified the changes in vasculature through two established metrics of 
angiogenesis – vascular length density, and arteriolar diameter. We did not see significant 
changes in the overall length density of the vasculature after treatment with IL-10 only 





















































































































































































significant increases in vascular length density in animals treated with AT-RvD1 alone or 
in combination with IL-10 (Figure 26B). When measuring arteriolar diameter, 
immunomodulatory PEG-MAL hydrogels significantly increase arteriolar diameter 
compared to internal control at days 3 and 7 (Figure 26C). There is also a significant 
increase in AT-RvD1 arteriolar diameter compared to IL-10 at day 3, but this increase is 
only transient. By day 7, IL-10+AT-RvD1 had significantly increased the arteriolar 
diameter compared to IL-10 and not AT-RvD1 alone (Figure 26C). In summary, this data 
shows that immunomodulatory hydrogels are able to modulate vascular remodeling and 
expansion after implantation, and that dual-delivery of IL-10+AT-RvD1 is able to enhance 
these remodeling processes above other groups. 
4.3 Discussion 
The use of biomaterial implants to deliver cells or bioactive molecules capable of 
directing the host immune response after injury can modulate processes critical to the 
restoration of tissue homeostasis, such as cellular cytokine release, vascular remodeling, or 
deposition of extracellular matrix. It is becoming increasingly apparent that these processes 
are regulated not only by cells of the innate immune system, such as monocytes and 
macrophages, but that cells of the adaptive immune system play active and important roles. 
It is our goal to develop a material that can enrich the wound microenvironment with pro-
regenerative cells of both the innate and adaptive immune system to enhance the 
regenerative response. Due to the wide variety of cell types involved, it is unlikely that 
single delivery is sufficient to recruit and activate all of these cells, and that delivery of 
multiple factors is necessary to generate the desired immune response. We have previously 
shown that local delivery of AT-RVD1 from polymer thin films is able to improve vascular 
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remodeling and enhance the accumulation of Ly6Clow non-classical monocytes and 
CD206+ M2 macrophages [178]. To attain a higher level of control over both innate and 
adaptive immune cell recruitment, we have developed a hydrogel-based system capable of 
the dual delivery of two factors crucial for the recruitment and activation of pro-
regenerative cells of both the myeloid and lymphoid lineages. PEG-MAL hydrogels were 
engineered to achieve simultaneous in vivo release of both AT-RvD1 and IL-10. We found 
that both AT-RvD1 and IL-10 alone are able to modulate the recruitment of various 
inflammatory and anti-inflammatory immune cells, but dual delivery of these factors 
enhances the recruitment and accumulation of Ly6Clow monocytes, CD206+ M2 
macrophages, IL-10+ dendritic cells, and Tregs, suggesting a synergistic interplay between 
AT-RvD1 and IL-10 that allows for increased control of the recruitment of cells from the 
innate and adaptive immune system compared to either treatment on its own. 
We have previously developed a dual-delivery protein-small molecule hydrogel 
system using PEG-diacrylate as the polymer backbone [166]. Here, we engineered a PEG-
maleimide-based hydrogel system that allows for the dual release of AT-RvD1 and IL-10. 
This PEG-MAL system allows for the incorporation of adhesive peptides into the hydrogel 
backbone, as well as control over gelling and degradation kinetics through the modification 
of component pH and chosen peptide crosslinker [201]. This control over gelation time 
allows for these hydrogels to be used as preformed implants or as an injectible in situ 
gelling system, depending on the context and desired material properties, allowing a greater 
application flexibility than other hydrogel systems which may require ultraviolet light or 
harsh chemicals for crosslinking and must be formed ex vivo. Because human IL-10 does 
not have a free cysteine group available for interaction with the maleimide groups, we 
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utilized the thiolation reagent 2-iminothiolane to add these groups to the IL-10. Without 
the addition of thiol groups, approximately 90% of the loaded unmodified IL-10 was 
released in vitro after 24 hours. After thiolation, the release of IL-10 was much slower, 
with nearly 70% of the loaded IL-10 remaining in the gel at day 5. The thiolated IL-10 was 
also able to modulate the expression of TNF- α in RAW264.7 macrophages following LPS 
treatment, indicating that thiolation does not affect the ability of IL-10 to modulate pro-
inflammatory responses after inflammatory stimulus. The AT-RvD1, which was not 
tethered to the PEG-MAL backbone, was delivered from the hydrogel primarily in a burst 
release over the first 24 hours, consistent with our previous release kinetics from AT-
RvD1-loaded PLGA thin films. This dual-release profile will allow for fast release of AT-
RvD1 after in situ hydrogel gelation to target the myeloid first responders followed by a 
more gradual release over time of thiolated IL-10 to influence the activity of cells involved 
in the later stages of the inflammatory response, mimicking the natural progression of the 
immune response. 
The accumulation of immune cells in injured tissue is important in the process of 
restoring tissue homeostasis after injury, but perhaps more important is the cellular 
phenotype and effector functions [63]. For example, macrophages and exist on a spectrum 
of activation ranging from pro- to anti-inflammatory, with the M1 CD86+CD206- 
phenotype considered to be more pro-inflammatory, and the M2 CD86-CD206+ phenotype 
considered to be more anti-inflammatory [202]. Persistent accumulation and activation of 
M1 macrophages has been associated with disease states such as type 2 diabetes and 
atherosclerosis [137], but complete blockage of M1 pathways has been associated with 
impaired tissue repair and wound healing [64]. When designing immunomodulatory 
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materials with the overall goal of ameliorating inflammation and promoting tissue repair, 
it is important to consider the necessary balance between allowing pro-inflammatory 
signaling to occur and amplifying anti-inflammatory signals, as both are needed in the 
regenerative process [67]. Indeed, allowing an unabated “M2-like” anti-inflammatory 
response can result in excessive tissue remodeling and fibrosis [179]. We subcutaneously 
injected immunomodulatory hydrogels containing IL-10, AT-RVD1, or a combination of 
these factors into excisional skin wounds and chronicled the immune response to these 
hydrogels over time. We observed significant decreases in the recruitment of circulating 
pro-inflammatory immune cells following delivery of immunomodulatory hydrogels – 
namely, hydrogels containing AT-RvD1 dampened local neutrophil infiltration, while IL-
10 and AT-RvD1 treatment modulated Ly6Chi infiltration. However, these treatments 
were not able to completely block the recruitment of these pro-inflammatory cells. 
Additionally, with our combination treatment we saw a transient increase in M1 
macrophages after one day followed by a significant decrease in this population by day 7 
in animals treated with AT-RvD1 or the combination hydrogels. Taken together, these 
findings indicate that while these immunomodulatory hydrogels are indeed capable of 
modulating the immune system, they still allow for the necessary actions of  “pro-
inflammatory” cell subsets. On the other hand, the recruitment of Ly6CLow monocytes 
and M2 macrophages was significantly increased at days 3 and 7 following AT-RvD1 
treatment. Interestingly, IL-10 only treatment was not able to modulate the recruitment of 
these immune cell subsets, but dual delivery of IL-10 and AT-RvD1 significantly increased 
these populations compared to AT-RvD1-only hydrogels, indicating the existence of a 
synergistic feed-forward mechanism between AT-RvD1 and IL-10 that is able to amplify 
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the recruitment of differentiation of these anti-inflammatory cells. Our finding of increased 
CD206+ M2 macrophages via flow cytometric analysis was further supported using 
analysis of whole mount immunohistochemistry, where we observed significantly more 
CD68+CD206+ cells in the peri-implant dorsal tissue. This synergy may be explained by 
recent expanded understanding of the M2 subset of macrophages. This population exists in 
at least three polarization states, deemed M2A, M2b, and M2c [203]. M2a and M2c have 
similar effector functions, but M2c is polarized by IL-10, whereas M2a is polarized in the 
presence of IL-4 [69]. Dual delivery of AT-RvD1 and IL-10 could increase the M2c pool, 
thereby expanding the overall CD206+ population. However, more in-depth studies 
examining the gene expression of the CD206+ macrophages treated with AT-RvD1 only 
or combination therapy is needed to definitively differentiate between M2a and M2c 
macrophage subsets. 
It was then our goal to expand our inquiry into cell subsets involved in wound 
healing that we not explored previously, dendritic cells and lymphocytes. We are 
particularly interested in the populations of dendritic cells polarized by IL-10. These DC 
subsets have been sometimes called “tolerogenic DCs” or DC-10s, and have the ability to 
signal to Treg populations and promote their activity. Additionally, these tolerogenic DCs 
have been shown to improve cardiac function and survival after myocardial infarction 
through the induction of Tregs and promotion of neovascularization and amelioration of 
pathologic left ventricle wall remodeling [204]. Due to these actions, IL-10+ DCs may 
serve as a cellular bridge between the pro-regenerative arms of the innate and adaptive 
immune systems. We found that combination IL-10+AT-RvD1 treatment reduces the 
overall CD11c+ DC population at day 3 and 7 following injury compared to AT-RvD1-
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only treatment. We observed significant decreases in overall expression of TNF- α within 
the DC population among all groups compared to control, indicating the ability of all 
treatments to diminish the pro-inflammatory activity of immune cells. By day 7, flow 
cytometric and whole mount immunohistochemistry analysis showed that IL-10+AT-
RvD1 combination treatment significantly expanded the population of IL-10+ DCs. When 
we measured IL-10 staining via IHC, we saw additional IL-10 that was not colocalized 
with CD11c. This IL-10 staining could be extracellular IL-10 that has been released from 
cells and is in the interstitial tissue. The IL-10 could also be intracellular IL-10 present 
within Tregs. Future analyses could modify our IHC staining panels to include a T cell 
marker to visualize the contributions of these cells. Owing to the ability of IL-10+ DCs to 
signal to lymphocytes, we also examined the kinetics of B and T lymphocytes to the injured 
dorsal tissue. It remains unclear as to what role B lymphocytes may play in the wound 
healing process, and the implications of the observed transient increase in B cells with IL-
10+AT-RvD1 combination treatment must be explored further. Within the T lymphocyte 
pool, different subsets and their roles in wound healing have previously been studied. 
CD8+ cytotoxic T cells have been shown to secrete IFN-y and TNF- α and can delay bone 
fracture healing and osteogenesis [205]. Subsets of CD4+ T helper (Th) cells have been 
shown to have differing roles on the inflammatory process, and the Th2 response is 
associated with an increased pro-regenerative response [72]. We did not observe changes 
in the overall CD4+ Th pool after immunomodulatory biomaterial implantation, but more 
thorough discrimination of the Th pool may show differences in the type of Th response 
elicited by hydrogel implantation. Although we did not see any differences in the total Th 
population, we found that IL-10 and AT-RvD1 are able to significantly increase the 
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proportion of CD4+ CD25+ Tregs by one week. Similar to the synergy observed in the 
monocyte and macrophage populations, combination IL-10+AT-RvD1 therapy 
significantly increases the Treg population over internal control, as well as over the IL-10 
or AT-RvD1 single therapy. Tregs can modulate neutrophil behavior and can direct 
monocyte and macrophage polarization through the secretion of IL-10, IL-4, and IL-13 
[206, 207]. Tregs also contribute to wound healing via the attenuation of conventional 
CD8+ and CD4+ T cell activity, although Treg activity seems to be largely tissue dependent 
[77]. In skin, Tregs can inhibit M1 inflammatory activity and promote wound closure via 
the Jag1-Notch signaling pathway[74]. Overall, recruitment of IL-10+ DCs and Tregs is 
associated with positive wound healing outcomes. 
Post-injury vascular remodeling is a crucial step in the tissue repair process that is 
necessary to ensure the delivery of nutrients and recruited cells to the regenerating tissue. 
The vascular network is expanded via formation of new vessels and by remodeling of 
existing vasculature. This vascular network expansion is carried out by recruited 
leukocytes of many varieties, including monocytes, macrophages and T lymphocytes [135, 
202, 208]. Leukocytes are able to drive this process through the secretion of growth factors 
and matrix-remodeling enzymes [43, 170, 174, 208-211]. We have previously shown that 
local delivery of FTY720, SDF-1a, and AT-RvD1 are able to promote vascular remodeling 
processes. In this study, we show that immunomodulatory bioamterials loaded with IL-10, 
AT-RvD1, or combination are able to affect vascular remodeling over time. IL-10 single 
therapy is able to enhance arteriolar enlargement but is not able to promote expansion of 
the vascular network. On the other hand, AT-RvD1 and combination treatments 
significantly increased both arteriolar caliber and vascular network length density, 
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indicating a remodeling of existing vasculature as well as expansion of new vessels. While 
we cannot definitively prescribe a mechanism underlying these findings, increased 
vascular network expansion may be associated with non-classical monocyte and M2 
macrophage accumulation observed after AT-RvD1 therapy that was not seen following 
IL-10-only therapy. Overall, the dual delivery of IL-10 and AT-RvD1 via PEG-MAL 
hydrogel is able to enhance the recruitment of pro-regenerative immune cells of both 
myeloid and lymphoid lineages and modulate innate wound healing processes, such as 
vascular remodeling after injury. This dual-delivery system has the potential to improve 
therapeutic wound healing outcomes following trauma or tissue transplantation via synergy 
of cellular recruitment and polarization processes to promote anti-inflammatory cell 
recruitment and activity. 
4.4 Methods 
4.4.1 Thiolation of IL-10 
 Carrier-free recombinant human IL-10 was purchased from BioLegend. IL-10 was 
thiolated using 30 molar excess of Traut’s reagent (Sigma) for one hour in PBS containing 
0.1uL EDTA per uL buffer to chelate free metals. The thiolation reaction was shaken at 
RT for one hour. Thiolated IL-10 was separated from unreacted Traut’s reagent using a 
Zeba desalting column according to manufacturer’s instructions. Thiolation was detected 
using a Measure-IT™ Thiol Assay Kit (Invitrogen) according to kit instructions. Number 
of thiol groups per IL-10 was calculated using the concentration of detected thiols and the 
known concentration of IL-10 in each measured sample. 
4.4.2 Hydrogel Fabrication 
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 Four-arm poly(ethylene glycol) (PEG, 10 kDA molecular weight) end-
functionalized with maleimide (>95% purity, Laysan Bio) at 4.5% weight/volume was 
used for all hydrogel formulations. PEG macromers were functionalized with RGD peptide 
(GRGDSPC), crosslinked with the cysteine-flanked peptide VPM 
(GCRDVPMSMRGGDRCG) (AAPPTec) in 0.5M MES buffer, pH 5.5. The final 
concentration of RGD was 1.0mM. Gels were also loaded with 50ug/mL IL-10, and 
4ug/mL AT-RvD1 (Cayman Chemical). The crosslinker concentration was based on the 
concentration of non-reacted maleimide groups remaining on PEG macromers. For 
hydrogels used in animal studies, all components were filtered through a spin column after 
pH measurements and kept under sterile conditions until injection into the animals. To 
generate pre-formed hydrogels for release studies, the hydrogel was formed on a sterilized 
petri dish. After crossslinking, hydrogels were incubated at 37˚C for 15 minutes and then 
swelled in PBS for at least 30 minutes. Release of thiolated and unthiolated IL-10 was 
measured over time in 1% BSA solution using IL-10 tagged Alexa Fluor 405 NHS Ester 
(Life Technologies) according to the manufacturer’s recommendation and quantified using 
a standard curve of known fluorescent IL-10 concentrations. Release of AT-RvD1 was 
measured with a Shimadzu UFLC High Performance Liquid Chromatograph (Columbia, 
MD, USA) equipped with a Shimadzu Premier C18, 5µm (250x4.6mm) column. AT-RvD1 
elution was measured at 8.6 minutes using a wavelength of 301nm. Known quantities of 
AT-RvD1 were used to generate a standard curve relating AT-RvD1 mass to total peak 
area. Using serial dilutions, we determined that the limit of detection was below 0.5pg/µL. 
The total amount of AT-RvD1 in each release sample was calculated using the standard 
curve.  
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4.4.3 Macrophage TNF- α Expression Assay 
 Expression of TNF- α by RAW264.7 macrophages after treatment with 
Lipopolysaccharide was used as a metric for measuring bioactivity of IL-10 and AT-RvD1. 
One million RAW264.7 cells were cultured in 6 well plates with Dulbecco's modified 
Eagle medium (Gibco) containing 1mM sodium pyruvate (Gibco) and 2mM L-glutamine 
(Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco). Cells were pretreated 
with IL-10, thiolated IL-10, PEGylated thiolated IL-10, AT-RvD1, AT-RvD1 and thiolated 
IL-10 combination, or control PBS for one hour. Pretreatment dosages were equal to 
dosages loaded into hydrogels. Pretreatment was removed and cells were washed once with 
PBS. Cells were then stimulated with 50ng/mL LPS for two hours in 2mL media 
supplemented with 100uL Brefeldin-A (manufacturer) per mL cell culture media. Cells 
were removed from wells and fixed with 4% paraformaldehyde for 30 minutes at RT. Cells 
were permeabilized through two washes of PBS containing 1% FBS and 0.1% Saponin. 
Cells were stained for TNF- α (eBioscience) and TNF- α staining was detected using a 
FACS-AriaIIIu flow cytometer (BD Biosciences). 
4.4.4 Dorsal Skinfold Window Chamber Surgery 
 Animal experiments were performed using sterile techniques in accordance with an 
approved protocol form the Georgia Institute of Technology Institutional Animal Care and 
Use Committee. Male C57BL/6 mice (Jackson) aged 6-12 weeks were anesthetized by 
inhaled isofluorane and surgically fitted with sterile dorsal skinfold window chambers (APJ 
Trading Co.) as previously described [178]. Briefly, the dorsal skin was shaved, depiliated, 
and sterilized via three washes with 70% ethanol and chlorhexidine. The dorsal skin was 
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drawn away from the back of the mouse and one side of the titanium frame was attached 
to the underside of the skin. Sterile surgical micro scissors were then used to expose the 
microvasculature through the removal of the epidermis and dermis in a 12mm diameter 
circle. 25ul sterile hydrogels were then mixed, drawn into a syringe, and injected 
underneath the exposed vascular bed. For internally controlled experiments, the unloaded 
control hydrogel was injected on the caudal side of the window chamber, and the loaded 
hydrogel was injected rostrally. Exposed tissue was then sealed with a sterile glass 
coverslip. Mice were administered sustained-released buprenorphine i.p. (0.1-0.2 mg/kg) 
and allowed to recover in heated cages.  All mice received standard laboratory diet and 
water ad libitum throughout the course of the experiment. 
4.4.5 Vascular Metrics 
 Mice were anesthetized with isofluorane, the glass window was removed, and 
dorsal tissue was superfused with adenosine in Ringer’s solution (1mM) to prevent 
desiccation and to maximally dilate exposed vessels. The mouse was mounted on a 
microscope stage and imaged non-invasively at 5x magnification on a Zeiss Imager.D2 
microscope with AxioCam MRC 5 color digital camera (Zeiss). Images were acquired on 
day 0 immediately following film implantation and again on days 3 and 7. Microvascular 
length density measurements were made within a 4000x4000 pixel square region of interest 
(ROI) around the film. Vessels within these ROIs were traced and total vessel length per 
unit area was quantified via ImageJ. Arteriolar diameter measurements were made within 
the ROIs by identifying arteriolar-venular pairs at day 0. Internal diameter changes were 
measured via ImageJ and days 3 and 7 diameters were normalized to day 0. 
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4.4.6 Tissue Harvest and Flow Cytometry 
 To collect samples for flow cytometry analysis, mice were euthanized via CO2 
asphyxiation. The dorsal tissue was excised and digested with collagenase type 1-A 
(1mg/ml, Sigma) at 37°C for 30 minutes and further separated with a cell strainer to create 
a single cell suspension. Single cell suspensions of dorsal tissue were stained for flow 
cytometry analysis using standard methods and analyzed on a FACS-AriaIIIu flow 
cytometer (BD Biosciences). Dead cells were excluded through staining using Zombie Red 
fixable viability stain (BioLegend). The antibodies used for identifying cell populations of 
interest were: PE conjugated MerTK (Biolegend), PE-Cy7 conjugated MHC-II 
(BioLegend), BV605 conjugated CD206 (BioLegend), BV510 conjugated Ly6C 
(BioLegend), APC-Cy7 conjugated Ly6G (BioLegend), BV711 conjugated CD64 
(BioLegend), BV785 conjugated CD19 (BioLegend), APC conjugated Cd11b 
(BioLegend), BV421 conjugated CD11c (Biolegend, FITC conjugated CD86 (BioLegend), 
PerCP-Cy5.5 conjugated CD3 (Biolegend), BV785 conjugated CD8 (BioLegend), BV605 
conjugated CD4 (BioLegend), and BV711 conjugated CD25 (BioLegend). Staining using 
BV dyes was performed in the presence of Brilliant Stain Buffer (BD Biosciences). Cells 
were stained for intracellular cytokines using PE conjugated IL-10 (BioLegend) and PE-
Cy7 conjugated TNF- α (eBiosciences). Positivity was determined by gating on 
fluorescence minus one controls. Absolute quantification of cell numbers was performed 
by adding 25μL of AccuCheck counting beads to flow cytometry samples (Thermo Fisher 
Scientific). 
4.4.7 Tissue Whole Mount Immunohistochemistry and Confocal Imaging 
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 Following euthanasia, mouse vasculature was perfused with warm saline and then 
with 4% paraformaldehyde until tissues were fixed. The dorsal tissue was excised and 
permeabilized overnight at 4°C with 0.2% saponin. The tissues were blocked overnight in 
10% mouse serum at 4°C. Tissues were incubated at 4˚C overnight in staining solution 
containing 0.1% saponin, 5% mouse serum, 0.5% fatty-acid free bovine serum albumin, 
and the following fluorescently conjugated mouse antibodies: Alexa Fluor 594 anti-CD31 
antibody (1:100 dilution, BioLegend) for blood vessel visualization, Brilliant Violet 421 
anti-CD68 (1:200 dilution, BioLegend) for visualization of macrophages, and Alexa Fluor 
647 anti-CD206 (1:200 dilution, Biolegend) for visualization of M2 macrophages. The 
following unconjugated antibodies were also used: Biotin anti-CD11c (1:200 dilution, 
BioLegend) for visualization of dendritic cells, and Rabbit polyclonal anti-IL-10 (1:200 
dilution). Tissues were washed four times for 30 minutes with 0.2% saponin and stained 
with Streptavidin-conjugated Alexafluor 430 (1:200 dilution, Invitrogen) and Goat anti-
rabbit Alexa Fluor 488 (1:200 dilution, Abcam) secondary antibodies for 4 hours at room 
temperature. Tissues were washed twice for 30 minutes with 0.2% saponin and again 
overnight at 4˚C. Specimens were then washed once in PBS for 30 minutes and mounted 
in 50/50 glycerol/phosphate buffered saline. Mounted samples were imaged on a Zeiss 
LSM 710 NLO confocal. 
4.4.8 Statistical Analysis 
 All statistical analyses were performed using Graphpad Prism version 6.0 (La Jolla, 
CA). Results are presented as mean ± standard error of the mean (SEM). For grouped 
analyses, one-way ANOVA with Tukey’s post-test was used for multiple comparisons. For 
internally controlled experiments, two-way ANOVA was used. Tukey’s post-hoc test was 
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utilized when comparing paired samples, and Bonferroni’s post hoc test was employed 
when comparing between treatment groups. Unless otherwise noted, p<0.05 was 
considered statistically significant. 
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CHAPTER 5. IMMUNOMODULATORY HYDROGELS 
LOCALLY MODULATE THE IMMUNE RESPONSE TO 
ALLOGRAFT TISSUE 
5.1 Introduction 
 Solid organ transplantation procedures have been on the rise in the past decade in 
the United States and currently, organ transplant is the most effective treatment option in 
the context of end-stage organ failure [2, 8]. The most common procedures are kidney, 
liver, heart, and lung transplantations, but our ability to perform other transplant procedures 
including vascularized composite allograft of face or upper limb is increasing and soon 
these procedures may become more commonplace [2]. Currently, the use of post-
transplantation immunosuppressive regimens (IS) has resulted in significant increases in 
survival after solid organ allograft, with rates nearing 90% after one year[9]. Donated tissue 
rejection is prevented through the use of systemic immunosuppression  (IS) regimens that 
alter the immune response and block the recognition of and response to donor antigens  
[212]. Despite decreases in acute rejection of transplants with IS, significant complications 
stemming directly from systemic IS are still prevalent, in both the acute and chronic time 
frame after transplant. Chronic use of systemic IS is associated with an increased risk of 
opportunistic infection, particularly fungal infection, lymphoproliferative disorders, and 
wound toxicity including cardiovascular disease or renal failure[2, 3]. Acutely, surgical 
wound complications following transplantation are still extremely common [3]. Therefore, 
there exists an opportunity to try to prevent acute post-surgical wound healing 
complications through the development of alternative therapies  outside of systemic IS that 
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are able to exploit endogenous mechanisms of wound healing and tissue acceptance to 
prevent acute wound closure complications and promote early tissue integration. 
 Impaired wound healing after transplant surgery is one of the most common 
complications arising from high doses of systemic immunosuppression. Wound dehiscence 
and other complications have been reported in the context of nearly every transplant 
procedure, including heart, kidney, and liver [3, 10]. For example rates of surgical wound 
complications including superficial or deep wound infection, lymphocele, and wound 
dehiscence have been reported in 8-15% and sometimes up to 40% of heart transplant 
recipients compared with 0.5-10% of patients after similar general cardiac surgery 
procedures that do not involve transplantation [3]. These complications can be exacerbated 
by a multitude of patient risk factors, including age, obesity, and diabetes [11]. Given the 
aging population and rising obesity rates, wound healing complications following 
transplant are at risk of becoming more and more common. At the root of many of these 
wound healing complications are drugs used for IS that also impair key processes in the 
wound healing cascade. The mammalian target of rapamycin (mTOR) inhibitors sirolimus 
and everolimus, corticosteroids, and other common immunosuppressive drugs such as 
cyclosporine A, tacrolimus, and mycophenolate motefil have all been reported to impair 
wound healing processes resulting in decreases in tensile wound strength or anastomotic 
breaking strength in animal models [12-17]. These studies indicate that the common 
combinatorial approach of immunosuppression taken to prevent the rejection of 
transplanted organs may be compounding the impairment of processes necessary to ensure 
proper healing of surgical sites and prevent wound healing complications. 
 107 
 In lieu of systemic IS, local modulation of the immune response to transplant can 
potentially allow for early integration of transplanted tissue and surgical wound closure 
while concurrently delaying allograft rejection. In fact, many of the immune cells 
responsible for directing wound healing processes can also play roles in preventing the 
rejection of transplanted tissue. For example, we have previously shown that Ly6CLow 
non-classical monocytes are skewed toward long-term anti-inflammatory cell fate, and that 
these monocytes are active mediators of vascular remodeling and restoration of tissue 
homeostasis [61, 178]. Non-classical monocytes are biased progenitors of M2a/c 
macrophages, and these macrophages can release cytokines that reduce inflammatory 
dendritic cell (DC) activity [92, 93]. These non-classical monocytes can also promote 
regulatory T cell (Treg) differentiation through PD-1 signaling [95]. Additionally, IL-10+ 
DCs have previously been shown to improve ventricular function following ischemic 
myocardial infarction and can also promote the differentiation and activation of 
immunosuppressive Treg populations[184, 204, 213]. Tregs themselves have become cells 
of interest during regeneration and have demonstrated context-dependent involvement in 
wound healing processes in skin, bone, muscle, and other tissues[73, 75, 77]. In response 
to transplant, Tregs can facilitate graft survival through numerous molecular signaling 
pathways, including induction of T and B cell cycle arrest and apoptosis, secretion of 
suppressive cytokines such as IL-10 and TGF-ß, prevention of T cell expansion, 
costimulation, and activation, and inhibition of DC maturation[186, 214, 215]. Therefore, 
enriching the transplant milieu with these dual-acting cells is a novel therapy aimed at early 
graft wound healing with the ability to prevent rejection without the need for high doses of 
systemic IS. 
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 We have previously developed dual-loaded poly(ethylene glycol)-maleimide 
(PEG-MAL) hydrogels capable of locally delivering therapeutic doses of the specialized 
proresolving mediator aspirin-triggered resolvin D1 (AT-RvD1) and the 
immunomodulatory cytokine interleukin 10 (IL-10) to enrich the injured tissue niche with 
pro-regenerative immune cells with the goal of promoting wound healing. We found that 
these hydrogels were able to increase the populations of Ly6CLow monocytes, CD206+ 
M2 macrophages, IL-10+DCs, and Tregs after full thickness skin injury. Delivery of these 
factors to injured tissue also enhanced vascular remodeling, one of the early markers of the 
wound healing cascade. In the present study, we utilize these previously characterized 
immunomodulatory hydrogels in a murine model of skin transplant to track the modulation 
of the immune response over time and examine graft tissue integration and acceptance. 
This model was chosen because it creates a robust immune response following tissue 
transplant and allows for numerous outcomes to be measured. We demonstrate that 
immunomodulatory hydrogels can tune the immune response to both syngraft and allograft 
skin transplant. These hydrogels enhance the recruitment of anti-inflammatory myeloid 
and lymphoid cells to the transplanted tissue, resulting in enhanced wound closure in the 
syngraft model. In complete MHC-mismatch allografts, although we are able to induce the 
recruitment of cells involved in wound healing and graft acceptance, the local response 
was ultimately unable to overcome systemic rejection signals. Although the allografts were 
rejected, these results indicate that local modulation of immune populations is possible 
after allograft, and that these immunomodulatory hydrogels could potentially be used in 
conjunction with systemic IS to promote wound healing after tissue transplant. 
5.2 Results 
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5.2.1 Skin Transplant Histopathological Assessment 
 We utilized the murine skin transplant model to characterize the immune response 
to transplanted tissue and concurrent injection of immunomodulatory PEG-MAL 
biomaterials (Figure 27A). This model was chosen because of the overall surgical ease and 
its ability to elicit a spectrum of immune responses – from no rejection to swift acute 
rejection of grafted tissue over the course of 8-10 days. This model also allows for the 
utlization of numerous techniques to record outcome measures. In this work, we 
characterize the response to transplanted skin through flow cytometry, multiplex cytokine 
array, and immunohistochemical staining.  
 
Figure 27. Skin transplant experimental schematic and flow cytometry gating 


















































hydrogel placement. (B) Flow cytometry gating strategy showing major cell types 
investigated with our panels . 
First, we examined the wound healing and integration of genetically identical donor-to-
host tail skin tissue grafts and complete MHC mismatch tail skin tissue allografts . Figure 
28 shows macroscopic gross images of the grafted syngraft skin over time. As expected, 
there was complete acceptance of all skin transplants, including control, by 14 days post-
transplant, with minor wound contracture appearing after AT-RvD1-loaded hydrogel 
treatment. At day 10, the dual-loaded IL-10+AT-RvD1 hydrogel treatment group appeared 
to have complete wound closure, while control hydrogel and IL-10-only or AT-RvD1-only 
groups had not yet fully healed. 
 
Figure 28. Macroscopic images of syngraft skin transplants. Macroscopic images 
showing the progression of wound healing and syngraft integration over time following 
injection of immunomodulatory PEG-MAL hydrogels. Scale bar 0.5mm 






















 Figure 29 shows macroscopic images of the wound and transplanted tissue over 
time following allograft transplant. We observed enhanced early integration of the 
transplanted tissue with the host tissue following dual-loaded hydrogel treatment at day 3 
compared to other groups, where the wound area remained open. At day 7, the dual-loaded 
hydrogel groups were still healing, while the control and IL-10-treated animals had begun 
to exhibit signs of transplant rejection, namely scabbing and darkening of the graft tissue. 
By day 10, there was marked darkening and contraction of the graft, indicating tissue 
rejection. By day 14, all of the allografted skin had been rejected in all groups.  
 
Figure 29. Macroscopic images of allograft skin transplants over time. Macroscopic 
images showing the progression of allograft integration and rejection over time following 
injection of immunomodulatory PEG-MAL hydrogels. Scale bar 0.5mm 
  Microscopic assessment of H&E-stained sections of the skin transplant and 
surrounding skin tissue revealed no observable differences in mononuclear cell infiltration 
or overall staining between the control or experimental groups following syngraft (Figure 




















30). When we examined the allograft tissue, we found that there is a marked increase in 
infiltration of cells into the tissue across all groups compared to syngraft. This indicates a 
more robust immune response following allograft compared to syngraft (Figure 30). 
 
 
Figure 30. H&E staining of skin tissue following syngraft or allograft. 10x brighfield 
micrographs showing H&E staining of the skin tissue surrounding the donated skin in 
syngraft and allograft animals 10 days after immunomodulatory hydrogel injection. Scale 
bar 300µm 
5.2.2 Principal Component Analysis of Flow Cytometric Measurements on Syngraft Skin 
Tissue 
 In order to quantify the kinetics of immune cell recruitment following syngraft skin 
transplant and immunomodulatory hydrogel injection, we harvested skin, lymph node, and 
blood at days 3, 7, 10, and 14 after transplant. By flow cytometry we are able to identify T 
cells, including T-helper, T-cytotixic, and T-regulatory subsets, B cells, macrophages and 
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monocytes including classical and alternatively activated subsets (Figure 27B). 
 
Figure 31. Unsupervised principal component analysis of flow cytometry 
quantification in syngraft skin transplant skin tissue(A) 3D scores plot of 
immunomodulatory biomaterial treatments over time. (B) 3D loadings (weight 
coefficients) plot of the 9 input variables in the reduced principal component space. (C-D) 
Scores and loadings plots reduced to two dimensions. Input variables are: Macrophages(% 
of cells), CD206+ (% of Macrophages), CD86+ (% of Macrophages),  DC (% of cells), IL-
10+ DCs (% of CD11c+), neutrophil (% of CD11b+), Ly6Clo (% of CD11b+), Ly6CHi (% 
of CD11b+),and Treg (CD25+CD4+CD3+ % of CD4+CD3+). N=4 animals per treatment 
group at each timepoint. 
 Because this type of analysis produces large multivariate datasets, we used 
unsupervised principal component analysis (PCA) to describe the progression of the 
immune response in a reduced-dimensionality model. We wanted to see how the different 
hydrogel treatments modulated the immune response over time and how similar those 
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treatments were to the response to transplant and unloaded hydrogel. Figure 31A and B 
show the three-dimensional scores of each sample and the cell subsets that contribute to 
each sample’s placement within the 3D PCA space. In the syngraft skin tissue, the first 
three principal components (PCs) account for 72.58% of the variability in the data. The 
data generally clustered by sample type and timepoint in the PC space suggesting that the 
different treatments produce distinct immune profiles over time. Interestingly, the 
combination IL-10+AT-RvD1 treatment and AT-RvD1-only treatment groups cluster 
together over time. This is expected due to the large number of myeloid cell subsets 
involved in the inflammatory response, and we have shown previously that AT-RvD1 has 
the largest influence on myeloid immune cells[178]. 
 To more clearly visualize the data in the PC space, we plotted the PCA data 
in two dimensional pairwise plots(Figure 31C-D). When we plot PC1 vs PC3, we see that 
the AT-RVD1 and IL-10+AT-RVD1 treatments cluster away from the IL-10 and control 
groups, due to increased populations of Tregs, M2 macrophages, and IL-10+ DCs which 
are heavily weighted in PC3 while loading in PC1 indicates that later timepoints are 
distinguished by Ly6CLow monocytes, CD25 Treg, and CD86+ macrophage populations.  
5.2.3 Circulating Immune Cell Recruitment After Syngraft 
Given the differences observed between treatment groups observed by PCA, we 
then quantified the recruitment kinetics of each cell subset captured by our flow cytometric 
measurements over time. After syngraft and immunomodulatory hydrogel injection, we 
saw early modulation of circulating myeloid cell recruitment to the injured tissue. At day 
3, we observe significantly fewer neutrophils in the AT-RVD1 and combination IL-
 115 
10+AT-RvD1 treatment groups compared to control or IL-10 only treatment(Figure 32A). 
By day 7, all treatment groups had significantly fewer neutrophils compared to control.  
 
Figure 32. Neutrophil and monocyte recruitment to syngraft skin graft Flow 
cytometric analysis of (A) neutrophil, (B) Ly6Chi monocyte, and (C) Ly6CLow monocyte 
recruitment into skin following syngraft transplant and treatment with immunomodulatory 
PEG-MAL Hydrogels. Statistical analysis was performed using one-way ANOVA with 






















































































































































































































































































































































































 When examining monocyte populations, AT-RvD1 and IL-10+AT-RvD1 
hydrogels significantly reduced the classical Ly6C high population compared to control at 
days 3 and 7(Figure 32B). Conversely, AT-RvD1 and IL-10+AT-RvD1 significantly 
increased Ly6CLow alternatively activated monocytes in the tissue at days 3 and 7 
compared to both control and IL-10-loaded hydrogels (Figure 32C). At all timepoints, 
monocyte recruitment was unaffected by IL-10 treatment, consistent with our earlier 
observations (Figure 32B-C). This effect is again likely due to the differences in release 
kinetics between AT-RvD1 and IL-10. By the time a therapeutic dose of IL-10 is released 
from the hydrogel, the peak recruitment period of monocytes has passed and the released 
IL-10 cannot modulate monocyte infiltration. When examining the temporal recruitment 
profile, we see similar kinetics across all groups. At day 3, the majority of circulating cells 
infiltrating the tissue are neutrophils and Ly6Chi monocytes(Figure 32A-B). The 
proportions of these cells decrease over time, as Ly6Clow cells are recruited to the tissue. 
Then at days 10 and 14, consistent with the progression of a normally-healing wound, no 
differences are seen in neutrophil or monocyte populations between all groups, and 
Ly6Clow monocytes comprise the majority of these cell populations (Figure 32C). 
5.2.4 Anti-Inflammatory Macrophages are Increased after IL-10+AT-RvD1 Treatment 
in Syngraft Skin Tissue  
 We then analyzed the recruitment of macrophages and macrophage subsets. From 
days 3-10, CD64+ MerTK+ macrophages comprised 10-20% of the live cell population in 
the skin tissue and decreased to less than 5% by day 14 (Figure 33A). This differs from 
previous analysis of dorsal tissue, where monocytes made up less than 5% of infiltrating 
cells. This difference is likely due to the pool of tissue resident macrophages present in the 
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dermis that are not present after window chamber surgery. Combination IL-10+AT-RvD1 
treatment significantly increased the macrophage population in the skin at day 3 compared 
to IL-10-only and at day 7 compared to both IL-10-only and AT-RVD1-only hydrogels 
(Figure 33A). At day 3, AT-RvD1 treatment also significantly increased the overall 
macrophage population compared to IL-10-only treatment. There were no differences in 
macrophages at day 10, but after 14 days, significantly more macrophages were present in 
the skin tissue of animals treated with AT-RVD1 hydrogels or dual-loaded hydrogels, but 
this increase was greater following AT-RvD1-only treatment (Figure 33A). 
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Figure 33. Macrophage recruitment to syngraft skin graft Flow cytometric analysis of 
(A) macrophage, (B) CD86+ Macrophage, and (C) CD206+ M2 Macrophage populations 
in the skin following syngraft transplant and treatment with immunomodulatory PEG-
MAL Hydrogels. Statistical analysis was performed using one-way ANOVA with Tukey’s. 
post hoc test Data presented as mean ± SEM. *p>0.05, **p>0.01 , n=4. 
. 
 We then utilized differential surface receptor staining to analyze M1 and M2 































































































































































































































































































































































































































population of these macrophages was significantly reduced with AT-RvD1 and dual-
loaded hydrogel treatment compared to control at days 3 and 7 (Figure 33B). Curiously, 
we observed a significant increase in M1 macrophages at day 14 in the combination 
treatment compared to control (Figure 33B). M2 macrophages were characterized by their 
expression of CD206 and do not express CD86. At all timepoints, AT-RvD1 and 
combination hydrogel treatment significantly increased the M2 macrophage population 
compared to control, and combination treatment resulted in significantly increased M2 
populations compared to IL-10 only at days 3, 10, and 14 (Figure 33C). These observations 
indicate that the recruitment of myeloid populations is largely affected by AT-RvD1 
treatment and not IL-10 delivery. 
5.2.5 Dendritic Cell Recruitment to Syngraft Skin Tissue 
 Dendritic cells were classified based on their CD11c surface marker expression. 
These CD11c+ cells comprise a significant portion of the immune cell population in the 
skin. The predominance of these cells is likely due to the presence of resident CD11c+ 
Langerhans Cells, antigen presenting cells that are abundant in the dermis and epidermis  
[216]. At day 3, CD11c+ cells were decreased in IL-10 and AT-RvD1-only hydrogel 
treated groups compared to control, but not in the dual-loaded hydrogel group. We then 
saw a significant reduction in the DC population in IL-10+AT-RvD1-treated animals 
compared to all other groups. By day 14, total DCs were significantly decreased following 
AT-RvD1 and IL-10+AT-RvD1 combination treatments compared to control or IL-10 
hydrogels (Figure 34A). We then examined the population of IL-10+ DCs, as these cells 
are important not only in signaling to Treg lymphocytes, but also play active roles in wound 
healing on their own[183]. While AT-RvD1 treatment seems to affect the overall DC 
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population, it does not have as much of an influence on the induction of IL-10+ DCs. Levels 
of IL-10DCs found in the skin after hydrogel delivery of AT-RvD1 were significantly 
increased compared to control at days 7 and 10, but IL-10 treatment alone or in combination 
with AT-RvD1 was able increase this population even further at the same timepoints 
(Figure 34B).  
 
Figure 34. Dendritic cell recruitment to syngraft skin graft Flow cytometric analysis of 
(A) total CD11c+ dendritic cell and (B) IL-10+ DC populations in the skin following 
syngraft transplant and treatment with immunomodulatory PEG-MAL Hydrogels. 
Statistical analysis was performed using one-way ANOVA with Tukey’s. post hoc test 
Data presented as mean ± SEM. *p>0.05, **p>0.01 , ***p>0.001 n=4. 




































































































































































































































































 We then repeated PCA on the skin after syngraft but instead this time we attempted 
to see if clustering of the data occurred on the basis of lymphatic cell markers. Contrasting 
with the earlier PCA, there is very little observable clustering both in 3D and 2D renderings 
(Figure 35A-D). This indicates that following syngraft, most of the differences seen in the 
data are due to changing dynamics of myeloid cell recruitment.  
 
Figure 35. Unsupervised PCA of flow cytometric quantification of syngraft skin graft 
using lymphoid markers(A) 3D scores plot of immunomodulatory biomaterial treatments 
over time. (B) 3D loadings (weight coefficients) plot of the 5 input variables in the reduced 
principal component space. (C-D) Scores and loadings plots reduced to two dimensions. 
Input variables are: B cells (% of cells), T cells (% of cells), CD8+ T cells (% of CD3+), 
CD4+ T cells (% of CD3+), and Treg (CD25+CD4+CD3+ % of CD4+CD3+). N=4 animals 
per treatment group at each timepoint. 
































































































 Although we do not see apparent clustering in the data due to differential lymphoid 
cell recruitment, there are still observed differences over time in the recruitment of these 
cells and subsets. Most of the differences observed between treatment groups were 
transient. For example, there was a significant increase in B cells in the AT-RvD1 and IL-
10+AT-RvD1-treated skin compared to IL-10 at day 3, but this difference is not sustained 
throughout the rest of the analysis timepoints (Figure 36A). Additionally, we see 
significant modulation in T cells, CD8+ T cells, and CD4+ T cells at various times (Figure 
36B-D). Most persistent, however, are the differences seen in the CD25+ Treg population 
over time. There are no changes in Tregs at 3 days, but at day 7, the proportion of CD25+ 
cells out of the total CD4+ T cell population was significantly increased in the skin of 
animals treated with IL-10+AT-RvD1-loaded hydrogels compared to all other treatment 
groups, with CD25+ cells comprising over 40% of the total CD4+ population in the dual-
loaded hydrogel group (Figure 36E). IL-10-only treatment significantly increased Tregs 
over both control and AT-RvD1-only treatment. At day 10, all groups had more Tregs 
present compared to control, but there were no differences between groups. Then, at day 
14, the differences observed at day 7 were again seen, with significant increases in Tregs 
following IL-10 treatment. These results demonstrate that IL-10 alone or in combination 
with AT-RvD1 is better able to enrich injured skin with pro-regenerative lymphocytes than 


















































































































































































































































































































































































































































































































































































































































Figure 36. Lymphocyte recruitment to syngraft skin graft Flow cytometric analysis of 
(A) B cell, (B) total T cell, (C) CD8+ T cell, (D) CD4+ T cell, and (E) CD25+ Treg 
recruitment in the skin following syngraft transplant and treatment with 
immunomodulatory PEG-MAL Hydrogels. Statistical analysis was performed using one-
way ANOVA with Tukey’s. post hoc test Data presented as mean ± SEM. *p>0.05, 
**p>0.01 , ***p>0.001 n=4. 
5.2.7 Analysis of Immune Cell Profiles in Draining Lymph Nodes and Blood After 
Syngraft 
 We also performed PCA on the flow cytometry data gathered from the draining 
lymph nodes and blood (Figure 37 and Figure 38). PCA on these cells following syngraft 
and immunomodulatory hydrogel treatments are similar in that there is no definitive 
clustering of one treatment group from another, but the main separation that is observed in 
the data is from timepoint to timepoint.  
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Figure 37. Unsupervised PCA of flow cytometric quantification of syngraft LN 
data(A) 3D scores plot of immunomodulatory biomaterial treatments over time. (B) 3D 
loadings (weight coefficients) plot of the 13 input variables in the reduced principal 
component space. (C-D) Scores and loadings plots reduced to two dimensions. Input 
variables are: Macrophages(% of cells), CD206+ (% of Macrophages), CD86+ (% of 
Macrophages),  DC (% of cells), IL-10+ DCs (% of CD11c+), neutrophil (% of CD11b+), 
Ly6Clo (% of CD11b+), Ly6CHi (% of CD11b+), B cells (% of cells), T cells (% of cells), 
CD8+ T cells (% of CD3+), CD4+ T cells (% of CD3+), and Treg (CD25+CD4+CD3+ % of 
CD4+CD3+). N=4 animals per treatment group at each timepoint. 
 The clustering found in the skin data is not present in the blood or LN data, 
indicating that the effects on the immune cell recruitment and populations are largely 
localized to the area of treatment itself, and there seems to be little systemic response 
following placement of genetically identical syngrafts. 

















































































































Figure 38. Unsupervised PCA of flow cytometric quantification of syngraft blood 
data(A) 3D scores plot of immunomodulatory biomaterial treatments over time. (B) 3D 
loadings (weight coefficients) plot of the 13 input variables in the reduced principal 
component space. (C-D) Scores and loadings plots reduced to two dimensions. Input 
variables are: Macrophages(% of cells), CD206+ (% of Macrophages), CD86+ (% of 
Macrophages),  DC (% of cells), IL-10+ DCs (% of CD11c+), neutrophil (% of CD11b+), 
Ly6Clo (% of CD11b+), Ly6CHi (% of CD11b+), B cells (% of cells), T cells (% of cells), 
CD8+ T cells (% of CD3+), CD4+ T cells (% of CD3+), and Treg (CD25+CD4+CD3+ % of 
CD4+CD3+). N=4 animals per treatment group at each timepoint. 
5.2.8 Principal Component Analysis of Immune Response to Allograft 
 To examine the effect of immunomodulatory PEG-MAL hydrogels on the 
integration and acceptance of allograft transplants, we again used the murine skin 
transplant model where the tail skin of a Balb/C mouse was transplanted onto the back of 
a C57Bl/6 mouse following the generation of a full thickness defect. In the same manner 

















































































































as the syngraft data, we applied PCA to the data gathered from flow cytometry on allograft 
skin and the surrounding tissue. Three PCs were able to account for 67% of the variability 
in the data, and we observed distinct clustering of the treatment groups, indicating that the 
immune responses generated following each treatment differed from the other treatment 
groups (Figure 39A-B). The observed clusters are the result of differential recruitment of 
subsets of myeloid and lymphoid immune cells. We then collapsed the 3D PCA scores and 
loadings into two dimensions so we can get a better idea of what cells are contributing to 
each cluster. PC1 primarily separated samples by groups, while PC3 separated the 
lymphoid vs myeloid cell subsets (Figure 39C-D). When we map the PCA scores onto 
components 1 and 3, we see separation of the AT-RvD1 and IL-10+AT-RvD1 cluster seen 
in the component 1 and 2 graph. In this graph, Treg and IL-10+DC populations are mapped 
onto quadrant one, while M2 macrophage and Ly6Clow monocytes are projected into 
quadrant four (Figure 39C-D). The IL-10+AT-RVD1 samples are influenced by both of 
these cell populations, whereas AT-RvD1-only samples have higher populations of M2 
macrophages and Ly6CLow monocytes, while IL-10-only samples have higher 
populations of Tregs and IL-10DCs.  
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Figure 39. Unsupervised principal component analysis of flow cytometry 
quantification in allograft skin transplant skin tissue(A) 3D scores plot of 
immunomodulatory biomaterial treatments over time. (B) 3D loadings (weight 
coefficients) plot of the 9 input variables in the reduced principal component space. (C-D) 
Scores and loadings plots reduced to two dimensions. Input variables are: Macrophages(% 
of cells), CD206+ (% of Macrophages), CD86+ (% of Macrophages),  DC (% of cells), IL-
10+ DCs (% of CD11c+), neutrophil (% of CD11b+), Ly6Clo (% of CD11b+), Ly6CHi (% 
of CD11b+),and Treg (CD25+CD4+CD3+ % of CD4+CD3+). N=4 animals per treatment 
group at each timepoint. 
 
5.2.9 Circulating Myeloid Cell Recruitment into Allograft and Surrounding Tissue 
 As with syngraft, we next analyzed the recruitment kinetics of immune cells into 
the allograft and surrounding tissue over time. Neutrophil infiltration at all timepoints was 
























































































































controls (Figure 40A). IL-10-only treatment had no effect on neutrophils except at day 7. 
Additionally, at day 14, neutrophil levels in AT-RvD1-treated tissue were significantly 
lower compared to IL-10-only treatment (Figure 40A). 
 
Figure 40. Neutrophil and monocyte recruitment to allograft skin transplant Flow 
cytometric analysis of (A) neutrophil, (B) Ly6Chi monocyte, and (C) Ly6CLow monocyte 
recruitment into skin following allograft transplant and treatment with immunomodulatory 
PEG-MAL Hydrogels. Statistical analysis was performed using one-way ANOVA with 






















































































































































































































































































































































































 Immunomodulatory hydrogels were also able to modulate monocyte infiltration 
and accumulation over time. Unlike syngraft, there were no differences in Ly6Chi 
monocyte recruitment at days 3 or 7, but these levels were significantly reduced at days 10 
and 14 in treatment groups containing AT-RvD1. (Figure 40B) We observed further 
reduction in Ly6Chi monocytes after dual-loaded hydrogel treatment compared to AT-
RvD1-only treatment. In the Ly6CLow monocyte population, we saw significant 
modulation of recruitment kinetics at all timepoints (Figure 40C). At Day 3, dual-loaded 
hydrogels had significantly more recruitment of these cells to the skin tissue compared to 
all other groups. By day 7 and into day 10, the levels of Ly6CLow monocytes in AT-RvD1-
treated animals were similar to that of the dual-loaded hydrogels, and both of these were 
significantly higher than IL-10-only treatment and control. Then at 14 days post-transplant, 
the high levels of Ly6CLow cells persisted in the tissue treated with AT-RvD1-only 
hydrogels and was significantly elevated above all other groups (Figure 40C). Ly6CLow 
monocytes at two weeks in the IL-10 and IL-10+AT-RvD1 treated groups were 
significantly higher than control, but not at the same level as AT-RvD1 only. This data 
indicates that even after adding allogeneic tissue to the wound area, immunomodulatory 
PEG-MAL hydrogels are able to modulate the recruitment and infiltration of circulating 
monocuclear cells and neutrophils, although the modulation observed after allograft is not 
the same as was seen following syngraft. 
5.2.10 Macrophage Recruitment and Polarization after Allotransplant 
 We observed modulation of macrophage recruitment after allograft and delivery of 
immunomodulatory PEG-MAL hydrogels. Compared to syngraft, CD64+MerTK+ 
macrophages made up a smaller portion of the total live cell population, but this may be 
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due to increased cellular accumulation of other populations (Figure 41A). At day 3 there 
were no differences in macrophage accumulation between all groups. There was then a 
transient increase in the total macrophage population in AT-RvD1 and IL-10+AT-RvD1 
combination treatments compared to control and IL-10 hydrogels. This increase was not 
present at day 10, and by day 14 there was an overall decrease in the population of 
macrophages in AT-RvD1 and IL-10+AT-RvD1 groups compared to IL-10 and control 
(Figure 41A).  
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Figure 41. Macrophage recruitment to allograft skin transplant Flow cytometric 
analysis of (A) macrophage, (B) CD86+ Macrophage, and (C) CD206+ M2 Macrophage 
populations in the skin following allograft transplant and treatment with 
immunomodulatory PEG-MAL Hydrogels. Statistical analysis was performed using one-
way ANOVA with Tukey’s. post hoc test Data presented as mean ± SEM. *p>0.05, 
**p>0.01 , n=4. 
When measuring CD86+ M1 macrophages, this population started out as a small 
proportion of the total macrophage pool, but then continued to grow over time, reaching 


























































































































































































































































































































































































































RvD1-treated tissue, and 8% in IL-10+AT-RVD1-treated tissue (Figure 41B). The M1 
population expanded more rapidly in control and IL-10-only groups and was significantly 
higher in these groups compared to AT-RvD1 and IL-10+AT-RvD1 at day 10 and again at 
day 14 (Figure 41B). When analyzing the M2 macrophage population, we see significantly 
higher levels of CD206+ macrophages across all timepoints in groups that received AT-
RvD1 compared to groups that did not (Figure 41C). This observation is similar to what 
was found in the syngraft experiments, and further strengthens the conclusion that myeloid 
immune cell recruitment is largely influenced by AT-RvD1. 
5.2.11 Total Dendritic Cell and IL-10+ Dendritic Cell Populations after Allotransplant 
 Dendritic cell populations were modulated after allograft and immunomodulatory 
hydrogel injection. CD11c+ DCs still made up a large proportion of live cells, but their 
levels were lower compared to syngraft, and the kinetics of their accumulation were 
different (Figure 42A). This is likely due to increased infiltration or expansion of other cell 
populations, similar to what was observed with CD64+MerTK+ macrophages. There were 
no differences in DCs at day 3, but they were significantly reduced at day 7 in groups 
receiving hydrogel formulations that contained AT-RvD1 (Figure 42A). At day 10, groups 
receiving hydrogels that contained IL-10 had significantly fewer CD11c+ cells compared 
to control or AT-RvD1-only treatment. This reduction in CD11c+ cells was transient in the 
IL-10-only group, as CD11c+ cells were significantly increased at day 14 compared to all 
other groups, whereas AT-RvD1-containing formulations significantly reduced the 
CD11c+ population(Figure 42A).  
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Figure 42. DC recruitment to allograft skin transplant Flow cytometric analysis of (A) 
total CD11c+ dendritic cell and (B) IL-10+ DC populations in the skin following allograft 
transplant and treatment with immunomodulatory PEG-MAL Hydrogels. Statistical 
analysis was performed using one-way ANOVA with Tukey’s. post hoc test Data presented 
as mean ± SEM. *p>0.05, **p>0.01 , ***p>0.001 n=4. 
Although we observed fluctuations in the total DC population, levels of IL-10DCs were 
largely constant between groups after allograft (Figure 42B). Starting at day 3, animals that 
were treated with hydrogel formulations containing IL-10 had significantly increased IL-
10DC polarization than control or AT-RVD1-only tissue. We did not observe these 
differences in syngraft tissue at day 3, and this disparity may be due to fluctuations in the 
inflammatory response following allograft that result in earlier degradation of the PEG-
MAL hydrogels, allowing for earlier release of IL-10 and subsequent polarization of early 













































































































































































































































































5.2.12 Lymphocyte Infiltration Following Allotransplant 
 We again performed PCA using only lymphoid markers to see if IL-10-containing 
hydrogel formulations clustered together away from AT-RVD1 or control hydrogel 
samples. In the 3D PCA plot, there is observable clustering of these samples, likely due to 
the influence of CD25+ Tregs (Figure 43A-B). However, when mapping these points onto 
two-dimensional space, the clustering is not quite as apparent as it was in three dimensions, 
but samples that have been treated with IL-10 closely follow the CD25 Treg variable 
loading and are pulled into the quadrants where these cells are represented (Figure 43C-
D).  
 
Figure 43. Unsupervised principal component analysis of flow cytometry 

































































































scores plot of immunomodulatory biomaterial treatments over time. (B) 3D loadings 
(weight coefficients) plot of the 5 input variables in the reduced principal component space. 
(C-D) Scores and loadings plots reduced to two dimensions. Input variables are: B cells (% 
of cells), T cells (% of cells), CD8+ T cells (% of CD3+), CD4+ T cells (% of CD3+), and 
Treg (CD25+CD4+CD3+ % of CD4+CD3+). N=4 animals per treatment group at each 
timepoint. 
 
 When quantifying the overall lymphocyte recruitment to allografts, we found that 
the profile differs from syngraft. B cell recruitment is not different between any treatments 
at days 3, 7, and 10 (Figure 44A). However, there is a significant increase in  cells at day 
14 in the tissue that had been treated with combination IL-10+AT-RvD1 compared to all 
groups. B cells were significantly increased in AT-RvD1-treated tissue compared to control 
(Figure 44A). T cells made up a larger proportion of live cells following allograft compared 
to syngraft. We observed a transient increase in T cells at day 3 in AT-RvD1-treated tissue 
compared to control and dual-loaded hydrogels. There were no differences in T cells at day 
7, but then at days 10 and 14, T cells were increased in IL-10+AT-RvD1 tissue compared 



















































































































































































































































































































































































































































































































































































































































Figure 44. Lymphocyte recruitment to allograft skin transplant tissueFlow cytometric 
analysis of (A) B cell, (B) total T cell, (C) CD8+ T cell, (D) CD4+ T cell, and (E) CD25+ 
Treg recruitment in the skin following allograft transplant and treatment with 
immunomodulatory PEG-MAL Hydrogels. Statistical analysis was performed using one-
way ANOVA with Tukey’s. post hoc test Data presented as mean ± SEM. *p>0.05, 
**p>0.01 , ***p>0.001 n=4. 
 Although we saw increases in T cells, we did not see modulation in the proportion 
of CD4+ or CD8+ cells between groups until day 14, where we observed a significant 
decrease in the proportion of CD8+ T cells in all treatment groups compared to controls 
(Figure 44C-D). However, within the CD4+ compartment, we observed differential Treg 
accumulation depending on the treatment type. Tregs in control allografts remained at 
around the level of 20% of all CD4+ T cells over the entirety of the timepoints surveyed 
(Figure 44E). The proportion of Tregs after IL-10 treatment increased to over 40% of CD4+ 
cells at day, before dipping to around 20% at one week and rising back to 40% at 10 days 
and reaching 60% of the total CD4+ population at two weeks. At 3  and 10 days, this was 
significantly higher than control, and significantly higher than control and AT-RvD1-only 
treatment at day 14. (Figure 44E) Treg levels following AT-RvD1 treatment did not 
increase as much as in tissue that was treated with IL-10m and only transiently increased 
compared to control at day 10. Treg recruitment to tissues receiving combination IL-
10+AT-RvD1 treatment were elevated to the same levels at IL-10-only at day 3, but 
remained high throughout, also rising to 60% of the total CD4+ cell population. 
5.2.13 Analysis of Immune Cell Profiles in Draining Lymph Nodes and Blood Following 
Allograft 
 We again performed PCA on the flow cytometry data gathered from the draining 
lymph nodes and blood after allograft (Figure 45 and Figure 46). PCA on these cells 
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following skin allograft and immunomodulatory hydrogel treatments are similar in that 
there is no definitive clustering of one treatment group from another. In the allograft LN 
PCA, there seems to be separation of the early day 3 timepoint from the rest of the data, 
but then the subsequent timepoints cluster together into quadrants 2 and 3. This is likely 
due to the strong influence of lymphocyte populations that predominate the lymph node 
environment (Figure 45).  
 
Figure 45. Unsupervised principal component analysis of flow cytometry 
quantification in allograft skin transplant LN(A) 3D scores plot of immunomodulatory 
biomaterial treatments over time. (B) 3D loadings (weight coefficients) plot of the 13 input 
variables in the reduced principal component space. (C-D) Scores and loadings plots 
reduced to two dimensions. Input variables are: Macrophages(% of cells), CD206+ (% of 
Macrophages), CD86+ (% of Macrophages),  DC (% of cells), IL-10+ DCs (% of CD11c+), 
neutrophil (% of CD11b+), Ly6Clo (% of CD11b+), Ly6CHi (% of CD11b+), B cells (% of 



















































































































Treg (CD25+CD4+CD3+ % of CD4+CD3+). N=4 animals per treatment group at each 
timepoint. 
 
 In the blood PCA, there is no discernible clustering whatsoever over time or 
treatment (Figure 46). This strengthens the argument presented with the syngraft PCA, that 
the immunomodulation occurring after hydrogel implantation is local in scope and has little 
influence on the overall systemic immune populations found in the blood or in lymph 
nodes. 
 
Figure 46. Unsupervised principal component analysis of flow cytometry 
quantification in allograft skin transplant blood(A) 3D scores plot of 
immunomodulatory biomaterial treatments over time. (B) 3D loadings (weight 
coefficients) plot of the 13 input variables in the reduced principal component space. (C-
D) Scores and loadings plots reduced to two dimensions. Input variables are: 





















































































































Macrophages(% of cells), CD206+ (% of Macrophages), CD86+ (% of Macrophages),  DC 
(% of cells), IL-10+ DCs (% of CD11c+), neutrophil (% of CD11b+), Ly6Clo (% of 
CD11b+), Ly6CHi (% of CD11b+), B cells (% of cells), T cells (% of cells), CD8+ T cells 
(% of CD3+), CD4+ T cells (% of CD3+), and Treg (CD25+CD4+CD3+ % of CD4+CD3+). 
N=4 animals per treatment group at each timepoint. 
 
5.2.14 Alloantibody and Complement Deposition After Allograft and Immunomodulatory 
Hydrogel Treatment 
 Finally, we wanted to investigate the possible role of anti-donor antibody 
deposition in the process of skin transplant rejection. We took frozen sections of the skin 
transplant and surrounding tissue at day 14 and stained the tissue for complement C3c, 
anti-mouse IgM, and anti-mouse IgG. We also stained syngraft control tissue to serve as a 
negative indicator for the presence of anti-mouse antibodies. In normal tissue, there is very 
little complement C3c or anti-mouse antibody staining, because the immune response is 




Figure 47. Staining tissue for alloantibody-mediated rejection markers (A) 
Fluorescence confocal microscopy of skin tissue surrounding transplanted skin stained 
with markers of humoral immune activation, Complement C3c, IgM, and IgG at two weeks 
following skin transplant and immunomodulatory hydrogel treatment. (B-D) 
Quantification of fluorescence intensity of staining using ImageJ. Data presented as mean 
± SEM statistical analyses was performed using one-way ANOVA with Tukey’s post-hoc 
test, *p>0.05, **p>0.01, n=4. 














































































































































 However, in the case of allogeneic skin transplant, the Balb/C tissue is recognized 
as foreign, and the adaptive immune system generates and releases antibodies against these 
antigens. In mouse to mouse transplants, these antibodies can be detected using anti-mouse 
secondary antibodies. We see significant increases in complement C3c and IgM deposition 
across all allograft groups after two weeks (Figure 47B-C). However, in the case of IgG, 
deposition is significantly decreased in the combination IL-10+AT-RvD1 group compared 
to all other groups (Figure 47D). This may indicate that rejection to allotransplant in this 
group is not as severe as the others. 
5.3 Discussion 
 The immune response to allografts is complex and multifactorial. T and B 
lymphocytes are known mediators of transplant rejection, and much of the field of 
transplant immunology has focused on modulating the response of the adaptive immune 
system after allograft. Indeed, the mechanisms of action of the most common 
immunosuppressive agents prescribed following organ transplantation mainly focus on 
inhibiting the actions of T cells: calcineurin inhibitors block IL-2 synthesis, anti-
proliferative agents like mycophenolate motefil are able to limit lymphocyte proliferation 
via bloackade of de novo purine synthesis, and new immunosuppressive agents like 
belatacept or abatacept act like CTLA-4 to prevent costimulation of T cells during antigen 
presentation, thereby decreasing their activity[212, 217]. However, targeting of innate 
immune cells including mononuclear phagocytes and granulocytes has gained increasing 
interest due to their ability to play both detrimental and beneficial roles [4].  Neutrophils 
are recruited to graft tissue in response to ischemia reperfusion injury (IRI) inherent in all 
transplant procedures[85]. There they can exacerbate graft tissue damage through the 
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release of metalloproteinases and neutrophil elastase, and actively mediate acute rejection 
through CD8+ cytotoxic T cell signaling[86-88]. Additionally, while the interaction of 
neutrophils and cells of humoral immunity is not well-understood, it has been found that 
neutrophils have the capacity to leave peripheral sites of injury and deliver antigen to 
lymph nodes[89]. On the other hand, there are subsets of neutrophils that may promote 
wound healing and tissue repair, and aid in the reperfusion of graft tissue[43]. Mononuclear 
cell infiltration, including monocytes (MO), dendritic cells (DCs) and macrophages, and 
the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-
α), interleukin (IL)-1α, and IL-1β are inherent to the transplant milieu[5]. Macrophages of 
both donor and recipient origin infiltrate the allograft and proliferate in situ, and comprise 
40-60% of cellular infiltrate in acute rejection[90]. Up-regulation of surface MHC class II 
and increased expression of T cell costimulatory molecules by activated DCs are also 
implicated in acute rejection. Upon functional maturation, “passenger” DCs in donor tissue 
migrate to recipient secondary lymphoid organs along chemokine gradients where they are 
key mediators in alloantigen presentation. Early activation of DCs also leads to 
allotransplant injury due to accumulation of interferon-γ-producing neutrophils, infiltrating 
macrophages, CD4+ T cells, B cells, and invariant natural killer T (NKT) cells[91]. 
Conversely, the phenotypic plasticity of monocyte precursors and DCs in response to 
microenvironmental signals, the presence of tolerogenic mononuclear phagocyte subsets 
that coincide with allograft acceptance, and their roles in Treg expansion are evidence that 
MO and DC subsets are key targets in the quest for transplant acceptance[92, 93]. It was 
our goal to manipulate this inherent cellular response set off by tissue injury and transplant 
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to tune the microenvironment surrounding the transplanted tissue and wound to promote 
integration and healing of the allograft. 
 We have previously demonstrated that the localized co-delivery of IL-10 and AT-
RvD1 from an injectable hydrogel scaffold modulates the recruitment, accumulation, or 
polarization of pro-regenerative, anti-inflammatory innate and adaptive immune cell 
subsets in injured tissue. We have also shown that these hydrogels promote vascular 
network expansion and remodeling. In this study, we aimed to apply these findings to a 
model of murine skin transplantation to observe how immunomodulatory PEG-MAL 
hydrogels modulate the immune response after injury when an additional immune stimulus, 
i.e. an allograft or syngraft, is applied. The skin transplant model is a simple model to study 
the transplant response, as transplanted allogeneic skin is extremely antigenic and rapidly 
rejected without intervention over the course of days[218]. Oppositely, syngeneic skin 
transplants will not be rejected and so the syngraft model can be used to chronicle wound 
healing and tissue integration. We transplanted syngeneic and allogeneic tail skin onto the 
backs of C57Bl/6 mice and measured the kinetics of immune cell recruitment into the 
transplant and surrounding tissue. 
 The immune response to syngraft transplant proceeds similar to that of normal 
wound healing. Qualitative observations of macroscopic images of the transplanted tissue 
area over time show that the syngraft transplant heals and integrates with the tissue over 
time, with full healing seen across all groups by 14 days. We observed differences in wound 
and graft contracture between groups, and the control and AT-RvD1-treated syngrafts were 
noticeably smaller than IL-10-only or IL-10+AT-RvD1 treated syngrafts. This may be due 
to the ability of IL-10 to reduce scar formation and fibrosis in cutaneous wounds[219]. This 
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time to healing is accurate for wounds of this size [220]. With delivery of dual-loaded IL-
10+AT-RvD1 hydrogels, integration of the graft with host tissue was seen at day 10 post-
transplant, whereas there was still healing occurring in other groups. This indicates possible 
acceleration of the wound healing process following IL-10+AT-RvD1 delivery, however 
closer analysis of wound closure metrics would be needed to determine the strength of this 
integration. We also stained frozen tissue sections with H&E to observe tissue morphology 
and cellular infiltration into the graft area. In syngraft, leukocytes were present in the tissue 
at all timepoints across all groups. There was no appreciable differences between any 
treatment groups, meaning that the delivery of immunomodulatory hydrogels does not 
suppress the immune response after injury, but modulates the recruitment, activation, or 
polarization of cells found within the injury niche. Given that both pro- and anti-
inflammatory responses are necessary for normal wound healing, a complete suppression 
of the immune response is not desired in this case[64, 67, 221]. When we took similar 
images of allograft transplants, we saw visible signs of rejection in all groups by day 10, 
and all allografts were completely rejected by day 14 post-transplant. H&E micrographs of 
the graft tissue reveal significant immune cell infiltration at all timepoints within all groups. 
Compared to syngraft, there was marked increase in cellular infiltration, meaning that the 
immune response to allograft was also not suppressed by hydrogel delivery of 
immunomodulatory biomolecules. This outcome was not unexpected due to the use of 
complete MHC-mismatch Balb/c to C57Bl/6 grafts. Skin allograft transplants are 
extremely antigenic and will be rejected without robust systemic immunosuppression[218]. 
Future analyses using this model could instead utilize a partial MHC-mismatch, or pair 
local immunomodulation therapy with traditional systemic IS to try to attain better tissue 
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integration without rejection. We do believe that early integration of the transplanted tissue 
was improved with combination IL-10+AT-RvD1 treatment, as evidenced by decreases in 
the wound size at days 3 and 7, however this early positive response was quickly 
overshadowed by allograft rejection processes. 
 This study presents a thorough analysis of the immune response to both syngraft 
and allograft over different timepoints, treatments, and tissues. We analyzed the immune 
response after skin transplant at days 3, 7, 10, and 14 in the transplant tissue itself, as well 
as in blood and the draining lymph nodes. Analysis of blood and draining LNs allows us 
to draw conclusions about the extent of the immunomodulation occurring after hydrogel 
treatments. We used principal component analysis as our main analytical tool to look for 
patterns that emerge between treatment groups over time. When we examined the 
clustering analysis of both syngraft and allograft LN and blood, we did not see 
discrimination between treatment groups except for clustering of timepoints. This indicates 
that any observed changes in the immune response within the tissue is due to local 
modulation of cell recruitment, proliferation, or polarization. We and others have 
previously shown that the local delivery of immunomodulatory factors via biomaterial can 
influence the local immune environment without affecting the systemic immune system as 
a whole. Local immune modulation is ideal in this context, because systemic 
immunomodulation, like with systemic IS therapies after transplant, can have unwanted 
off-target side effects that are detrimental to the host [2]. When we examine the clustering 
of the transplanted tissue data in both syngraft and allograft, we see clear clusters that 
emerge between treatment groups. The AT-RvD1 and IL-10+AT-RvD1 samples appear to 
be closely related over time, separating from the other data due to the influence of 
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Ly6CLow monocytes and CD206+ M2 macrophages. When we quantified the flow 
cytometry data over time for each cell subset included in our flow panels, we saw that AT-
RvD1 and IL-10+AT-RvD1 treatment increased the proportions of these cell subsets in 
syngraft and allograft. We and others have shown that these cell subsets are positively 
correlated with healing outcomes, and in the context of allograft, these cells may enhance 
graft acceptance due to their ability to signal to and stimulate Treg populations[95, 222]. 
One notable difference observed between the temporal immune cell recruitment profiles of 
syngraft and allograft was that the levels of many cells, including neutrophils, monocytes, 
and lymphocytes seemed to return to baseline levels at around days 10 and 14 in syngraft 
skin tissue, but that levels of these cell populations remained elevated in allografts. For 
example, at day 14, the proportion of neutrophils found in syngraft skin tissue was less than 
15% of the CD11b+ pool for all groups, whereas neutrophils comprised up to 50% of the 
cells in this same gate in the allograft skin tissue. This persistent activation of the immune 
system indicates on ongoing response to the allograft that was not completely ameliorated 
with immunomodulatory treatment. 
 We also previously observed expansion of IL-10+ DC and Treg populations 
following delivery of PEG-MAL hydrogels containing thiolated IL-10. We showed that 
thiolation slows the release of IL-10 from the hydrogels, allowing it to be released over 
time. Expansion and activity of these populations is vital to acceptance of transplanted 
tissue, and cell-based therapies utilizing both IL-10+DCs or Tregs have been pursued in an 
attempt to enhance allograft transplant acceptance[198, 223-227]. Following syngraft and 
allograft, we observe increased proportions of these cell types in tissues treated with IL-
10, with and without concurrent AT-RvD1 delivery. One marked difference between 
 149 
syngraft and allograft was that both IL-10+ DCs and Tregs were increased after three days 
following allograft, whereas these populations were not expanded in syngraft until day 7. 
One possible explanation could be due to changes in the cytokine milieu following 
allograft. PEG-MAL hydrogels are protease-degradable, and the stimulus of MHC-
mismatch allograft may increase the release and activity of protein-degrading enzymes, 
leading to earlier degradation of the PEG-MAL hydrogel and subsequent release of IL-10. 
We observed increased T cell migration to the allografts compared to syngraft. In syngraft, 
T cells comprised less than 10% of the overall proportion of live cells, with the majority of 
samples having less than 5% T cells out of total cells. In the allograft, however, T cell 
levels were doubled compared to syngraft at 14 days, making up 10-15% of the total live 
cell population. While we saw expansion in T cell numbers following allograft, we did not 
observe much modulation in the proportions of CD4+ and CD8+ T cells.  In fact, these 
populations comprised a small amount of the total CD3+ T cell pool. There was a large 
proportion of CD3+ cells that were CD4 and CD8 double negative. It is possible that these 
CD3+CD4-CD8- T cells are gamma delta T cells, or double negative alpha beta T cells. 
Both of these T cell populations exist in small proportions during homeostasis but may 
expand in response to injury or other immune system stimulus, however the roles of these 
T cells has not clearly been elucidated, but these cells may act to promote transplant 
rejection [200, 228], and further inquiry is required to determine the exact function and 
origin of these cells after skin injury and tissue transplant. 
 Although we observed significant alterations in the recruitment and accumulation 
of pro-regenerative immune cells that have been shown to promote processes leading to 
transplant acceptance, the allografts were still rejected after 10-14 days. The increased T 
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cell infiltration that we see in the allografts may be contributing to this rejection response. 
While the overall proportions of CD4 and CD8 T cells were unaltered compared to 
syngraft, the overall increase in total number may promote rejection. One other mechanism 
that we did not explore fully to explain why rejection persisted is due to humoral immunity. 
We observed a significant increase in CD19+ B cells  in the allograft tissue after dual-
loaded IL-10+AT-RVD1 delivery at two weeks, a response that was not seen in syngraft 
tissue samples. It is possible that this increased recruitment of B cells is a compensatory 
mechanism activated by the host immune system to deal with the detection of foreign 
antigen. We stained skin sections for immunoglobulins IgG and IgM, as well as 
complement C3c, a downstream component of the humoral immune response, and saw 
significant deposition of IgG, IgM, and C3c compared to syngraft in all allograft groups at 
two weeks following transplant. B cell responses have been shown to play a role in 
mediating organ transplant rejection, and the anti-CD20 monoclonal antibody rituximab 
has been used off-label in kidney transplant immunosuppression to prevent this humoral 
rejection response [229]. It is not known if AT-RvD1 or IL-10 can promote or prevent B 
cell actions, so more study is necessary to determine how to ameliorate this response while 
utilizing local, hydrogel-based immunomodulation. Overall, this study is a promising first 
step in the exploration of local therapies to improve allograft tissue integration and healing, 
and future studies should focus on combining this therapy with systemic IS to attain a 
balance between prevention of rejection and enhancement of wound healing outcomes. 
5.4 Methods 
5.4.1 Hydrogel Fabrication 
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 Four-arm poly(ethylene glycol) (PEG, 10 kDA molecular weight) end-
functionalized with maleimide (>95% purity, Laysan Bio) at 4.5% weight/volume was 
used for all hydrogel formulations. PEG macromers were functionalized with RGD peptide 
(GRGDSPC), crosslinked with the cysteine-flanked peptide VPM 
(GCRDVPMSMRGGDRCG) (AAPPTec) in 0.5M MES buffer, pH 5.5. The final 
concentration of RGD was 1.0mM. Gels were also loaded with 50ug/mL IL-10, and 
4ug/mL AT-RvD1 (Cayman Chemical). The crosslinker concentration was based on the 
concentration of non-reacted maleimide groups remaining on PEG macromers. For 
hydrogels used in animal studies, all components were filtered through a spin column after 
pH measurements and kept under sterile conditions until injection into the animals. 
5.4.2 Skin Transplant Graft Experiments 
 Female C57BL/6 aged 5-7 weeks (Charles River) were transplanted with full 
thickness tail skin grafts from age- and sex-matched Balb/c or C57Bl/6 mice as previously 
described[218]. Briefly, donor mice were sacrificed under terminal anesthesia via cervical 
dislocation.  Donors were placed tail-first into a sterile decapicone with the tail exposed. 
The tail skin was sterilized via three washes with 70% ethanol and chlorhexidine. The tail 
skin was removed with surgical scissors and kept in ice cold sterile saline until use. 
Recipient mice were anesthetized with 50uL Ketamine-Xylazine-Saline cocktail (ratio 
5:1:4) and shaved and sterilized with via three washes with 70% ethanol and chlorhexidine. 
A full thickness defect was cut into the dorsal skin of the recipient mouse. Hydrogels were 
mixed and loaded into a syringe and injected in depots in the defect area. For experiments 
utilizing soluble IL-10 and AT-RvD1, dosages to match hydrogel dosages were dissolved 
in 30uL sterile saline and injected underneath the graft area. Skin grafts were cut from 
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donor tails to fit into the defect area. Wounds were bandaged, and mice were administered 
sustained-released buprenorphine i.p. (0.1-0.2 mg/kg) and allowed to recover in heated 
cages. Bandages covering grafts were removed 7 days after graft placement. All mice 
received standard laboratory diet and water ad libitum throughout the course of the 
experiment. 
5.4.3 Tissue Harvest and Flow Cytometry 
 To collect samples for flow cytometry analysis, mice were euthanized via CO2 
asphyxiation. The skin graft and surrounding tissue was excised, minced, and digested with 
collagenase type 1-A (3.3mg/ml, Sigma), hyaluronidase type IV-S (1mg/mL, Sigma), and 
DNASE-I (0.1mg/mL, Sigma) in RPMI in a shaking water bath at 37°C for 90 minutes and 
further separated with a cell strainer to create a single cell suspension. Peripheral blood 
was collected via cardiac puncture. From cardiac puncture, 50uL blood was used for flow 
cytometric analysis. Erythrocytes within blood were lysed with ammonium chloride 
(StemCell Technologies) and the remaining leukocytes were isolated for flow cytometry 
analysis. Brachial and axillary lymph nodes were isolated and mashed through a 40 micron 
cell strainer to create a single cell suspension. Single cell suspensions of skin tissue, lymph 
nodes, and blood were stained for flow cytometry analysis using standard methods and 
analyzed on a FACS-AriaIIIu flow cytometer (BD Biosciences). Dead cells were excluded 
through staining using Zombie Red fixable viability stain (BioLegend). The antibodies 
used for identifying cell populations of interest were: PE conjugated MerTK (Biolegend), 
PE-Cy7 conjugated MHC-II (BioLegend), BV605 conjugated CD206 (BioLegend), 
BV510 conjugated Ly6C (BioLegend), APC-Cy7 conjugated Ly6G (BioLegend), BV711 
conjugated CD64 (BioLegend), BV785 conjugated CD19 (BioLegend), APC conjugated 
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Cd11b (BioLegend), BV421 conjugated CD11c (Biolegend, FITC conjugated CD86 
(BioLegend), PerCP-Cy5.5 conjugated CD3 (Biolegend), BV785 conjugated CD8 
(BioLegend), BV605 conjugated CD4 (BioLegend), and BV711 conjugated CD25 
(BioLegend). Staining using BV dyes was performed in the presence of Brilliant Stain 
Buffer (BD Biosciences). Cells were stained for intracellular cytokines using PE 
conjugated IL-10 (BioLegend) and PE-Cy7 conjugated TNF- α (eBiosciences). Positivity 
was determined by gating on fluorescence minus one controls. Absolute quantification of 
cell numbers was performed by adding 25μL of AccuCheck counting beads to flow 
cytometry samples (Thermo Fisher Scientific). 
5.4.4 Immunohistochemistry 
 Skin transplant graft and surrounding tissue, retrieved at the end of the experiments, 
were flash frozen, cryosectioned, and post-fixed with ice cold acetone. Sections were 
stained with hematoxylin and eosin (H&E) to observe morphology. Immunofluorescence 
was also used to assess cell infiltration and response to skin graft. Sections were blocked 
at RT for one hour in PBS containing 0.4% Triton-X and 5% goat serum. Tissues were 
stained overnight at 4°C in PBS-Triton-X supplemented with 1% goat serum with FITC 
conjugated Anti-C3b/c (1:300 dilution, Abcam) primary antibody to detect C3 deposition 
in the tissue. Alexafluor 568 conjugated Goat anti-rat IgG (1:200 dilution, Abcam) and 
Alexafluor 647 conjugated goat anti-rat IgM (1:200 dilution, Abcam) were used to detect 
tissue deposition of IgG and IgM, respectively. Images were acquired with a fluorescence 
microscope (Zeiss 710 NLO), and all images were captured with identical exposure times 
and settings in each experiment. 
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5.4.5 Statistical Analysis 
 All statistical analyses were performed using Graphpad Prism version 6.0 (La Jolla, 
CA). Results are presented as mean ± standard error of the mean (SEM). For grouped 
analyses, one-way ANOVA with Tukey’s post-test was used for multiple comparisons. 
Unless otherwise noted, p<0.05 was considered statistically significant. 
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Overall Summary 
 The work presented in this thesis represents a significant contribution to the fields 
of biomaterials and regenerative medicine by demonstrating that local delivery of 
endogenous anti-inflammatory factors can enhance the recruitment and differentiation of 
immune cell subsets of both the innate and adaptive immune system to enhance post-injury 
vascularization and tissue repair. This work expands the understanding of the relationship 
between pro-regenerative myeloid and lymphoid cells, and identifies methods in which this 
relationship can be manipulated to promote wound healing. 
 In Aim 1, we explored how biomaterial-mediated delivery of the specialized 
proresolving mediator AT-RvD1 was able to modulate the recruitment of the earliest cells 
involved in the immune response after injury. We were specifically interested in 
subpopulations of macrophages, monocytes, and a recently identified neutrophil 
population active in early vascular remodeling, CD49d+ neutrophils. We utilized PLGA 
thin films as a model biomaterial delivery system due to its ease of manufacturing and our 
prior experience with delivering lipid small molecules from these thin films. We found that 
delivery of AT-RvD1 via biomaterial to injured tissue was able to modulate neutrophil and 
monocyte recruitment and phenotype better than a single dose of AT-RvD1 dissolved into 
saline given at the time of surgery. We also explored macrophage recruitment and found 
significantly more CD206+ M2 macrophages in the tissue at three days following injury 
compared to unloaded PLGA films. We observed the beginnings of early vascular 
remodeling, finding significantly increased expansion of CD31+ capillary networks in 
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peri-implant areas. In addition, we saw significant recruitment of pro-angiogenic CD49d+ 
neutrophil subsets following implantation of AT-RvD1-loaded films. For this analysis, we 
utilized SPADE, an emerging technique to map flow cytometry data based on receptor 
expression levels that is able to remove the need for manual gating. Ours was the first study 
to identify a potential method to target  and enrich the injured tissue with these pro-
angiogenic neutrophils to enhance vascularization around biomaterial implants. The 
significance of this work lies in our identification of the cell subsets that are modulated by 
AT-RvD1, and our novel findings that locally delivered AT-RvD1 has the ability to 
promote the recruitment of these cells in areas of injury. 
 In aim 2, we demonstrated for the first time the ability to target the recruitment of 
wound healing pro-regenerative cells from both the innate and adaptive branches of the 
immune system. Mounting evidence suggests that the wound healing process is driven in 
part by both branches, and we engineered a hydrogel delivery system to achieve 
simultaneous in vivo release of both AT-RvD1 and IL-10. IL-10 or AT-RvD1 delivery 
alone from PEG-MAL hydrogels are able to differentially promote the recruitment of pro-
regenerative immune cell subsets, but combined delivery of these two factors allows for 
synergy  in their actions and promotes the recruitment of Ly6CLow monocytes, M2 
macrophages, IL-10 DCs, and Tregs to injured tissue. Assessment of vascular regeneration 
parameters revealed that IL-10+AT-RvD1 hydrogels promoted the expansion of vascular 
networks and arteriolar diameter. Taken together these results indicate that local 
immunomodulation using combinatorial delivery of bioactive factors can recruit expanded 
populations of cells positively involved in the wound healing process. 
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 In aim 3, we applied these immunomodulatory PEG-MAL biomaterials to a model 
of syngeneic or allogeneic skin transplantation. We hypothesized that local modulation of 
the immune response following transplant would be sufficient to promote grafted tissue 
integration and wound healing while staving off rejection in the short term. While we did 
observe significant differences in the local immune response following 
immunomodulatory hydrogel injection, this local response was unable to overcome the 
greater systemic rejection response. Although the allogeneic transplants were rejected, we 
observed early recruitment of Ly6CLow monocytes, and enhanced accumulation of 
CD25+ Tregs in the allograft and surrounding tissue. Syngraft tissue transplants extended 
and further confirmed our aim 2 findings, and in the case of IL-10+AT-RvD1 combined 
delivery, we qualitatively observed earlier wound closure and increased recruitment of pro-
regenerative cells to the injury niche. 
6.2 Improved characterization of innate and adaptive immune cell function 
following transplantation and injury and new analysis techniques 
 While the studies presented here employ well-accepted paradigms to characterize 
phenotypes of innate and adaptive immune cells, the field of immunology continues to 
uncover additional layers of heterogeneity and complexity that exist within these cell types. 
Our growing understanding of the spectrum of cellular phenotypes present in vivo means 
that more sophisticated techniques are necessary to elucidate the origin, activation status, 
and function of immune cells involved in the response to tissue injury. Neutrophils are now 
recognized to possess distinct subpopulations along the same vein as monocytes and 
macrophages, and identification of these cells solely based on CD11b+Ly6G+ flow 
cytometric staining is likely no longer sufficient to determine their definitive population. 
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Identification of macrophage polarization status via CD86 or CD206 also does not provide 
the full story of what functions these cells carry out in vivo. Already we know that M2 
macrophage polarization can be subdivided into at least three distinct populations in vitro, 
and many more may exist in vivo, where complex signaling mechanisms may lead to dual-
polarized cells, or intermediate populations. Further characterization of lymphoid cell 
populations in the response to injury is also necessary. We focused our analysis on CD25+ 
Tregs due to the growing evidence that these cells are active mediators of wound repair, 
but additional subpopulations within CD4+ T cells, such as Th1, Th2, and Th17 are 
involved in the immune response to injury, and we have yet to characterize their 
recruitment or activity following implantation of immunomodulatory biomaterials. Future 
studies looking to characterize the immune response to implanted materials and locally 
delivered immunomodulatory factors could employ high-dimensional, single-cell 
analytical techniques such as single cell qPCR or highly multiplexed mass cytometry. 
These techniques allow for a much wider array of markers to be tested compared to 
traditional flow cytometric analysis, which is limited to 10-15 markers of interest, and 
could potentially identify novel subpopulations of immune cells involved in inflammation 
and healing. Analysis of this data could employ emerging dimensionality reduction 
techniques such as SPADE. We have found that SPADE is able to identify neutrophils at 
the subpopulation level, but have not yet expanded this analysis to larger datasets.  
6.3 Extension of immunomodulatory therapies to other regenerative medicine 
applications 
 In the initial characterization of immunomodulatory hydrogels capable of 
promoting the recruitment of wound healing cells from the innate and adaptive arms of the 
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immune system, we utilized the murine dorsal skinfold window chamber as our test model. 
This model provides a significant inflammatory injury and robust immune response, 
allowing for the use of a multitude of techniques to measure this response and perturbations 
following immunomodulatory factor delivery. However, due to the size of the wound 
generated and that the wound area is held under tension, it is unlikely that the skin will 
heal. Future studies could modulate the size of the defect generated during dorsal window 
chamber placement to observe closure of full thickness wounds and how 
immunomodulatory hydrogels are able to influence wound closure. We started to examine 
wound healing in our use of the syngraft skin transplant model, and we could expand upon 
our findings by examining metrics of wound healing and tissue integration such as collagen 
deposition and fibrosis and by measuring tissue tensile strength after healing.  
 Additionally, future applications of our dual-loaded PEG-MAL hydrogels could be 
used in the context of other injury models. Any tissue injury is accompanied by an 
inflammatory response, which provides opportunities for modulating that response to 
accelerate or enhance repair. We focused on the repair of skin wounds in this work, and it 
is likely that there exist context dependent immune responses that vary from tissue type to 
tissue type. Such areas of interest for potential application of our immunomodulatory PEG-
MAL hydrogels include muscle regeneration after volumetric muscle defect, promoting 
cardiac repair after infarct injury, or to direct palatal wound healing and prevent fistula 
formation after cleft palate repair. 
6.4 Further characterization of immune modulation following allotransplant 
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 It was our overall goal in this work to use immunomodulatory biomaterials to 
promote allograft tissue integration and wound healing following transplant. While we 
observed the modulation of local recruitment of immune cells after hydrogel treatment, 
ultimately, all of the allograft skin transplants were rejected over the course of 10-14 days. 
Skin tissue is one of the most antigenic tissues, and therefore host response to skin 
alloantigens is swift and robust when the transplanted skin is from an animal with complete 
MHC mismatch, as is the case with Balb/c to C57Bl/6 transplants. While the use of 
complete MHC mismatch allows for the study of a rapid rejection response, this model is 
not clinically relevant, as complete MHC mismatch transplants are exceedingly rare. 
Instead, future studies could utilize partial MHC-mismatch transplants, which do not 
exhibit rejection as quickly and may allow for closer study of allograft healing and 
integration.  
 Other areas of interest are to expand our analysis of the humoral immune response 
to immunomodulatory hydrogel treatment and allotransplant. We observed expansion of B 
cell populations and immunoglobulin deposition in the transplant milieu, but our current 
experience with the humoral adaptive immune response is limited. Further analysis of this 
B cell response could identify possible mechanisms that could be exploited to promote 
allograft healing and integration. Additionally, it is well known that passenger donor 
immune cells can migrate to host lymph nodes and set off immune response cascades 
leading to rejection. With the current skin transplant model, we are not able to differentiate 
host immune cells from tissue resident donor immune cells. It would be beneficial to 
identify the origins of the cells whose recruitment and activation are modulated via PEG-
MAL hydrogels. Transgenic models utilizing CD45.1 and CD45.2 allellic variants would 
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allow us to identify immune cells originating from the donated tissue versus those host 
immune cells recruited in response to injury and transplant. 
 Finally, models of solid organ transplant could also be employed, and these models 
would allow us to explore wound healing and revascularization following solid organ 
anastomoses with host vasculature as well as the progression of surgical wound healing. 
Combinatorial treatments utilizing sliding scale doses of systemic IS and 
immunomodulatory hydrogels could allow for optimization of regimens that are able to 
durably prevent transplant rejection while also allowing for early enhancement of 
transplanted organ integration and surgical wound healing could have the potential to all 
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